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Abstract 
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder in 
humans. It is characterised by the progressive loss of the A9 (Girk2+) subpopulation 
of dopamine (DA) neurones in the Substantia Nigra Pars Compacta (SNpc) resulting 
in resting tremor, bradykinesia and rigidity. The majority of PD cases are idiopathic. 
However, environmental toxins that inhibit the mitochondrial electron transport chain 
cause PD-like symptoms and recent studies of rare familial PD implicate metabolic 
dysfunction as a possible cause of DA nerve cell loss. We propose that the 
homeostatic hormone, acyl-ghrelin, may prevent DA neurone loss by preserving nerve 
cell metabolism during bioenergetics stress. In the in-vivo MPTP-toxin model of PD 
acyl-ghrelin prevents SNpc DA neurone loss in an acyl-ghrelin receptor (GHSR)-
dependent manner (Andrews et al.2009). Here, using the eGFP-GHSR reporter 
mouse we demonstrate co-localised expression of the GHSR with TH+ and Girk2+ 
SNpc neurones. This suggests that acyl-ghrelin may exert a direct protective effect on 
A9 DA neurones via GHSR+ signalling. We show that acyl-ghrelin attenuated the 6-
OHDA-induced SN lesion in unilateral lesioned rats. Moreover, this neuroprotection is 
consistent with the preservation of motor function. Using a mouse-midbrain-derived 
neuronal cell line (SN4741), immune-positive for TH+/ Girk2+/GHSR+, we assess the 
neuroprotective potential of acyl-ghrelin and GHSR1a agonist, JMV2894, in an in-vitro 
rotenone-based PD model. Furthermore, we show acyl-ghrelin as a modulator of intra-
cellular AMPK and ACC phosphorylation and investigate the protective effects on 
mitochondrial health and morphology using automated images analysis and TEM. 
Acyl-ghrelin activated cellular pathways associated with protecting against energetic 
stress and promoting healthy aging. These data suggest that Acyl-Ghrelin may be a 
potential new therapeutic target for PD. 
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1.0. Chapter 1: Introduction    
1.1. Parkinson’s Disease 
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder 
worldwide, following Alzheimer’s disease. PD patients experience debilitating 
progressive motor and cognitive decline. PD itself is not a direct cause of mortality, 
however, it results in life-threatening complications such as pneumonia or severe 
swallowing difficulties (Bertram & Tanzi, 2005). In the later stages of PD, patients 
require full-time care. PD is usually diagnosed in the mid to late stages of life (over 
~60 years) although there is exception in rare cases of early onset PD (Van Den 
Eeden et al., 2003). Prevalence of PD is likely to parallel the increase in average age 
of the population. According to research carried out by Parkinson’s UK: 1 in every 500 
person has Parkinson's (roughly 127,000 in the UK) and by 2020 the number of 
people with Parkinson's in the UK is set to rise by 28% (Parkinson’s UK). This 
predicted increase in PD prevalence establishes PD as a major disease with unmet 
clinical need that will pose increasing pressure on healthcare sectors. 
 
PD is characterised by the progressive degradation of dopaminergic neurones 
(catecholamine sub-group A9) that project to the dorsal striatum from the substantia 
nigra (SN) pars compacta (pc) region of the midbrain (Bjorklund & Dunnett, 2007). 
The pathway between the SN and striatum is part of the basal ganglia motor loop. 
Striatal function in this pathway is to regulate controlled movement (Stocco, Lebiere, 
& Anderson, 2010). The progressive death of SNpc dopamine (DA) neurones results 
in decreased release of the neurotransmitter, DA, in the striatum and decreased DA 
turnover rate. Disruption of the nigrostriatal pathway results in motor control 
dysfunction. PD patients also suffer non-motor symptoms i.e. cognitive decline, loss 
of appetite, smell, weight, and reduced gastric motility/emptying (Faulkner, 2014). 
Typically, PD sufferers remain mostly asymptomatic prior to the death of ~60-70% of 
SN DA cells (Schapira, 2007). The severity and time of onset of symptoms in PD 
varies between individuals, however end-stage PD results in a vegetative state (Van 
Den Eeden, et al., 2003).  
The neuropathology of PD is not restricted to SN A9 DA cells (Bjorklund & Dunnett, 
2007). Cellular dysfunction and abnormalities have been found in various other DA 
and non-DA cell groups (Dauer & Przedborski, 2003). Besides progressive cell death, 
another key hallmark of PD is the accumulation of intracellular proteinaceous 
inclusions (which are partly composed of α-synuclein) named Lewy Bodies (LBs) that 
deter normal cellular function (Bove, Prou, Perier, & Przedborski, 2005).  Alpha-
17 
 
synuclein is a 140-amino acid long protein coded for by the gene SNCA. Since alpha-
synuclein does not possess a defined structure in aqueous, it is called a “natively 
unfolded protein”. However, this protein can form alpha-helical structures upon 
interaction with the negatively charged lipids of the phospholipid cell membrane. Beta-
sheet-rich structures may also form under these conditions with prolonged incubation 
times. Alpha-synuclein is composed of 3 main domains. The first is a 60-residue long 
apolipoprotein inclusive of lipid-binding motifs which are thought to form amphiphilic 
helices that form alpha helical structures upon binding to the cell membrane.  
Secondly, a central hydrophobic region spanning residues 61 to 95. This region has 
been termed non-Aβ component (NAC) which is thought to contribute to formation of 
beta-sheets. The third distinct domain is a negatively charged carboxyl terminus that 
is prone to an unstructured form. Alternative splicing results in at least 2 shorter alpha-
synuclein variants of the SNCA gene transcript. However, the exact roles in normal 
physiology and detrimental pathological roles are yet to be fully elucidated. In addition, 
there are at least two shorter alternatively spliced variants of the SNCA gene transcript 
that have not been well characterized (Maroteaux, Campanelli, & Scheller, 1988; 
Maroteaux & Scheller, 1991; Ueda et al., 1993). 
As the death of dopaminergic neurons (TH+) due to apoptosis, mitochondrial 
dysfunction, and/or oxidative stress are well-established causes of PD and underlie 
its characteristic symptoms (Albarran-Zeckler, Sun, & Smith, 2011; Fedorow et al., 
2005; German & Manaye, 1993) this project will focus on examining the A8, A9 & A10 
DA neurones of the SN. The DA neurones in this region project towards many other 
regions including striatum, globus pallidus, and subthalamic nucleus of the basal 
ganglia, playing an integral role in regulating motor function in the central nervous 
system (CNS) (Bjorklund & Dunnett, 2007). 
 
The cause of PD is unknown. However currently identified PD-associated genes (see 
table 1) are thought to account for ~5% of cases (Pirkevi, Lesage, Brice, & Basak, 
2009). Identification and study of PD-associated genes is a means of (1) increasing 
risk prediction and (2) delineating possible defects in cellular pathways that may 
contribute to non-familial PD pathology. Many genetic targets have been uncovered 
with potential PD pathology-associated effects (see table 1. for some PD-associated 
genes).  
 
Mutations found in PD-genes appear to either: (1) alter pathways affecting 
mitochondrial function (Valente et al., 2004), (2) lead to protein accumulations (i.e. 
alpha-synuclein and protein tangle deposits) (Olanow & Brundin, 2013) or (3) promote 
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a dysfunctional clearance of damaged/unnecessary protein inclusions and cellular 
organelles (e.g. dysfunctional mitochondria) in autophagy/mitophagy (Kanki et al., 
2009). Mitochondrial function and clearance of damaged organelles is essential to 
maintain cellular integrity. Therefore, such genetic mutations may contribute to 
pathogenic pathways that effect mitochondrial activity, increase oxidative stress and 
impair proteasome function resulting in neuronal death (Bayliss & Andrews, 2013). 
Collectively, it is evident that mitochondrial bioenergetics, function and metabolism is 
a key area of interest in uncovering pathways in PD pathology (Hardy, 2010). 
 
 
 
This illustration shows the catecholaminergic biosynthesis pathway. Names of the 
catecholamine products are shown in red; names of the enzymes involved in the 
enzymatic conversions between products are shown in blue 
 
 
 
 
Figure 1: Catecholamine Biosynthesis Pathway.  
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1.2. Current PD Therapy 
Current therapies aim to replenish lost DA. Levodopa (L-DOPA) is a molecular pre-
cursor for DA and is currently the most common and effective drug given to PD 
sufferers (see figure 2 for L-DOPA mode of action). This treatment is often 
supplemented with other drugs to increase L-DOPA efficacy. (See table 2 for more 
details on PD drugs and their side-effects). L-DOPA treatment is not effective in ~50% 
of patients and the majority of patients develop debilitating side effects termed L-
DOPA induced dyskinesia’s (LIDS) after prolonged use.  However, there are no 
therapeutics in use to attenuate the dopaminergic cell death which lies at the heart of 
PD. 
 
In light of this, current research showed that the orexigenic stomach hormone, ghrelin 
exerts neuroprotection in a mouse model of PD (Andrews, 2011). Further studies 
show that these effects are at least partially mediated via an un-coupling protein 2 
(UCP-2) dependent pathway following ghrelin receptor agonization (Andrews, 2011); 
(Andrews et al., 2009).These findings have fuelled intense interest in understanding 
the molecular mechanisms underpinning ghrelin receptor involvement in 
neuroprotection. The utilization of ghrelin and other ghrelin receptor agonists as novel 
neurodegenerative disease therapeutics may hold the key to attenuating the 
progressive dopaminergic cell death displayed in PD. 
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The most common current PD treatment, which is orally administrated dopamine-
replacement therapy using dopamine precursor molecule dihydroxyphenylalanine (L-
DOPA). L-DOPA is the immediate precursor molecule to dopamine (DA) (see figure 
1). Unlike dopamine, L-DOPA can transverse the blood brain barrier and is utilised in 
the catecholamine biosynthesis pathway at the terminals of nigrostriatal dopaminergic 
nerones. Decarboxylation of L-DOPA by DOPA Decarboxylase (DDC) produces DA. 
DA is stored in synaptic vesicles before its release into the synaptic cleft (space 
between vesicles). This acts to replenish decreased midbrain DA levels and normalise 
motor function associated with DA depletion (Jenner & Rose, 1974).  This treatment 
strategy is only effective in ~50% of patients, and the treatment itself has a short time 
of efficacy (~5 years) before increased doses are required. Short-term side effects 
include nausea and vomiting. In addition, Levodopa-induced dyskensias 
(uncontrollable, involuntary movements) arise following prolonged use (~5-10 years) 
of L-DOPA based treatments, resulting in progressive debilitating side-effects over 
time (Udd et al., 2017). Vesicular Monoamine Transporter 2 (VMAT2) is an integral 
membrane protein which transports monoamine neurotransmitters such as dopamine 
within synaptic terminals. (See table 2 for an overview of other PD drugs and side 
effects) 
 
Figure 2: Current PD Treatment.  
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Table 1: Overview of PD-Associated Genes and Roles in Pathology 
Gene Gene 
locus 
Mutation  Inheritance: 
Autosomal-
Dominant (AD) 
or Autosomal-
Recessive (AR) 
Clinical features in 
PD 
Gene mutations 
contribution to 
PD pathology 
Lewy 
bodies 
α-synuclein 
(SNCA) 
4q21 Park 1 / 4 AD Typical PD but 
sometimes have 
dementia 
presentation. 
Onset/age 40s 
SNCA encodes 
for alpha 
synuclein protein. 
A large 
component of 
degradable 
protein deposits. 
Leads to protein 
accumulation & 
LBs  
Yes 
Parkin 6q25 Park 2 AR Presents itself very 
slowly and 
progressively at an 
early age of onset 
(early onset-PD) 
with sleep 
benefit.Onset/age 
20s 
Gene encodes a 
component of 
ubiquitin ligase 
associated with z 
region of the 
ligase 
proteasome 
system – playing 
a role in recycling 
of unneeded 
cellular 
components. 
No 
PINK1 1p35 Park 6 AR Usually very slow 
progressive early 
onset disease 
usually with sleep 
benefit. Onset/ age 
30s 
One case with 
LBs. 
? 
DJ-1 1p36 Park 7 AR Onset/age 30s Little data-similar 
to Parkin. 
DJ-1 is thought to 
protect cell from 
oxidative stress. 
? 
Leucine 
rich repeat 
kinase 2 
(LRRK2) 
12p Park 8 AD Typical PD Encodes for 
protein in 
cytoplasmic 
protein ‘Dardarin’. 
This protein also 
associates itself 
with mitochondrial 
membranes. 
Mutations 
associated with 
macro-autophagy 
dysfunction. 
 
Usually LBs, 
sometime protein 
tangles. Rare 
cases of no 
protein 
accumulation. 
Yes/No 
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1.3. Ghrelin 
Ghrelin was discovered in 1999 by Kojima et al following the earlier discovery of a 
growth hormone secreting receptor, the growth hormone secretagogue receptor 
(GHS-R) (Smith et al., 1999). Ghrelin is a circulating 28-amino acid acylated hormone 
discovered by reverse pharmacology as the endogenous ligand for the GHS-R 
(Kojima et al., 1999). Since its discovery, research has highlighted the complexity of 
ghrelin’s roles in a multiplicity of biological functions mediating endo/para and 
autocrine actions on a variety of tissues. Ghrelin is predominantly produced in the 
stomach and is regulated by feeding. Circulating levels of ghrelin are increased under 
calorie restriction and decrease following feeding (Andrews, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
Table 2: Overview of Current PD Drug Treatment and Side Effects 
PD Therapy Action in PD Patient Side effects 
Levodopa Orally administered drug (often co-
administered with benserazide or 
carbidopa to ensure efficient dose if L-
dopa crosses blood-brain barrier). As 
an input to the catecholamine 
biosynthesis pathway, L-dopa is 
converted to dopamine, increasing 
dopamine concentration in the brain, 
thus alleviating motor dysfunction. 
 
Usually administered after the efficacy 
of catechol-O-methyl transferase 
(COMT) and monoamine oxidase 
(MAO-B) inhibitors are decreased.  
 
Short term use can lead to nausea and 
vomiting as body adjusts to the drug. 
 
Long term use of levodopa results in 
uncontrolled/involuntary movement termed 
dyskinesia. 
 
As DA neurone death progresses, the drug’s 
effect decreases and dosage must be 
increased incrementally.  
COMT 
inhibitors 
Orally administered. 
 
Act primarily on the intestine to reduce 
breakdown of levodopa in the periphery 
and enhance its penetration into the 
central nervous system. 
 
Dose of levodopa can be decreased if 
used in conjunction with COMT 
inhibitors. 
May increase side effects caused by 
levodopa (dyskinesia). 
 
Other reported side effects include 
abdominal pain, diarrhoea and discoloured 
urine. 
 
(https://www.parkinsons.org.uk/information-
and-support/comt-inhibitors) 
 
MAO-B 
inhibitors 
Orally administered.  
 
MAO-A and MAO-B metabolise 
synaptic DA by auto-oxidation. MAO 
inhibitors increase synaptic DA half-life 
and degree of DA re-uptake by pre-
synaptic terminals by reducing synaptic 
DA breakdown. 
When taken with levodopa, side effects such 
as dyskinesia, hallucinations or vivid 
dreaming may sometimes occur or worsen. 
 
When taken without levodopa, most 
common side effects include: headache, 
aching joints, flu-like symptoms and 
depression. 
 
Not to be taken with some anti-depressants 
as some drug-drug interactions result in 
increased blood pressure 
 
(https://www.parkinsons.org.uk/information-
and-support/mao-b-inhibitors)  
Dopamine 
receptor 
agonists 
Orally administered. Drug is absorbed 
and crosses blood-brain barrier in order 
to activate dopamine receptors (D1, D2 
& D3 receptors). Drug dose must be 
increased incrementally according to 
drug efficacy. 
Common side effects include: 
Nausea and vomiting, headache, 
constipation, drowsiness and sudden onset 
of sleepiness. 
 
Dizziness or fainting due to low blood 
pressure. 
 
Pathological gambling and punting 
 
Delusions or hallucinations and confusion. 
Existing dyskinesia becoming more troubling 
initially 
 
(https://www.parkinsons.org.uk/information-
and-support/dopamine-agonists   
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Ghrelin is produced in ghrelinergic cells of the gastrointestinal tract and is the product 
of proteolytic cleavage and posttranslational modification/acylation of inactive 
preproghrelin (Andrews, 2011; Kojima, et al., 1999; Korbonits et al., 2002). Ghrelin is 
produced by X/A cells in the stomach at times of negative energy balance where it is 
post-transcriptionally modified to Acyl-Ghrelin by enzymatic activity of ghrelin-o-
acyltransferase (GOAT) which catalysed the addition of an acyl side chain to the 
nascent ghrelin peptide at serine 3 (Kojima, Hamamoto, & Sato, 2016; Kojima, et al., 
1999). In humans this inactive peptide is coded by a single copy gene located of the 
short (p) arm of chromosome 3, GHRL (Gahete et al., 2014), which is detailed in 
(Figure 3). Transcription of GHRL produces a 117-amino acid nascent product 
containing an N-terminus signal peptide (23-amino acids) and pro-ghrelin peptide (94-
amino acids). Transcribed mRNA sequence is ribosomally translated on the rough 
endoplasmic reticulum (RER) surface. Signal peptides are identified by signal 
recognition particles (SRPs) associated with the RER. Translation of nascent peptide 
is then momentarily retarded until SRP docks at the ER membrane-bound SRP 
receptor. Co-translational translocation then resumes, and the peptide is fed through 
RER translocon (sec61 translocation complex, in eukaryotes) into the ER lumen. 
Preproghrelin signal peptide is then cleaved in the ER lumen, producing proghrelin. 
Here proghrelin is post-translationally modified by an integral membrane protein, 
ghrelin o-acyl transferase (GOAT) (Gutierrez et al., 2008). Un-acylated ghrelin (UAG) 
is also a product of the GHRL gene. This ghrelin isoform accounts for ~90% of 
circulating ghrelin - however its physiological role and receptor is yet to be elucidated 
(Andrews, 2011; Delhanty, van der Eerden, & van Leeuwen, 2014; Gahete, et al., 
2014). 
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This is an overview of the human ghrelin (GHRL) gene structure and gene-derived 
variants (UAG, AG and Obestatin), transcripts and putative peptides. Signal peptide 
(SP) is shown in green, ghrelin in grey, obestatin in blue and C-peptides in yellow. 
This figure was modified from (Gahete, et al., 2014).  
 
 
 
 
 
 
 
 
 
Figure 3: Overview of Human Ghrelin Gene Structure and Variants 
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1.4. Ghrelin O-Acyl Transferase (GOAT) 
The human GOAT gene, MBOAT4, is located on chromosome 8p12 (Gutierrez, et al., 
2008). GOAT is expressed in a variety of human tissues including pancreas, skeletal 
muscle, heart, intestine, bone and predominantly in the stomach - specifically the 
ghrelin-containing oxyntic cells of the gastric mucosa (Bayliss & Andrews, 2013). Here 
there is extensive expression of GOAT mRNA and protein (Gahete, et al., 2014; 
Muller et al., 2011). 
Within the vertebrate subphylum the amino acid sequence of GOAT is highly 
conserved, much like ghrelin (~90% in the case of GOAT). This high homology is 
substantiated in rat and mouse GOATs ability to catalyse the acylation of human 
ghrelin. Also, a strong homology exists between rat and human ghrelin as their 
peptide sequences only differ by 2 amino acids (Date et al., 2000).  
 
The enzyme product of MBOAT4 utilizes fatty acids as acyl-CoA donors to catalyse 
the addition of octanoic acid to the N-terminal ser3 residue of pro-ghrelin. Once 
acylated, ghrelin is often referred to as acyl-ghrelin (AG) (Kojima, et al., 1999). 
Acylation of Ser3 is essential for the activation of the GHS-R type 1a (GHS-R1a). The 
5 N-terminus ghrelin amino acids [Glycine]-[Serine]-[acyl-Serine]-[phenylalanine]-
[Leucine] are the minimal requirement for GHS-R1a activation (Date, et al., 2000). 
 
 
1.5. Growth Hormone Secretagogue Receptor (GHS-R) 
GHS-R1a receptors are primarily expressed in β-cells of pancreatic islets, distinct 
areas of the hypothalamus (known to play roles in body weight and food intake), 
pituitary somatotrophs, hippocampus, the ventral tegmental area (VTA), the dorsal 
raphe nucleus, all three components of the dorsal vagal complex and the substantia 
nigra (SN)  (Albarran-Zeckler, et al., 2011) (Zigman, Jones, Lee, Saper, & Elmquist, 
2006)  
In humans, as well as in rats and mice, there are two identified GHS-R receptor sub-
types (GHS-R1a and GHS-R1b), both of which are products of alternative splicing of 
a single-copy gene located on chromosome 3q26.31. The GHSR gene was first 
cloned from human pituitary glands and hypothalamus in 1996 (Howard et al., 1996). 
The sequence is highly conserved throughout many vertebrate species including 
humans, chimpanzees, mice and rats, swine and cows (H. J. Wang et al., 2004). 
GHS-R1a mRNA includes exon 1 and 2 of the GHSR gene, encoding a 366 amino 
acid long 7 transmembrane (TM) G-protein coupled receptor (GPCR). GHS-R1b 
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mRNA is produced by the retention of intron 1 separating exon 1 and 2. This mRNA 
product produces a 289-amino acid long 5TM GPCR isoform (Gahete, et al., 2014). 
Interestingly, codons 1-265 are identical in both isoforms. However, sequence 
variation between subtype 1a and 1b exists at a 24-amino acid sequence at the C-
terminus. In GHS-R1b, the 24 amino acids following 265Leu are encoded by the intron 
of GHS-R1a (Camina, 2006; H. J. Wang, et al., 2004)  
 
On-going research is yet to elucidate the function of the C-terminal truncated GHS-
R1b and whether GHS-R1b encodes a functional protein or not. (Gahete, et al., 2014; 
Gnanapavan et al., 2002).  The GHS-R1b gene is expressed in various tissues, so it 
is possible that GHS-R1b’s function is yet to be elucidated. Moreover, some studies 
show that GHSR1b acts as a dominant negative mutant of the ghrelin receptor(Leung 
et al., 2007). When over-expressed in HEK-293 cells it decreases the constitutive 
activity of GHS-R1a. Indicating that GHS-R1b may act as an endogenous modulator 
for GHS-R1a constitutive activity (Chu et al., 2007; Yin, Li, & Zhang, 2014). 
 
1.6. Hypothalamic and Extra-Hypothalamic Functions of Ghrelin  
The role of AG, which is secreted from the stomach into the circulation, is a hot topic 
in endocrine and neuro-molecular studies (Bayliss & Andrews, 2013; H. J. Wang, et 
al., 2004). The ghrelin-GHS-R1a axis modulates and influences an array of complex 
biological functions relating to energy homeostasis, including adiposity and 
gastrointestinal mobility (Bayliss & Andrews, 2013; Engel & Jerlhag, 2014). Binding 
of AG to hypothalamic and pituitary gland GHS-R1a stimulates food intake and growth 
hormone release, respectively, in order to regulate energy homeostasis and body 
weight (Andrews, 2011). GHS-R1a is responsible for the signal transduction of natural 
‘active’ AG and various synthetic growth hormone secretagogues (GHSs) (Andrews, 
2011; Gahete, et al., 2014; Moulin et al., 2007). The G-proteins, Gi/o, are associated 
with GHS-R1a. Once a ligand has bound to the receptor the heterotrimeric G proteins 
(Gα, β, and γ subunits) dissociate, leaving a free Gα subunit and a βγ complex 
(Niswender et al., 2008).  Hypothalamic expression of GHS-R1a is important in the 
ghrelin-GHS-R1a axis in metabolic homeostasis as it stimulates the orexigenic 
neuropeptide-Y and agouti gene-related protein NPY/AgRP neurones to induce 
feeding (Cowley et al., 2003).  Ghrelin activation of GHS-R1a mediates an increase 
in [Ca2+] and downstream signalling pathways: (1) mitogen-activated protein kinase 
(Waseem, Duxbury, Ashley, & Robinson, 2014); (2) Phosphoinositide 3-kinase / 
Protein kinase 3 (PI3K/Akt) (Waseem, et al., 2014; Yin, et al., 2014); (3) nitric oxide 
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synthase (Slomiany & Slomiany, 2014); (4) AMP Activated Protein Kinase (AMPK) 
cascades (Andersson et al., 2004) and (5) mechanistic target of rapamycin (mTOR) 
signalling in a multiplicity of cellular systems (Pazos, Casanueva, & Camina, 2008; 
Yin, et al., 2014).  
 
Recently, the role of ghrelin in extra-hypothalamic brain regions has generated 
significant research interest. This is substantiated by the growth in evidence for 
ghrelin’s role(s) in neuronal function and association with learning and memory 
(Carlini et al., 2010; Diano et al., 2006), reward and motivation (Menzies, Skibicka, 
Leng, & Dickson, 2013) and neuroprotection (Andrews, et al., 2009). Further studies 
are necessary to elucidate the potential neuroprotective properties of ghrelin and its 
therapeutic implications in PD. 
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(a) This is a schematic of ghrelin’s appetite regulating effects via activation of 
neuropeptide-Y (NPY) neurons in the hypothalamic arcuate nucleus. Ghrelin and 
other GHS-R agonists bind to GHS-R1a on orexigenic NPY neurons and increase 
appetite and fat mass. NPY neurons are also sensitive to both leptin and insulin. (b) 
This diagram shows the sequence of 28 amino acids of ghrelin (in their abbreviated 
form) and lists ghrelin’s hypothalamic and extra-hypothalamic roles. 
 
 
 
 
Figure 4: Hypothalamic and Extra-Hypothalamic Roles of Ghrelin.  
 
30 
 
1.7. PD Toxin Models 
Little is known about the initial cause and progression of PD (Bove, et al., 2005). 
However, over the last 20 years information regarding PD pathophysiology has been 
brought to light thanks to many clinical trials, autopsy investigations and in-vitro / in-
vivo pre-clinical models of PD (Dauer & Przedborski, 2003). Nonetheless there are 
significant limitations to our understanding of PD at cellular and molecular levels. 
Consequently, due to the reproducibility of cell specific cytotoxicity, in-vitro and in-vivo 
neurotoxin-based PD models are well-established tools for investigating the 
underpinning molecular mechanisms of cell death in PD. 
Common neurotoxins used to model neurone loss in PD are (1-methyl-4-phenyl-1, 2, 
3, 6-tetrahydropyridine (MPTP), 6-hydroxydopamine, paraquat and rotenone (Dauer 
& Przedborski, 2003). Due to reproducibility and reliability in previous experiments 
(Beynon et al., 2013), we have chosen to use rotenone in order to simulate DA cell 
death in-vitro. See figure 5 for detail on rotenone’s mode of action. 
 
The lipophilic nature of Rotenone allows ease of access into tissue, organelle and 
cellular membranes. Rotenone is utilized in in-vivo mouse models of PD. Rotenone is 
an inhibitor of the electron transport system’s complex 1 (NADH Dehydrogenase). 
Inhibition of electron transfer from NADH ubiquinone in complex 1 of the electron 
complex system causes a build-up of electrons in mitochondrial inter-membrane 
space. This results in the reduction of molecular oxygen and subsequent formation of 
radical species (i.e. 02 → 02-). Reactive oxygen species may damage DNA and other 
mitochondrial components (Mehta & Li, 2009). 
 
 
Figure 5: Complex 1 Inhibitor Rotenone as a Neurotoxin.  
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In-vivo rat studies investigating rotenone neurotoxicity show that midbrain neurones 
are particularly sensitive to rotenone-induced cell toxicity (Choi, Palmiter, & Xia, 
2011). Exposure to Rotenone has been proven to cause highly selective nigrostriatal 
dopaminergic lesions in animals (Sherer, Kim, Betarbet, & Greenamyre, 2003). Rats 
challenged with rotenone displayed a significant increase in the gene expression of 
cytoplasmic pro-inflammatory cytokine allograft inflammatory factor 1 (AIF-1) and the 
pro-apoptotic caspase-3, as well as a decrease in midbrain TH levels. Suggesting that 
rotenone-neurotoxicity is mediated via microglial activation and apoptosis (Swarnkar 
et al., 2013). Moreover, previous findings from our group show that this mitochondrial 
toxin exerts a dose-dependent increase in cell death on midbrain derived cell line 
(SN4741) in-vitro. 
 
Literature has already described acyl-ghrelin (AG) as a potential neuroprotection 
agent in 1-methyl-4-phenyl-1,2,5,6 tetrahydropyridine (MPTP) models of PD. Studies 
have suggested that ghrelin induces an enhancement of uncoupling protein 2 (UCP-
2) dependent mitochondrial respiration and proliferation. This results in a bioenergetic 
status which makes DAergic neurons more resistant to cellular stress, suggesting that 
UCP-2 has a key role in AG-induced neuroprotection in MPTP models (Andrews, et 
al., 2009). (Bayliss, Lemus, Stark, et al., 2016) found that AG mediates the 
neuroprotective capability of calorie restriction by attenuating the effects induced by 
MPTP, such as loss of TH neurons, TH neuronal volume and dopamine content in the 
striatum.  It is also found that AMPK in SN dopamine neurons is a molecular target 
for the neuroprotective effects of AG (Bayliss, Lemus, Stark, et al., 2016). It is 
concluded that acyl ghrelin, and its target AMPK, can produce the neuroprotective 
effects of calorie restriction without the need for severe dietary control.  This implicates 
AG-AMPK signalling as having therapeutic applications in the treatment of PD 
(Bayliss, Lemus, Stark, et al., 2016).  
The AG-mediated neuroprotection is paralleled with MPTP in-vitro MPTP models of 
PD. Published work shows that MPTP-induced neurotoxicity via anti-oxidation in 
MES23.5 cells is attenuated by AG.  This study by (L. Liu et al., 2010) shows that 
these MTPT-induced effects are abolished in cells treated with AG (L. Liu, et al., 
2010). MPTP has also been proven to cause upregulation and aggregation of α-
synuclein, a major constituent in Lewy bodies (Bezard, Yue, Kirik, & Spillantini, 2013). 
Despite these findings, MPTP does have its limitations.  It is well known that MPTP 
induces multi-systemic lesions, despite being presented as specific to DAergic neuron 
it has been shown to attack all three types of catecholaminergic cell as well as the 
brain stem, spinal cord and the enteric nervous system (Bezard, et al., 2013). These 
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limitations highlight the need for the testing of AG in other PD models. One such 
model is the very well-established 6-hydroxydopamine (6-OHDA) model, which also 
has the added benefit of assessing sensorimotor function (Simola, Morelli, & Carta, 
2007). The effectiveness of AG as a neuroprotector in the 6-OHDA model is not widely 
studied in the literature and any such testing is novel and innovative in nature.  This 
would contribute knowledge to wider field of PD study. 
 
1.8. Proposed Neuroprotective Mechanism of Ghrelin 
Studies to date have delineated the stomach hormone ghrelin as a promoter of DA 
neurone survival via reduced microglial (M. Moon et al., 2009) and caspase activation 
and improved mitochondrial function (Andrews, et al., 2009). Mitochondrial 
dysfunction results in decrease ATP synthesis, increased reactive oxygen species 
(ROS) production that can result in damage to other cellular components (lipids, 
proteins etc.), ultimately leading to neuronal dysfunction and death. Mitochondrial 
dysfunction is a prominent feature in PD (Winklhofer & Haass, 2010) and therefore 
enhancing or restoring mitochondrial function may represent a potential therapeutic 
option. See figure 6 for schematic and brief description of ghrelin’s proposed 
neuroprotective mechanism- modified from (Andrews, 2011). 
In order for a neuroprotective therapeutic to be of use to a patient it must be able to 
cross the blood brain barrier (BBB). Endogenous UAG and AG readily passes through 
the BBB (Banks, 2012), raising the possibility of UAG acylation at region specific sites 
in the brain. Recent studies using exogenous small-molecule ghrelin receptor 
agonists have shown that non-peptide agonists also pass this barrier- possibly 
offering a new approach to treat CNS diseases (Atcha et al., 2009). 
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Whilst both AG and UAG demonstrate DA cell protection in-vitro by upregulating 
ERK1/2, AKt1/2, PI3K and PKC, the proposed neuroprotective mechanisms for UAG 
remains unknown (Andrews, et al., 2009). However, it is well documented both in-vivo 
and in-vitro that AG mediates its neuroprotective actions in a UCP2 dependant 
manner via GHSR1a. Binding of receptor agonists, AG, results in the activation of 
kinase signalling pathways (Albarran-Zeckler, et al., 2011; Andrews, et al., 2009). 
Evidence from MPTP PD models suggests that AG attenuates neurodegeneration by 
synergistically restricting DA cell loss; regulating intracellular apoptotic modulators 
Bcl-2 and Bax; inhibition of microglial activation and reduction of their pro-
inflammatory markers Tumour Necrosis Factor α (TNF-α), interleukin-6 (IL-6) and 
interleukin-1β (IL-1β) and upregulation of mitochondrial UCP-2 which buffers reactive 
oxygen species (ROS) (Andrews, et al., 2009). Excessive ROS production may initiate 
apoptosis via apoptosis regulating proteins, such as Bcl-2 family of proteins. The 
many roles of these proteins include the regulation of the osmotic potential of the 
mitochondrial membrane.  One such protein is Bax. Upon activation Bax oligomerizes 
in the outer mitochondrial membrane. This Bax oligomerisation leads to depolarization 
of the mitochondrial membrane potential and release of cytochrome C, the final 
enzyme of the electron transport chain, from the inter-membrane space- which can 
occur as a result of excessive ROS production. This is achieved by the formation of 
membrane spanning pores in the mitochondrial outer membrane or by interaction with 
Figure 6: Ghrelin's Proposed Neuroprotective Mechanisms.  
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the mitochondria’s pore-forming proteins which allow cytochrome C, which is usually 
associated with the inner membrane of the mitochondria, to flow out. Upon release, 
cytochrome C, it binds to cytosolic Apoptosis protease activating factor-1 (Apaf-1), 
thus driving  formation of the apoptosome and apoptosis via caspase pathways 
(Elmore, 2007). Activation of GHSR1a is thought to inhibit this pro-apoptotic pathway 
by reducing ROS production in a UCP-2 dependant manner (Andrews, et al., 2009). 
This figure is a modified version of ghrelin’s neuroprotective mechanisms from 
(Andrews, 2011). 
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Evidence suggests that ghrelin is neuroprotective in several pre-clinical models. 
However, key questions remain to be answered. For example, 1) does AG exert 
neuroprotective effects on SNpc neurones by direct binding to cell surface receptors? 
2) does AG mediated neuroprotection require other molecular triggers (e.g. Growth 
Hormone, Insulin-like Growth Factor-I) to mediate its effects? 3) Is GHS-R expressed 
on particular DA cell phenotypes within the SN? E.g. the A9 subset which express the 
G-protein-activated inwardly rectifying potassium 2 (Girk2) channel or the A10 subset 
that express calbindin – these markers are used to distinguish between the DA 
neurones of the SN and VTA , respectively (Bjorklund & Dunnett, 2007).  
 
1.9. Hypothesis 
Published studies suggest that AG-based therapies may prevent or slow the 
progression of PD. I will test the hypothesis that AG and novel synthetic GHS-R 
agonists provide direct protection to DA neurones in toxin-based models of PD. 
 
1.10. Aims/objectives:  
We will; 
1) Characterize GHS-R expression in dopaminergic nerve cells of the SNpc 
2) Determine whether AG and a novel GHS-R agonist directly protect DA neurones 
in in-vitro toxin PD model using SN4741 mouse cell line.  
3) Determine whether elevated AG, either directly (infusion) or indirectly (restricted 
feeding), protects SNpc DA neurones and motor function in the rat unilateral 6-OHDA 
MFB-lesion model of PD. 
4) Characterise cellular signalling pathways underlying AG-mediated neuroprotection. 
5) Develop a computer protocol for high-throughput analysis of cellular organelle form 
and function. 
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2.0. Chapter 2: Characterization of Rodent Midbrain 
and SN4741 Midbrain Derived Cell Line.  
2.1. Introduction 
Growing literature supports the neuroprotective effects of acyl-ghrelin (AG) in vivo 
disease models, however the exact mechanism of action observed remains elusive 
(Andrews, 2011). Both AG and unacylated-ghrelin (UAG) levels are increased during 
hunger and peaks prior to meal initiation (Bayliss, Lemus, Santos, et al., 2016) but 
AG is termed the ‘active’ form of ghrelin as it stimulates the release of growth hormone 
from the pituitary gland when bound to its endogenous receptor, the Growth Hormone 
Secretagogue Receptor Type-1a (GHSR1a) (Kojima, et al., 1999). The enzymes 
modulating the acylation status of ghrelin (GOAT in the endoplasmic reticulum and 
Acyl-Protein-Thioesterase-1 (APT-1) in plasma) play a pivotal role in determining the 
ratio of circulating AG to UAG (Satou, Nishi, Yoh, Hattori, & Sugimoto, 2010). If acyl-
ghrelin binding to GHSR1a is the initiator of sub-cellular events leading to the 
neuroprotection observed in models of PD (Bayliss, Lemus, Santos, et al., 2016), then 
the AG-GHSR1a axis and its acylation/de-acylation enzymes represent putative 
therapeutic targets to explore within the mammal midbrain, more specifically the 
SNpc. As defining the localization of GOAT and APT-1 in mammal midbrain neurons 
may enhance our understanding of ghrelin’s acylation and de-acylation dynamics in 
an area of the brain strongly associated with PD pathology. 
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 Acylation and De-Acylation Enzymes GOAT and APT-1. Schematic of ghrelin 
acylation and de-acylation cycle. An acyl side-chain [O-CO-(CH2)6CH3] is attached 
enzymatically to the third amino acid of the ghrelin peptide (Serine) to form AG, a 
ligand for GHSR1a. The acyl side-chain of AG may be enzymatically cleaved via APT-
1/LYPLA1, forming UAG, a ghrelin peptide incapable of agonising GHSR1a. 
 
 
This chapter will investigate the expression of key ghrelin axis proteins, GOAT and 
APT-1 in the rat midbrain. To further the characterisation of ghrelin axis proteins we 
will also investigate the expression of GHSR1a on TH+ and Girk2+ neurones of the 
mouse SNpc. We will also characterize a mouse midbrain-derived neuronal cell line, 
SN4741, to validate whether these cells are an appropriate choice of cells to develop 
an in vitro PD model. We aim to utilise this in vitro PD model to test for direct 
neuroprotective effects of AG and other GHSR1a agonists against neurotoxin-
mediated cell loss.   
 
 
 
Figure 7: Acylation and De-Acylation Enzymes GOAT and APT-1 
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2.1.1. Girk2 and Calbindin as Markers of Midbrain Dopaminergic 
Sub-Types 
Published work shows a strong expression of the G protein-gated inwardly rectifying 
potassium channel 2 (GIRK2) (a member of an ion channel family involved in the 
regulation of neuronal activity (Kobayashi & Ikeda, 2006; Reyes et al., 2012) in the 
dorsal and ventral TH+ neurones of the SNpc and VTA of rodent midbrain (Eulitz, 
Pruss, Derst, & Veh, 2007; Fu et al., 2012). This expression is also observed in the 
majority of human TH+ neurones in the SNpc and VTA (Reyes, et al., 2012). Many 
previous studies use GIRK2 expression to distinguish between the dorsal and ventral 
tier of SNpc TH+ neurones (Thompson, Barraud, Andersson, Kirik, & Bjorklund, 2005). 
However, other studies find no significant difference in GIRK2 expression in both 
ventral and dorsal tier of human DA neurones (Reyes, et al., 2012). Another DA 
neurone subtype predominating in the midbrain is the A10 subtype. Classically the 
calcium binding protein, calbindin, is used to classify A10 subtype of DA neurones 
which predominate in the VTA (J. H. Rogers, 1992) (Damier, Hirsch, Agid, & Graybiel, 
1999a; Liang, Sinton, & German, 1996; McRitchie, Hardman, & Halliday, 1996) versus 
the A9 subtype predominating the SNpc of rodent and humans (Schein, Hunter, & 
Roffler-Tarlov, 1998).  
Some literature proposes (Luscher & Slesinger, 2010; Rajesh & Kelly, 2007) that the 
Girk2+ A9 subtype of DA neurones of the SNpc may possess a higher vulnerability to 
degeneration and are therefore preferentially lost in PD. This hypothesis was 
suggested as a result of early SNpc neurone degeneration observed in Weaver mice 
containing a Girk2 mutation. However, an accepted explanation of this observation 
has yet to be provided. Furthermore, a previous small study of familial and sporadic 
PD cases showed no mutation in the pore forming H5 region of Girk2 (Rajesh & Kelly, 
2007). 
Whether the presence of Girk2 protein contributes to the susceptibility of SNpc DA 
neurone degeneration in PD or not; TH+ neurones in the SNpc show higher Girk2 
immunoreactivity and mRNA levels in comparison to VTA (Chung et al., 2005; Fu, et 
al., 2012). Therefore, characterizing the SN4741 cell line for Girk2 and TH expression 
is fundamental in verifying, at least to some extent, the SN4741 cells as an 
appropriate cell line to model the neurodegeneration (cell loss) observed in the SNpc 
in PD. To assess the direct effects of AG or AG-mimetics in an in-vitro setting the 
endogenous ghrelin receptor should be expressed on the SN4741 cell line. The 
expression of GHSR1a on the TH+ (and Girk2+) neurones of the rodent SNpc and the 
40 
 
SN4741 cells would present some transferability between in vitro and in/ex-vivo 
studies. 
2.1.2. Immunochemistry Identifying the Ghrelin receptor 
Using fluorescence immunohistochemistry, we have tested whether GHSR1a is co-
localized with Girk2 and TH immunoreactivity in the mouse SNpc. GHSR1a is a G-
Protein Coupled Receptor. GPCRs possess an extracellular N-terminus which varies 
in length depending on which sub-type/family the GPCR belongs to (Family A, B, C 
or Frizzled). The extracellular termini are followed by 7-Transmembrane Domains (7-
TMD) found embedded in the cell membrane lipid bilayer. 7-TMDs transverse back 
and forth through the lipid bilayer, exposing fractions of its structure extracellularly. 
The 7th GPCR TMD is bound to an intracellular portion of the receptor, the C-terminus. 
Conformational change to the 7TM portion, upon ligand binding, results in the 
activation of the intracellular C-terminus and associated G-Proteins (K. Rogers, 
2017).  
Raising antibodies against GPCRs is challenging and GPCRs-specific antibodies can 
be difficult to acquire, especially for sub-types of receptors (e.g. as in the case of 
human adrenergic receptor sub-types) (Hamdani & van der Velden, 2009; 
Pradidarcheep et al., 2009). 
The challenges of raising antibodies to GPCRs are in obtaining a suitable 
antigen/epitope. GPCRs are often expressed at low levels in cells; the largest portion 
of the GPCR which might present a viable option for epitope structure is embedded 
in the lipid bilayer, and once the protein of interest is purified their 3D structures are 
unstable. Subsequently, antibodies generated may be specific for antigens of partially 
misfolded or altered structures. An accumulation of such challenges means that 
selection of GPCR antibody should not be taken lightly, particularly when the research 
of interest is receptor sub-type specific (Hutchings, Koglin, & Marshall, 2010). 
To address this challenge, whole eGFP-GHSR reporter mice brains were used to 
determine GHSR expression (a kind gift from Dr Zane Andrews, Monash University, 
Australia). Whole brains were processed for immunohistochemistry to investigate the 
expression and co-localization of the eGFP-tagged ghrelin receptor with 
dopaminergic (TH+) and A9 sub-type (Girk2+) neurones in the mouse SNpc. A specific 
antibody raised against eGFP was used to localize GHSR in the mouse SNpc.  
Characterization of GHSR expression in SN4741 cells was carried out using an 
antibody directly against an extracellular portion (2nd loop, amino acid residues 197-
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207 of the rat GHSR (Alomone Labs). Two transcript variants of GHSR are expressed: 
GHSR1a and GHSR-1b.  GHSR1a excises an intron and encodes a functional protein, 
the receptor for the acyl-ghrelin ligand in turn a pathway for growth hormone release 
is defined. GHSR-1b retains the intron and thus does not bind to acyl-ghrelin. By 
decreasing the cell surface expression of GHSR1a, GHSR-1b also acts as a repressor 
for GHSR1a activity. GHSR-1b contains 298 amino acids corresponding to the first 5 
TMDs encoded by exon 1 of the GHSR gene, therefore the antibody is not specific to 
either GHSR1a or -1b and so will bind to both receptors (Yin, et al., 2014). Therefore, 
it must be considered that any immunoreactivity observed is due to the presence of 
GHSR1a and/or GHSR-1b. To define the expression of AGs endogenous receptor, 
GHSR1a, in the SN4741 cells we will also collect protein and perform a Western blot 
using a GHSR1a-specific antibody. To study and characterise the SN4741 cell line, 
cells were grown under standard growth conditions (see methods) prior to fixation for 
immunocytochemistry or cell lysis for RNA/protein extraction for subsequent 
polymerase chain reaction (PCR)/Western blotting. 
 
2.2. Aims 
As little is known about ghrelin-axis protein expression in the mid-brain, in this chapter 
we will characterise; 
• The expression of ghrelin axis acylation and de-acylation proteins, GOAT and 
APT-1, in the adult Sprague Dawley rat midbrain; 
• The immunoreactivity of TH in the Sprague Dawley rat SNpc. 
• The expression of GHSR in TH+ and Girk2+ positive mouse SNpc neurones; 
and 
• The protein expression of the GHSR, GOAT, APT-1, TH, Girk2 & Calbindin 
immunoreactivity in the SN4741 mouse midbrain derived cell line.  
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2.3. Methods and Materials  
 
2.3.1. Nickel 3, 3’-diaminobenzidine (DAB) Immunohistochemistry 
 
2.3.1.1. Nickel (3, 3’-diaminobenzidine) DAB 
DAB (3,3'-diaminobenzidine) is oxidized in the presence of peroxidase and hydrogen 
peroxide resulting in the deposition of an alcohol-insoluble precipitate at the site of 
enzymatic activity. DAB (3, 3’-diaminobenzidine) is commonly used in 
immunohistochemistry as the reaction product is insoluble, stable and not light 
sensitive so stained samples may be preserved for extended periods of time without 
losing sensitivity and quality of prepared tissue samples. DAB reaction is also 
applicable for Western blot visualisation. 
 
2.3.1.2. Preparation of Nickel DAB (3, 3’-diaminobenzidine) Reaction 
Reagents 
The nickel DAB solution was prepared by the mixing of 2 preliminary solutions using 
specific DAB designated equipment for health & safety purposes. Solution 1 was 
prepared in 100ml of 0.2M sodium acetate by dissolving 5g nickel sulphate, 400mg 
glucose and 80mg ammonium chloride. A second solution was prepared by dissolving 
50mg DAB (3, 3’-diaminobenzidine) DAB in 100. Both solutions were then mixed 
together and aliquoted into 15ml centrifuge tubes and wrapped in foil to protect from 
light before storage in the freezer -20oC. 
Glucose oxidase (5mg/ml) is necessary for the nickel DAB reaction. This was 
prepared by dissolving 40mg of glucose oxidase in 8ml H2O. 5mg/ml glucose oxidase 
solution was then pipetted into 500ul aliquots for storage at -20oC. 
 
2.3.1.3. Histology: Tissue Preparation for Nickel DAB 
Immunohistochemistry 
The animal procedures described, including those involving genetically modified 
animals, were conducted in accordance with the UK Animals (Scientific Procedures) 
Act, 1986 (Dr T Wells’ Project Licence: 30/2979) and the ARRIVE Guidelines, and 
were specifically approved by ethical review at Cardiff University. Rat age: 3 months 
Rat weight range: 212-250g. After rotational testing on day 35 rats were anaesthetised 
with sodium pentabarbitone (Euthetal), nose-anus length measured, and subjected to 
throracotomy. After withdrawal of a terminal blood sample by cardiac puncture, rats 
were killed by transcardial perfusion of 1.5% paraformaldehyde. After perfusion, 
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brains were excised, and post-fixed in 1.5% PFA overnight at 4oC. Sprague Dawley 
rat brains were mounted onto the Freezing microtome (Microm HM 450) (-30oC) with 
JUNG-tissue fixing medium® for coronal sectioning (30µm thick). Sectioned tissue 
was collected 1:6 in a labelled 12-well plate and immersed in PBS+0.2% Sodium 
Azide (Sigma Aldrich). The tissue sections were then stored at 4oC prior to 
immunohistochemical preparation. 
 
2.3.1.4. Protocol for DAB Immunohistochemistry 
All incubations and wash step from here on were carried out in CELLSTAR® 12-well 
plate [665180] (greiner bio-one, UK) at room temperature and with gentle agitation 
unless stated otherwise. Free-floating tissue sections were removed from storage 
conditions washed thoroughly (2 x 10 mins) in PBS (Sigma Aldrich) with gentle 
rocking/agitation at room temperature. PBS washes were removed prior to 
permeabilization of tissue sections using 0.03% Triton-x100 in PBS (0.03% PBS-T) 
for 10mins. Following permeabilization tissue sections are immersed in 1.5% H2O2 in 
PBS for 20 mins in order to remove endogenous peroxidase activity before being 
washed for another 2 x 10 mins in PBS and 1 x 10 mins in 0.03% PBS-T. Tissue 
sections were then blocked using 5% Normal Goat serum (5% NGS) (Sigma Aldrich) 
in 0.1% PBS-T for 60 min at room temperature to block non-specific binding sites. 
Excess block was then removed prior to application of a primary antibody diluted in 
2% NGS in PBS-T and incubation at 4oC, overnight (approx. 16-24hrs). Primary 
antibody stained sections were then washed another 2 x 10 mins in PBS and 1 x 10 
mins in 0.03% PBS-T before a 70 minute incubation with biotinylated secondary 
antibody raised in goat with gentle agitation at room temperature whilst being 
protected from light. All steps from here onwards are carried out with minimum 
exposure to light as the sample is now light sensitive until the final oxidation reaction 
occurs and DAB precipitate has formed. Again, the sections were washed 2 x 10 mins 
in PBS and 1 x 10 mins in 0.03% PBS-T prior to incubation with VECTASTAIN®Elite® 
ABC Kit [PK-6100] (Vector laboratories, UK) ABC solution (a mix of 0.4% reagent 
solution A and 0.4% reagent solution B in 0.1% PBS-T). The VECTSTAIN®Elite® 
uses preformed Avidin and Biotinylated enzyme complexes to give a reproducible 
staining method which relies on the form and amount of active enzyme molecules 
within the reagents. ABC solutions A (Avidin DH solution) & B (biotinylated enzyme) 
were pre-mixed in 0.1% PBS-T for 30mins, making-up the ABC solution prior to its 
addition to sample tissues for 90mins. ABC solution was then removed and the tissue 
sections were washed 2 x 10mins in PBS before a final wash 10 minute wash in 0.1M 
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sodium acetate pH 6.0. Excess sodium acetate solution was then removed prior to 
initiating the DAB reaction by mixing 1ml Nickel DAB solution with 60ul of glucose 
oxidase solution (5mg/ml) in the presence of tissue sections. This reaction was 
performed in the following way: 
1ml of Nickel DAB solution was pipetted into a well of a corner of a weighing boat and 
60ul of glucose oxidase was pipetted adjacently but were not mixed. A fine-tipped 
painting bush was used to transfer tissue sections into the 1ml of DAB solution 
immediately prior to the mixing with glucose oxidase. The plate was then swirled (3-4 
times) to ensure solutions were thoroughly mixed prior to gentle rocking/agitation for 
nickel DAB staining to develop. 
Once sufficient Nickle DAB staining had developed, a paint brush was used carefully 
to transfer tissue sections from the DAB-glucose oxidase reaction solution into to PBS 
and washed twice for 10 mins in PBS. This reaction was also performed in a 12-well 
plate. This method was preferred as tissue section were easier to retrieve from the 
well of a 12-well plate rather than a weighing boat. This reduced the extent of 
mechanical sheering of precious sample tissue once sufficient stain had developed. 
 
2.3.1.5. DAB immunohistochemistry: Tyrosine hydroxylase (TH) 
Tissue Sections were incubated with the primary antibody, rabbit anti-TH [ab6211] 
(1:500, Abcam®, UK). Following this incubation, excess 1◦ antibody was removed 
and tissues were washed thoroughly and incubated in complementary 2◦ antibody, 
Biotinylated Goat Anti-Rabbit IgG Antibody (Vector Laboratories [BA-1000). 
 
2.3.1.6. DAB immunohistochemistry: LYPLA1, or acyl-protein 
thioesterase 1 (APT-1) 
Tissue Sections were incubated with the primary antibody, rabbit anti-
Lysophospholipase-1 [ab91606] (1:1000, Abcam®, UK). Following this incubation, 
excess 1◦ antibody was removed and tissues were washed thoroughly and incubated 
in complementary 2◦ antibody, Biotinylated Goat Anti-Rabbit IgG Antibody [BA-1000] 
(1:500, Vector Laboratories). 
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2.3.1.7. DAB Immunohistochemistry: Ghrelin-O-Acyl-Transferase 
(GOAT) 
Tissue Sections were incubated with the primary antibody, rabbit anti-GOAT [H-032-
12] (1:2000, Phoenix Pharmaceuticals.Inc). Following this incubation, excess 1◦ 
antibody was removed and tissues were washed thoroughly and incubated in 
complementary 2◦ antibody, Biotinylated Goat Anti-Rabbit IgG Antibody [BA-1000] 
(1:500, Vector Laboratories). 
Table 3: Table of primary and secondary antibodies used in Nickel DAB 
Immunohistochemistry 
 
Target  Primary antibody  Primary 
antibody 
concentration 
in PBS-T 
(0.1%) 
Secondary 
antibody  
Secondary 
antibody 
concentration 
in PBS-T 
(0.1%) 
Tyrosine 
Hydroxylase 
rabbit anti-TH 
[ab6211] 
(Abcam®, UK) 
1:500 Biotinylated 
Goat Anti-
Rabbit IgG 
Antibody [BA-
1000] (1:500, 
Vector 
Laboratories). 
1:500 
LYPLA1 
Or 
APT-1 
Rabbit anti-
Lysophospholipase-1 
[ab91606] (1:1000, 
Abcam®, UK). 
1:1000 Biotinylated 
Goat Anti-
Rabbit IgG 
Antibody [BA-
1000] (1:500, 
Vector 
Laboratories). 
1:500 
GOAT Rabbit anti-GOAT [H-
032-12] (1:1000, 
Phoenix 
Pharmaceuticals.Inc). 
1:2000 Biotinylated 
Goat Anti-
Rabbit IgG 
Antibody [BA-
1000] (1:500, 
Vector 
Laboratories). 
1:500 
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2.3.1.8. Sample Dehydration, Delipidation and Slide Preparation  
Following 2 x PBS washes tissue sections were suspended in TBS (Sigma Aldrich) 
filled petri dish. The tissue sections were mounted onto SuperFrost®Plus slides [25 x 
75 x 1.0mm] (VWR International LTD) and allowed to dry overnight. Once dry, tissue 
samples underwent dehydration by submerging the slides in increasing 
concentrations of ethanol (70%, 90%, 100%, and 100 %) for 3 minutes each. Samples 
were then de-lipified by submerging slides in Histo-Clear [HS-200] (national 
diagnostics) twice for 3 minutes. Slides were removed from Histo-Clear and 50ul of 
Entellan® [107960] (MerckMillipore) was pipetted evenly over the slide prior to 
carefully lowering a MENZEL-GLÄSER 24 x 60mm glass coverslip (Thermo Scientific, 
Germany) to complete slide preparation. Sample slides were then left to dry prior to 
inspection via light microscopy. 
 
2.3.1.9. Light Microscope Imaging 
Examination and imaging of tissue sections was carried out on Nikon ELIPSE 50i light 
microscope.  
 
2.3.2. Immunofluorescence 
In order to identify key targets of interest, immunofluorescence (IF) was utilized to 
characterize cells in mouse SN brain sections and midbrain-derived cell line (SN4741) 
using immunohistochemistry (IHC) and immunocytochemistry (ICC) techniques, 
respectfully.  
Primary antibodies were applied to all sections/cells, followed by addition of 
fluorescent-secondary antibodies. Primary antibody was omitted from negative 
controls.  
 
2.3.2.1. Histology: Tissue Preparation for Immunohistochemistry 
GHSR-GFP mouse brains were bisected: one hemisphere was selected and mounted 
onto the Freezing microtome (Microm HM 450) (-30◦C) with JUNG-tissue fixing 
medium® for coronal sectioning (30µm thick). Sectioned tissue was collected 1:6 in a 
labelled 96-well plate and immersed in PBS+0.2% Sodium Azide (Sigma Aldrich). The 
tissue sections were then stored at 4oC prior to immunohistochemical preparation. 
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2.3.2.2. General Fluorescence Immunohistochemistry Protocol                                                
Free-floating tissue sections were washed thoroughly (3x) in PBS (Sigma Aldrich) (5 
min) with gentle rocking/agitation before permeabilization with 1ml of methanol 
(Fisher Scientific) at -20◦C (2min). Before staining tissue sections were then washed 
thoroughly (3x) in PBS and blocked using 5% Normal Goat serum (5% NGS) (Sigma 
Aldrich) for 2o antibodies raised in goat, or 5% Normal Donkey Serum (5% NDS) 
(Sigma Aldrich) and 0.1% Triton X-100 in PBS (0.1% PBS-T) for 60 min at room 
temperature to block non-specific binding sites. Excess block was then removed prior 
to application of primary antibodies and subsequent secondary antibodies, both 
diluted in 0.1% PBS-T. Primary antibody incubations were carried out overnight 
(approx.16-24 hours) at 4oC. Subsequent secondary antibody incubations were 
carried out for 60 minutes at room temperature and protected from light. Dilutions of 
primary and secondary antibodies were prepared in 0.1% PBS-T prior to incubation 
with tissue sections. 
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 (A) Primary antibody binds specifically to epitope of target protein on prepared 
samples. (B) Excess Primary antibodies are washed away leaving only specifically 
bound antibodies on target sites. (C) Samples are incubated with excess fluorescent-
secondary antibody complimentary to primary antibody. Samples is then washed 
again to remove excess secondary antibodies leaving primary-secondary complex 
conjugated to target proteins. (D) Fluorescent probes are excited and give emissions 
at specific wavelengths of light.  
 
 
 
 
 
 
Figure 8: Illustration of Immunofluorescence Protocols. 
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2.3.2.3. Fluorescence Immunohistochemistry: Tyrosine Hydroxylase 
(TH) 
Tissue sections were incubated with the primary antibody, TH [ab6211] (1:500, 
Abcam®). Following this incubation, excess 1◦ antibody was removed and tissues 
were washed thoroughly washed again in PBS (3x 5min) and incubated in 
complementary 2◦ Goat anti-rabbit AlexaFluo®568 [A11041] (1:500, Invitrogen 
molecular probes, Oregon, USA), for fluorescent staining.   
 
2.3.2.4. Fluorescence Immunohistochemistry: GHSR-eGFP 
Tissue sections were incubated with the primary antibody, Chicken anti-GFP 
[ab13970] (1:1000, Abcam®). Following this incubation, excess 1◦ antibody was 
removed and tissues were washed thoroughly and incubated in complementary 2◦ 
antibody, Goat anti-chicken AlexaFluo®488 [A-11039] (1:500, Invitrogen molecular 
probes, Oregon, USA) for fluorescent staining. 
 
2.3.2.5. Fluorescence Immunohistochemistry: Girk2 
Tissue sections were incubated with the primary antibody, Rabbit anti-Girk2 [APC-
006] (1:200, Alomone Labs, Isreal). Following this incubation, excess 1◦ antibody was 
removed and tissues were washed thoroughly and incubated in complementary 2◦ 
antibody, Goat anti-rabbit AlexaFlour®488 [A-11034] (1:500, Invitrogen molecular 
probes, Oregon, USA), for fluorescent staining.   
 
2.3.2.6. Fluorescence Immunohistochemistry: Calbindin 
Tissue Sections were incubated with the primary antibody, Rabbit anti-Calbindin 
[ab108404] (1:50, Abcam®, UK). Following this incubation, excess 1◦ antibody was 
removed and tissues were washed thoroughly and incubated in complementary 2◦ 
antibody, Goat anti-rabbit AlexaFluo®568 [A11041] (1:500, Invitrogen molecular 
probes, Oregon, USA), for fluorescent staining.   
 
2.3.2.7. Fluorescence Immunohistochemistry: TH & GHSR-eGFP co-
localization 
Tissue sections were incubated with the first primary antibody, TH [ab6211] (1:500, 
Abcam®). Following this incubation, excess 1◦ antibody was removed and tissues 
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were washed thoroughly and incubated in complementary 2◦ antibody, 2◦ Goat anti-
rabbit AlexaFluo®568 [A11041] (1:500, Invitrogen molecular probes, Oregon, USA). 
Removal of excess 2° antibody was followed by another (x3) PBS wash (5min) and a 
24hr incubated in the second 1◦ antibody, Chicken anti-GFP [AB13970] (1:1000, 
Abcam®). Following the removal of excess primary antibody, the tissues were 
thoroughly washed again in PBS (3x 5min) before the application of the final 2◦ 
antibody, Goat anti-chicken AlexaFluo®488 [A-11039] (1:500, Invitrogen), and 
incubated for fluorescent staining.  
 
2.3.2.8. Fluorescence Immunohistochemistry: Girk2 & GHSR-eGFP + 
Girk2  
Tissue sections were incubated with the first primary antibody, Rabbit anti-Girk2 
[APC-006] (1:200, Alomone Labs, Isreal). Following this incubation, excess 1◦ 
antibody was removed and tissues were washed thoroughly and incubated in 
complementary 2◦ antibody, Goat anti-rabbit AlexaFluo®568 [A11041] (1:500, 
Invitrogen molecular probes, Oregon, USA).  Removal of excess 2° antibody was 
followed by another (x3) PBS wash (5min) and 24hr incubation in the second 1◦ 
antibody, Chicken anti-GFP [AB13970] (1:1000 Abcam®). Following the removal of 
excess secondary antibody the tissues were thoroughly washed again in PBS (3x 
5min) before the application of the final 2◦ antibody, Goat anti-chicken AlexaFluo®488 
[A-11039] (1:500, Invitrogen), and incubated for fluorescent staining. 
 
2.3.2.9. Slide Preparation and Analysis 
Finally, excess final secondary antibody was removed and the tissue sections were 
thoroughly washed (x3) PBS (5mins) before being suspended in TBS (Sigma Aldrich, 
Gillingham, UK) filled petri dish. The tissue sections were mounted onto 
SuperFrost®Plus slides [25 x 75 x 1.0mm] (VWR International LTD) and allowed to 
dry.  50µl of prolong gold (Life Technologies) anti-fade mounting media was applied 
to the slides before a MENZEL-GLÄSER coverslip was placed upon it - ensuring that 
no air bubbles formed over the tissue sections - and allowed to dry.  Examination and 
imaging of tissue sections was carried out on Fluorescent microscope ZEISS 
Imager.M1 system with AX10cam HRM.  
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Table 4: Table of primary and secondary antibodies applied in fluorescence 
Immunohistochemistry 
  
 
 
 
 
 
 
 
 
Target  Primary 
antibody  
Primary 
antibody 
concentration 
in PBS-T 
(0.1%) 
Secondary antibody  Secondary 
antibody 
concentration 
in PBS-T 
(0.1%) 
GHSR-eGFP Chicken anti-
GFP  
[AB13970] 
(Abcam®, UK) 
1:1000 Goat anti-chicken 
AlexaFluo®488  [A-
11039] (Invitrogen 
molecular probes, 
Oregon, USA), 
1:500 
Tyrosine 
Hydroxylase 
rabbit anti-TH 
[ab6211] 
(Abcam®, UK) 
1:500 Goat anti-rabbit 
AlexaFluo®568 
[A11041] (Invitrogen 
molecular probes, 
Oregon, USA), 
1:500 
Calbindin Rabbit anti 
Calbindin 
ab108404 
(Abcam®, UK) 
 
1:50 Goat anti-rabbit 
AlexaFluo®568 
[A11041] (Invitrogen 
molecular probes, 
Oregon, USA) 
1:500 
Girk2 
(Anti-Kir3.2 
antibody)  
Rabbit anti-
Girk2  
[APC-006] 
(Alomone 
Labs, Isreal) 
1:200 Goat anti-rabbit 
AlexaFlour®488  
[A-11034] &  
AlexaFluo®568 
[A11041] (Invitrogen 
molecular probes, 
Oregon, USA) 
1:500  
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2.3.3. Fluorescence Immunocytochemistry (ICC) 
 
2.3.3.1. SN4741 Cells Sample Preparation for ICC 
SN4741 cells were seeded at 3000/well into a 96-well plate Corning® Costar® 3596 
flat-bottom cell culture plate (CLS3596 SIGMA), and incubated for 24hrs (37◦C, 5% 
CO2) to allow SN4741 cells to adhere. Cells were then washed once with 200ul PBS 
and fixed with 100ul 4% paraformaldehyde (PFA) (15mins). 4% PFA was then 
removed and the SN4741 cells were washed (3x) in 100ul PBS. Following the removal 
of the final PBS wash, cells are ready to be used or can be stored at 4oc prior to 
beginning ICC protocol.  
 
2.3.3.2. Protocol for ICC 
PBS submerging the cells was removed and cells were blocked at room temperature 
using 5% Normal Donkey Serum (5% NDS) (Sigma Aldrich, St Louise, USA) for 60 
min. Excess block was removed and 1◦ antibody was applied to cells for 24 hours at 
4◦C. Excess 1◦ antibody was removed and cells were washed (x3) in PBS (5min). 2◦ 
antibody was then applied and left to incubate in the dark for 60min. Removal of 
excess antibody was then followed by another (x3) PBS wash (5min). Cells were 
stored in the final PBS wash at 4oC prior to fluorescence imaging of samples. See 
table 2 for a details on primary and secondary antibodies utilized. 
 
2.3.3.3. Fluorescence Microscope Imaging of Samples      
Immuno-reactive SN4741 samples were examined using Olympus IX51 inverted 
fluorescence microscope powered by PRIOR Lumen 200 and In Cell Analyser 2000 
HCA system (GE Healthcare). 
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Table 5: Table of Primary and Secondary Antibodies used in 
Immunocytochemistry. 
 
 
 
 
 
 
 
Target  Primary 
antibody  
Primary 
antibody 
concentration in 
PBS-T (0.1%) 
Secondary 
antibody  
Secondary 
antibody 
concentration in 
PBS-T (0.1%) 
Tyrosine 
Hydroxylase 
Rabbit anti-
Tyrosine 
Hydroxylase 
[ab6211] 
(1:1000, 
Abcam®). 
1:1000 Donkey anti-
rabbit 
AlexaFluo®488 
[A11041] 
(Invitrogen 
molecular probes, 
Oregon, USA) 
1:500 
GHS-R (Anti-
Ghrelin 
Receptor 
(extracellular)) 
Rabbit anti-
GHS-R 
[AGR-031] 
(Alomone 
Labs, Isreal) 
1:1000 Donkey anti-
rabbit 
AlexaFluo®488 
[A11041] 
(Invitrogen 
molecular probes, 
Oregon, USA) 
1:500 
Girk2 
(Anti-Kir3.2 
antibody)  
Rabbit anti-
Girk2  
[APC-006] 
(Alomone 
Labs, Isreal) 
1:200 Donkey anti-
rabbit 
AlexaFluo®488 
[A11041] 
(Invitrogen 
molecular probes, 
Oregon, USA) 
1:500 
Calbindin Rabbit anti- 
Calbindin 
[ab108404] 
(Abcam®, UK) 
 
1:50 Donkey anti-
rabbit 
AlexaFluo®488 
[A11041] 
(Invitrogen 
molecular probes, 
Oregon, USA) 
1:500 
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2.3.4. Western Blot 
 
2.3.4.1. Protein Extraction and Estimation from SN4741 Cells 
50,000 SN4741 cells were seeded into 6 well Greiner CELLSTAR® culture plates 
(M8562, SIGMA) and incubated in routine SN4741 cell culture media at 37oC, 5% 
CO2 until cells were 80% confluent (~48hrs). Cell culture media was then removed 
and the cells were washed 2x in cold PBS. PBS wash was then removed and 125ul 
lysis buffer (50ml lysis buffer was prepared containing: 2.5ml 50mM Tris HCl, pH 7.5; 
1.5ml 150mM NaCl; 0.5ml/1% of IGEPAL [I8896, SIGMA]; 0.5% sodium deoxycholate 
(DOC); 0.1% SDS; 45.5ml dH2O) containing 1% protease inhibitor cocktail was 
pipetted into the wells. Using a syringe plunger, the cells were scraped from the well 
surface. Contents of the well were then transferred to a 0.6ml micro-centrifuge tube 
on ice. Another 125ul of lysis buffer was added to the same well and the process was 
repeated. Contents were mechanically homogenized by passing through a 25G 
needle 10 times. Homogenate was left on ice for 15 mins prior to centrifugation at 
14,000 RPM to remove the cellular debris from protein. Following centrifugation 20ul 
and ~200ul of protein containing supernatant was collected carefully as to not disturb 
the pelleted cellular debris. To prepare protein samples for gel electrophoresis ~200ul 
supernatant was mixed 1:1 with Laemmli Lysis-Buffer [DTT, 400mM; Glycerol, 20%; 
SDS, 4%; TRIS, 0.125M] (38733, SIGMA) and briefly vortexed. Protein samples were 
left to denature at room temperature for 1hr before being stored at -20oC and being 
thawed out prior to use. 
 
 
Table 6: General Ratio of Lysis Buffer to Size of Cell Culture Vessel. 
Plate Volume of Lysis Buffer (µl) 
35mm 250 
60mm 500 
100mm 1000 
 
Estimation of protein sample concentrations were carried out using the absorption-
based PierceTM BCA Protein Assay Kit (23227, Thermo Scientific).  A standard curve 
of known protein concentrations (0.0, 0.1, 0.2, 0.4, 0.6, 0.8 & 1.0 ug/ul) was generated 
using Albumin Standard (23209, Thermo Scientific). Blanked sample concentrations 
were calculated by extrapolation against the BSA standard curve. 
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2.3.4.2. General Western Blot Protocol 
Preparing SDS-PAGE Gel: Glass gel molding plates were washed with tap and 
distilled water prior to a final 70% ethanol before use. Molding plates were then placed 
into a gel casting frame and clamped shut using a spacer to ensure liquid-tight seal. 
Seal was ensured by filling the area between molding plates with d.H2O and visual 
checking for leakage. 10ml (per gel) of the required acrylamide running gel was then 
prepared to the required percentage of acrylamide (see table 7) and pipetted into a 
sealed glass mold. 
 
Table 7: Acrylamide Gel Preparation Reagents 
Reagent 7.5% 10% 12% 15% 
Water 5 ml 4.2 ml 3.5 ml 2.5 ml 
4x Tris and 
SDS 
2.5 ml 2.5 ml 2.5 ml 2.5 ml 
30% 
acrylamide 
2.5 ml 3.3 ml 4 ml 5 ml 
APS 1 small 
spatula 
1 small 
spatula 
1 small 
spatula 
1 small 
spatula 
TEMED 10 µl 10 µl 10 µl 10 µl 
 
 
Polymerizing reagents, APS and TEMED, were added immediately prior to casting. 
Following the transfer of running gel into a glass casting mold, water-saturated butanol 
was gently pipetted on top of the gel to ensure a smooth, even gel edge. Running gel 
was then left to set for approximately 30 mins. Water-saturated butanol was poured 
away and the gel edge was rinsed 4 times with d.H2O. A stacking gel (3ml) was then 
prepared (see table 8) and poured on top of the running gel before a well-comb was 
inserted. 
 
 
 
 
 
 
 
56 
 
Table 8: Stacking Gel Reagents 
Water 1.75 ml 
4x Tris and SDS 0.75 ml 
30% acrylamide 0.5 ml 
APS Half Spatula 
TEMED 3 µl 
 
After approximately 20 mins the comb was removed and excess un-polymerized 
acrylamide was washed away with d.H2O. Casting plates were then removed from 
casting frame and inserted into the Mini-PROTEAN® Tetra System (Bio-Rad) 
electrode assembly clamping frame. Two gels were used per frame. In the absence 
of a second gel, a buffer dam was used. Once the clamping frame was placed into 
the Mini Tank the central reservoir was then filled with running buffer. A protein marker 
(5ul) and samples were then added to casted wells according to maximum volume or 
protein concentration before PowerPac Basic (Bio-Rad) was attached to the electrode 
assemble and run at 200 (Volts) V for 40 mins or until protein bands have sufficiently 
resolved. 
 
Semi-dry membrane transfer: a piece of Polyvinylidene difluoride PVDF membrane 
(1620177, Biorad.) was washed in methanol for 30 secs, then water for 2 mins before 
incubation in transfer buffer (5 mins). At the same time the SDS-PAGE gel was 
released from its clamping frame and casting mold and placed into transfer buffer (5 
mins). Both were placed on rocker for gentle agitation (30 RPM). At this time 2 pieces 
of CriterionTM size Extra Thick Blot (filter) Paper (1703967, Bio-Rad) were submerged 
in transfer buffer. A piece of filter was placed onto an opened cassette from the Trans-
Blot® TurboTM Transfer system (Bio-Rad) and rolled out to eliminate air bubbles. 
PVDF membrane followed by SDS-PAGE gel was then placed on top of the filter 
paper. The second piece of filter paper was then placed onto the transfer stack and 
rolled again (See figure 2 for transfer stack illustration). The cathode plate-containing 
lid of the transfer cassette was then placed onto the transfer stack and locked closed 
by engaging the latched with a clock-wise turn of the lids dial. The transfer cassette 
was then re-introduced into the main unit of the transfer system and transfer was 
initiated for 75 mins at 15V. 
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All components are soaked in transfer buffer and placed into transfer cassette as seen 
above (figure 9). Filter paper, PVDF membrane, SDS-PAGE gel and finally filter 
paper. The stack is rolled out a final time to remove any air bubble before transfer 
cassette lid is close and locked into place. 
 
Visualization of proteins on PVDF membrane: Following protein transfer into the 
PVDF, SDS-PAGE gel and filter papers are removed and PVDF membrane is placed 
in Penceau red stain. PVDF membranes are placed into Penceau red and shaken 
until protein bands are visible on the blotting paper. Penceau stain was then recycled 
and water was added to the blot membrane which was subsequently labeled with 
pencil and cut into band regions of interest using scissors. Blotting paper was then 
washed in TBS-Tween20 with mild agitation for approximately 5 mins to remove 
pink/red colour from blotting paper. 
 
Membrane blocking: 5% non-fat milk (NFM) blocking buffer solution was prepared in 
TBS-Tween20 by dissolving 1.25g of NFM powder in 25ml of TBS-Tween20. PVDF 
membrane was placed in a plastic dish and incubated in blocking buffer on a shaker 
for 1hr at room temperature or overnight at 4oC. 
 
Primary and secondary antibody incubation: Blocking buffer was removed and blots 
were incubated with 1.5ml primary antibody (see table 7 for antibody dilutions) 
between 2 plastic sheets sealed with CaiTronic (heat mechanism). Plastic bags were 
checked for leaks before being placed in a TBS-Tween20 filled vessel for 1-2hr 
Figure 9: Stack preparation for SDS-PAGE gel to 
PVDF membrane protein transfer. 
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incubation at room temperature or overnight at 4oC.  Following incubation, the sealed 
bag was opened and primary antibody was collected for re-use (3 times). Blotting 
membrane was then washed 5x in TBS-Tween20 - 5 mins for each wash. PVDF 
membranes were then incubated with secondary antibody diluted in blocking buffer 
(1:2500) between CaiTronic-sealed plastic sheets. Plastic bags containing blots and 
secondary antibody were placed in a TBS-Tween20 containing vessel and incubated 
at room temperature for 1-2hr on a rocker. Following incubation, secondary antibody 
was discarded and the blot was washes again 5 times for 5 mins in TBS-Tween20 
with mild agitation. 
 
Blot Development and Visualisation- Enhanced Chemi-luminescence (ECL): ECL 
solution was prepared by the 1:1 mixing of the 2 reagents (Peroxide Solution and 
Luminol Solution) from the AmershamTM ECL SelectTM Western Blotting Detection 
Reagent (RPN2235, GE Healthcare) and protected from direct light. Blots were 
incubated face-down in ECL solution for 1 minute on a flat plastic case before being 
positioned face-up for visualisation on the ChemiDoc XRS (Bio-Rad) tray using 
Quantity One Basic Software. Following visualisation and acquisition of pictures at a 
range of exposure times, the images were transformed using ‘AutoDisplay’ Quantity 
One software feature and saved. Blots were stored at 4oC in TBS-Tween20 should 
they need to be stripped and re-probed for another protein target. 
 
Stripping and re-probing: Blots destined for stripping and re-probing was removed 
from 4oC and placed in TBS-Tween20 for 10 mins at room temperature. To strip, blots 
were then sealed (CaiTronic) between 2 plastic sheets with 1.5ml RestoreTM PLUS 
Western Blot Stripping Buffer (46430, Thermo Scientific). Once sealed, bags were 
placed in a TBS-Tween20 containing vessel and incubated at room temperature for 
15-20 mins on a rocker. Following this incubation the stripping buffer discarded and 
the blots were washed twice in fresh water for 1 minute and once inTBS-Tween20 for 
5 mins on a shaker. To re-probe, steps ‘Membrane Blocking’ through ‘Blot 
Development and Visualisation- Enhanced Chemi-luminescence (ECL)’ were 
repeated with adjustments to primary and secondary antibodies. 
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Table 9: Table of Primary and Secondary Antibodies used in Western blot 
 
Target 
Primary 
Antibody 
 
Dilution 
Secondary 
Antibody 
 
Dilution 
 
GHSR1a 
41kDa 
Goat anti 
GHSR1a (F-16) 
Sc-10359, Santa 
Cruz 
1:200 In 5% NFM Anti-goat IgG-
HRP linked in 5% 
NFM 
1:2500 In 5% 
NFM 
 
LYPLA1 
25kDa 
Ab91606, Abcam  1:5000 In 5% 
NFM 
Anti-Rabbit IgG, 
HRP-linked 
Antibody (7074S, 
Cell Signaling 
Technology) in 5% 
NFM 
1:2500 In 5% 
NFM 
 
MBOAT4 50kDa  
Rabbit anti-
MBOAT4 
1:500 In 5% NFM Anti-Rabbit IgG, 
HRP-linked 
Antibody (7074S, 
Cell Signaling 
Technology) in 5% 
NFM 
1:2500 In 5% 
NFM 
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2.3.5. Endpoint / Semi-Quantitative PCR 
 
2.3.5.1. General Endpoint/Semi-Quantitative PCR Protocol 
End-point/ semi-quantitative PCR was carried out to investigate GHS-R1a, LYPLA1 
and MBOAT4 (encodes for ghrelin acylation enzyme, GOAT) mRNA expression in 
SN4741 cell line.  
RNA extraction: 50,000 SN4741 cells were seeded into 12 well-plate (150628, 
NUNCTM) and incubated overnight at 37oC, 5% CO2,Total RNA was isolated from 
SN4741 cell line using NORGEN Biotek corp. RNA/Protein Purification Kit (NORGEN, 
Canada (Cat#23500) with on-column DNA digestion by the deoxyribonuclease 
according to the manufacturer’s instructions.  Purity and concentration of RNA 
extracts are subject to Nanodrop® ND 8000 8-sample spectrophotometer (Thermo 
Scientific) readings. RNA was stored at -80°C for future cDNA synthesis. cDNA 
Synthesis: Four micrograms of the total RNA were reverse transcribed using 
superscript III RT (Life Technologies) in a total reaction volume of 20µl. 0.5µl of the 
resulting cDNA was used for endpoint PCR. PCR amplifications were performed with 
primers listed in the table below and Promega (USA) GoTaq® Green Master Mix [cat. 
#M7111]; following manufacturer’s instructions. DNA sample were then stored at -
20oC. PCR reaction was performed in Bio-Rad T100 Thermal cycler PCR System 
(BioRad, Herefordshire, UK) PCR was performed with the primers and ladder in table 
10.  
 
Preparation of agarose electrophoresis gel: using UltraPureTM agarose (16500-100, 
Thermo Scientific) electrophoresis gels were prepared at desired concentration for 
DNA resolution. See table 11 for agarose ratio to resolution range for 50ml gel. 
Desired weight of agarose is mixed with 50ml 1x Tris/Acetic Acid/EDTA (TAE buffer) 
(prepared from 50x TAE #1610743EDU, Bio-Rad) and swirled to evenly distribute in 
a glass conical flask. TAE-agarose mixture was then microwaved for 1.5 mins until all 
agarose powder had dissolved. Molten agarose gel solution was then cooled to 
approximately 60oC before 5ul (1:10,000 dilution) of SYBR®Safe DNA gel stain 
(S33102, Invitrogen) was added and swirled through the liquid. Stoppers and well 
combs were then put into place prior to pouring the molten agarose gel into a cast 
laying in a Life Technologies Horizon 58 PCR electrophoresis tank (41060039, 
Labrepco). Air bubbles were swiftly removed using a pipette before the gel was cooled 
and set.  
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Table 10: Table of Forward (Sense) and Reverse (Anti-Sense) Primer 
Sequences used in PCR. 
Target Forward primer sequence 
5’→3’ 
Reverse primer sequence 
5’→3’ 
Predicted 
Amplicon 
size (bp) 
mGHSR1a 
(Europhins) 
CTCCGATCTGCTCATCTTCC CCACAGCAAGCATCTTCACTG 539 
mBOAT4 1 
(kirchner) 
(Europhins) 
ACCCGGGCCAGGTACCT ACCCATGGCAGCAAAAGC 63  
LYPLA1 
(Europhins) 
GCAGCAGAAACCGTAAAAGC GGCACTGGACGGAAATA 235 or 133 
Ladder 
[Bioline® 
Hyper Ladder 
IV] 
N.A N.A 1000, 900, 
800, 700, 
600, 500, 
400, 300, 
200, 100 bp 
marker 
 
 
PCR agarose gel electrophoresis: combs and stoppers were removed from solidified 
gel before being submerged in 1x TAE buffer. 10ul DNA base-pair (bp) standard 
ladder (NO467G or NO468G, New England Bio-labs) and 5ul of cDNA samples were 
pipetted into wells. A lid containing electrodes was placed on the electrophoresis tank 
and power supply (BioRad) was set at 100V for 30 mins. Following electrophoresis 
gels were visualized under UV using the Chemidoc XR (1708265, BioRad) and 
analysed using Quantity One software. DNA bound to SYBR®Safe DNA stain 
appears bright white under UV light. 
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Table 11: Ratio of Agarose Percentage to Agarose Electrophoresis Gel 
Resolution Range 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Agarose Concentration  Resolution Range Weight of Agarose for 
50ml gel 
0.8% 500bp-12kb 0.4g 
1.0% 400bp-10kb 0.5g 
1.5% 200bp-4kb 0.75g 
2.0% 100bp-2kb 1.00g 
4.0% 10bp-400bp 2.00g 
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2.3.6. General SN4741 Mouse Midbrain Derived Neuronal Cell Line Cell 
Culture 
SN4741 are an immortalized mouse midbrain derived cell line (Son et al., 1999) from 
Fred Gage’s lab in the 1990’s 
 
2.3.6.1. SN4741 Cell Revival 
SN4741 cell were revived from liquid nitrogen storage. Cell name, date and passage 
were noted. Frozen cryovials were thawed by swirling 37oC water bath until only a 
small amount of ice remains. Using a P1000, content of the thawed cryovial were 
placed into a T75 cell culture flask containing 18ml of pre-warmed SN4741 cell culture 
medium (High-glucose (4.5g/L) DMEM supplemented with 10% filtered FBS, 1% 
PenStrep, 1% (100x) L-glutamine and 3% glucose (20% solution in d.d.H2O). The 
flask was then gently swirled to ensure even distribution of SN4741 cells. T75 flask 
containing cells was incubated at 37oC, 5%CO2 overnight (approx.16hrs). This allows 
the SN4741 (which are an adherent) cell line to settle to the floor of the culture vessel 
and become attached. The following day SN4741 cell culture media was removed, 
cells were washed 1x in 10ml PBS before 18ml fresh media was transferred into the 
flask. Cells were routinely passaged or cryo-frozen for a future date once they became 
80-90% confluent. Confluency refers to the approximate percentage of the cell culture 
vessel which is covered in cells. i.e. The floor of a 100% confluent flask has a complete 
monolayer covering of cells. Whereas a 0% confluent cell culture vessel or flask has 
no cells. Sterile technique was maintained throughout this procedure and other cell 
culture practice to ensure sterility where possible.  
 
2.3.6.2. Seeding SN4741 Cells in Preparation for Experiment 
In order to seed cells for an experiment, cell culture media was removed and the 
SN4741s were washed 1x with 10ml PBS. PBS was removed and 4ml 
1xTrypsin/EDTA is pipetted into the culture flask before placing the T75 into a cell 
culture incubator at 37oC, 5%CO2 for 5 mins. After 5 minutes T75 flasks were removed 
and inspected under a light microscope to ensure cell detachment. If cells were not 
fully detached a gentle tap was given to dislodge the remaining loosely-adhered 
SN4741s. Using a 10ml pipette cell/Trypsin/EDTA solution was taken up and expelled 
5-10 time to produce a single-cell suspension prior to neutralization of Trypsin/EDTA 
with 6ml of SN4741 cell culture medium. Contents of the flask were then pipetted up 
and down another 5-10ml for thorough mixing. A 20ul solution of 1:1 cell suspension 
and trypan blue was subsequently prepared to quantify percentage (%) cell viability. 
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Cell viability was determined and the number of cells required for an experiment were 
seeded into experimental vessel of choice depending on downstream application. 
Prepared cells were returned to standard culture conditions (cell culture incubator at 
37oC, 5%CO2 for 5 mins). 
 
2.3.6.3. Sub-Culturing SN4741 Cells from 80-90% Confluent T75 Flask 
• Add 0.5ml of SN4741 cell suspension to 19.5ml cell culture medium→80-90% 
confluent in 4 days. 
• Add 1ml of SN4741 cell suspension to 19ml cell culture medium→ 80-90% 
Confluent in 3 days 
• Add 2ml of SN4741 cell suspension to 18ml cell culture medium→ 80-90% 
Confluent in 2days 
• Add 3ml of SN4741 cell suspension to 17ml cell culture medium→80-90% 
Confluent in approx. 24hrs. 
Every 2-3 days cell culture media was removed and cells were washed (PBS) before 
replenishment of culture vessel with fresh medium. Label all flasks and experimental 
plates. 
 
Preparation of SN4741 cell stocks 
 
Table 12: Cryopreservation Medium Reagents 
Cryopreservation Medium 
Reagents FBS DMSO SFM (serum free 
medium) 
Volume 12.5ml 5ml 32.5ml 
Ratio 2.5 1 6.5 
 
 
SN4741 cell culture medium was removed from an 80-90% confluent culture flask and 
cells were washed 1x in 10 ml PBS before addition of Trypsin/EDTA (4ml) and a 5 
minute incubation in general cell culture conditions. Once cells had detached a 10ml 
pipette was used to create a single cell suspension (almost no clumps of cells) and 
the cell suspension was placed in a 50ml tube. The cell suspension was then 
centrifuged at 300 xg for 5min at room temperature to form a cell pellet. 
Supernatant/Medium was carefully removed as not to disturb the pelleted cells. Cell 
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pellet was re-suspended in 1-2 ml of cryopreservation medium. Quickly, re-
suspension was transferred into a cryovial labelled with cell type, date, passage and 
name and placed into a NalgeneTM (bottom contains Isopropanol) container and 
transfer to -80oC freezer. After 24hrs the cryovial was transferred into liquid nitrogen. 
Note was made of the deposit. 
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2.4. Results 
2.4.1. Immunohistochemistry: Tyrosine Hydroxylase  
 
 
Images of right (A) and left (B) hemisphere at x4 magnification demonstrates TH 
immunoreactivity in the SNpc. White dashed boxed areas in (A) and (B) highlight the 
SNpc regions which are displayed as x40 magnification in (C) and (D). (C) and (D) 
represent left and right hemisphere SNpc, respectively. Black arrows highlight TH+ve 
SNpc neurones Scale bar; 500 μm (in A & B), 50 μm (in C & D). VTA, ventral tegmental 
area; SNpc, substantia nigra pars compacta.  
 
 
 
 
 
 
 
 
Figure 10:Tyrosine Hydroxylase (TH) is Expressed on Adult Rat Midbrain SNpc 
and VTA Neurones 
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2.4.2. DAB Immunohistochemistry: Acyl-Protein Thioesterase 1 (APT-1) 
 
Adult male Sprague Dawley rats express APT-1 immunoreactivity on mid-brain SNpc 
& red nucleus neurones.. Image (A) demonstrates APT-1 immunoreactivity in rat 
midbrain regions including the SNpc at x4 magnification. Dashed blue box (in A) 
outlines region containing APT-1 +ve neurones  in the red nucleus. White dashed 
boxed region (in A) shows the area of x10 magnification image of SNpc-SNr cross 
section (B). C, D & E show x40 magnification images of APT-1+ve neuones in the 
SNpc. Dashed black and red lines outline SNpc and SNr, respectively in x4 
magnification image (A). White arrows seen in x40 images of SNpc (C, D and E) mark 
examples of APT-1 +ve SNpc neurones. Scale bar; 500 μm (in A), 100 μm (in B), 50 
μm (in C, D & E). SNpc, substantia nigra pars compacta; SNr, Substantia Nigra pars 
reticulata; ml, medial lemniscus. 
 
 
 
 
Figure 11: APT-1 is expressed on adult rat midbrain SNpc. 
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2.4.3. DAB Immunohistochemistry: Ghrelin-O-Acyl-Transferase (GOAT)  
 
Adult male Sprague Dawley rats express GOAT immunoreactivity on mid-brain SNpc 
& VTA neurones. Image (A) demonstrates GOAT immunoreactivity in rat SNpc & VTA 
at x4 magnification. Solid black line boxed regions (in A) along the SNpc denote areas 
of x40 magnification images (E, F, G & H). Dashed Black and red lines outline SNpc 
and SNr, respectively in x4 magnification image (B).  Whereas the dashed white and 
dashed yellow boxes (in B) highlight the location of x10 magnification images of SNpc 
(C) and VTA (D). Red arrows seen in x40 images of SNpc (E, F, G and H) mark 
examples of GOAT +ve SNpc neurones. Scale bar; 500 μm (in A & B), 100 μm (in C 
& D), 50 μm (in E, F, G & H). VTA, ventral tegmental area; SNpc, substantia nigra 
pars compacta; SNr, Substantia Nigra pars reticulata. 
 
 
 
 
 
 
 
Figure 12:Ghrelin-O-Acyl-Transferase (GOAT) is expressed on adult rat midbrain 
SNpc and VTA neurons. 
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2.4.4. Fluorescence Immunohistochemistry: Tyrosine Hydroxylase + 
GHSR-eGFP Co-localization 
 
 
Adult male GHSR-eGFP mice co-express eGFP (green) and TH (red) in mid-brain 
SNpc neurones. (A) x4 and (B) x10 magnification images demonstrate TH+/GHSR-
eGFP+ co-localization in the SNpc. Boxed medial and lateral SNpc regions shown at 
40x magnification in (C), (D) and (E), confirm TH+/GHSR-eGFP+ co-localization (white 
arrow heads). Green arrows and red arrows indicate eGFP+ and TH+ cells, 
respectively. Scale bar; 200 μm (in A), 100 μm (in B) and 20 μm (in C, D & E). VTA, 
ventral tegmental area; SNpc, substantia nigra pars compacta. 
 
 
 
 
 
 
 
Figure 13: Ghrelin Receptor is Expressed on TH+ Cells in Adult Mouse Midbrain. 
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2.4.5. Fluorescence Immunohistochemistry: Girk2 
 
 
Girk2+ cells (Red arrows in D, E & F) are found extensively in mouse midbrain SNpc 
& VTA (B & C respectively). 4x magnification image demonstrates Girk2 + cells in VTA 
and lateral SNpc (A). (B) & (C) represent 10x magnification images of SNpc and VTA, 
respectively. Boxed VTA and lateral SNpc regions shown at 40x magnification in (D, 
E and F). Scale bar; 200 μm (in A), 100 μm (in B) and 20 μm (in D - F). VTA, ventral 
tegmental area; SNpc, substantia nigra pars compacta. 
 
 
 
 
 
Figure 14: Girk2 is Expressed in Neurones of Adult Mouse Midbrain VTA & SNpc. 
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2.4.6. Fluorescence Immunohistochemistry: Calbindin 
 
 
 
Calbindin+ cells (White arrows in D, E & F) are found extensively in mouse midbrain 
VTA. Calbindin+ immunoreactivity is also seen in the lateral SNpc (B & F). (A) 4x 
magnification image demonstrates Calbindin + cells in VTA and lateral SNpc. (B) & (D) 
represent 10x magnification images of SNpc and VTA, respectively. Boxed VTA and 
lateral SNpc regions shown at 40x magnification in (D, E and F). Scale bar; 200 μm 
(in A), 100 μm (in B) and 20 μm (in D - F). VTA, ventral tegmental area; SNpc, 
substantia nigra pars compacta 
 
 
 
 
Figure 15: Calbindin is Expressed In Neurones of Adult Mouse Midbrain VTA & 
SNpc. 
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2.4.7. Fluorescence Immunohistochemistry: Girk2 & eGHSR Co-
localization 
 
GFP+ cells in adult mouse GHSR-eGFP co-localized with A9 dopamine cell marker, 
Girk2+ (F), in the SNpc (F). (A) 10x magnification image demonstrates co-localization 
in the SNpc. Boxed lateral SNpc regions shown at 64x magnification in (B, C, D, E 
and F), confirms co-localization (white arrow head in F). B & D show greyscale images 
of Girk2 and eGFP immuno-reactive cells acquired by confocal microscopy. C & E 
show pseudo coloured images D & E. SNpc in human and mouse brain with 10x 
magnification of mouse SNpc (I). Scale bar; 100 μm (in A), 10 μm (F). VTA, ventral 
tegmental area; SNpc, substantia nigra pars compacta. 
Figure 16: Ghrelin Receptor is Expressed on A9 Dopamine Cells in Adult Mouse 
Midbrain. 
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2.4.8. SN4741 Fluorescence Immunocytochemistry: Tyrosine 
Hydroxylase 
 
(A & B) x20 magnification greyscale and pseudo coloured images of SN4741 cell 
nuclei stained with Hoechst (1:10,000). (C & D) x20 magnification greyscale and 
pseudo coloured images of rabbit-anti TH antibody stained SN4741 cells. (E) 
Represents a merged image of B & D.  (F & G) x40 magnification greyscale and 
pseudo coloured images of SN4741 cell nuclei stained with Hoechst (1:10,000). (H & 
I) x40 magnification greyscale and pseudo coloured images of rabbit-anti TH antibody 
stained SN4741 cells. Merged x20 and x40 magnification images (E & J) show 
SN4741 cells possess strong TH immunoreactivity. Primary antibody was omitted 
from control and no TH immunoreactivity was observed. These 20x and 40x 
magnification Images were acquired using InCell Analyser 2000 (GE, Healthcare). 
Figure 17: SN4741 Midbrain Derived Neuronal Cell Line Express TH 
Immunoreactivity 
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X20 magnification images cale Bar = 80μm (in E). X40 magnification images scale 
bar 40µm (in J). 
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2.4.9. SN4741 Fluorescence Immunocytochemistry: Ghrelin Receptor, 
GHSR 
(A & B) Greyscale images of SN4741 cells stained with Hoechst (A) and Rabbit-anti 
GHSR antibody (B). (D & E) are blue and green pseudo coloured versions of A & B. 
(C) Merged x40 magnification images (D & E) indicate that SN4741 cells are 
immunopositive for GHSR. Primary antibody was omitted from control and no GHSR 
immunoreactivity was observed. These 40x magnification Images were acquired 
using inverted fluorescence microscope, Olympus IX51. Scale Bars = 25μm (in B). 
Figure 18: SN4741 Midbrain Derived Neuronal Cell Line Expressed 
GHSR Immunoreactivity. 
76 
 
 
 
2.4.10. SN4741 Fluorescence Immunocytochemistry: Girk2 
 
 
 (A & D) Greyscale Hoechst (1:10,000) counterstained SN4741 nuclei. (E) Greyscale 
image portraying strong Girk2 immunoreactivity in SN4741 cells. Girk2 
immunoreactivity was not observed in control group (B & C). Images (C & F) are 
merged pseudo coloured images (A, B and D, E, respectively.) Primary antibody was 
omitted from control. These 10x magnification Images were acquired using inverted 
fluorescence microscope –Olympus IX51. Scale bars = 100μm (A-F) 
 
 
 
 
 
 
 
Figure 19: Girk2 is Expressed in Neurones of Midbrain Derived Neuronal Cell 
Line SN4741 
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2.4.11. SN4741 Fluorescence Immunocytochemistry: Calbindin 
 
 
  
(B - G) Shows an array of greyscale images of SN4741 cells stained with various 
dilutions of Rabbit-anti Calbindin antibody. (H-N) show Hoechst (1:10,000) 
counterstained SN4741 nuclei. (A, C, E, G, I, K, M) indicate that SN4741 cells possess 
no detectable Calbindin immunoreactivity. Corresponding Hoechst stained nuclei are 
labelled (B, D, F, H, J, L, N) respectively. Calbindin immunoreactivity on SN4741 cells 
incubated with Calbindin antibody exhibited immunofluorescence typically observed 
in control group (A) where primary antibody was omitted. These 10x magnification 
Images were acquired using inverted fluorescence microscope –Olympus IX51. Scale 
Bars = 100μm (A-N). 
 
 
 
 
 
 
 
Figure 20: SN4741 Midbrain Derived Neuronal Cell Line Do Not Expressed Calbindin 
Immunoreactivity. 
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2.4.12. Western Blot & RT-PCR: SN4741 Cell Line Express Key Ghrelin 
Axis Proteins 
 
RT-PCR (A) and Immunoblotting (B) confirm expression of APT-1, GHSR1a, and 
MBOAT4 at protein and RNA level in SN4741 cells. MBOAT4, membrane bound O 
acyl transferase 4; APT-1, acyl-protein thioesterase 1. 
 
 
 
 
 
 
 
Figure 21: Ghrelin Receptor and Key Ghrelin Axis Enzymes are Expressed in 
Substantia Nigra Dopamine A9 (Girk2+) Neurones. 
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2.5. Discussion 
 
SN dopaminergic cell death is a key hallmark of PD pathology and ghrelin’s role in 
neuroprotection is likely mediated via GHSR activation (Andrews, et al., 2009), 
therefore highlighting the potential for ghrelin’s use as a neuroprotective agent on the 
cells which are degraded in PD. We used immunohistochemistry to confirm the co-
localization of TH+ and GHSR-eGFP+ neurones in the (mouse) SN.  Furthermore, we 
have characterized the midbrain neurones by Girk2 and calbindin immunoreactivity. 
Consistent with published literature we show that the A9 (SN) subset of dopamine 
neurones are predominantly Girk2 immunoreactive, and that Calbindin 
immunoreactivity predominates over Girk2 in the A10 subset of catecholaminergic 
neurones in the ventral tegmental area (VTA) (Bjorklund & Dunnett, 2007; Reyes, et 
al., 2012). We conclude that GHSR is expressed in the TH+/Girk2+ A9 (SN) neurones 
in-vivo.  
Also, we show that the TH+ mouse midbrain-derived SN4741 cell line (Beynon, et al., 
2013; Son, et al., 1999) express Girk2 and GHSR, as well as key ghrelin axis proteins, 
APT-1 & MBOAT4, thus confirming their suitability in neurotoxicity studies to study 
direct mechanisms of ghrelin neuroprotection. 
In previous literature it is suggested that ghrelin plays a multifaceted role in 
neuroprotection via GHSR activation and the subsequent down-regulation of pro-
apoptotic pathways (e.g. Caspase pathways) and increased mitochondrial function in 
a UCP-2 dependent manner (Andrews, et al., 2009; Bayliss & Andrews, 2013). This, 
along with ghrelin’s ability to decrease microglial activation and pro-inflammatory 
factor release, is the proposed method in which ghrelin promotes neuronal protection 
(Andrews, 2011; Beynon, et al., 2013).   
Although the complete mechanism(s) of ghrelin’s neuroprotective actions are yet to 
be elucidated, we will now aim to investigate the effects of known natural and synthetic 
GHSR activating agents in an in vitro PD-toxin model. Our data thus far shows that 
GHSR is expressed on the sub-population of DA neurones that are preferentially lost 
in PD (A9 subpopulation, Girk2+) (Damier, et al., 1999a; Damier, Hirsch, Agid, & 
Graybiel, 1999b). Our results also showed that SN4741 cells do not express Calbindin 
immunoreactivity. Together, we suggest that the SN4741 share properties of the A9 
subpopulation of midbrain neurones rather than the Calbindin+, A10 subpopulation. 
Subsequent investigations in Chapter 3, 4 and 5 will focus on testing the 
neuroprotective potential of GHSR agonists and to characterize the nature of this 
using both in vitro and in vivo models.  
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3.0. Chapter 3: Assessing Ghrelin-Mediated 
Neuroprotection in the Rat 6-OHDA Parkinson’s Disease 
Model 
 
3.1. Introduction 
3.1.1. Parkinson’s Disease Animal Models 
Animal models of PD are a powerful method for gaining insight into the mechanisms 
of PD pathogenesis. Etiological (gene-based models) of PD are required to reproduce 
the adult onset of nigrostriatal DA neurone degeneration which correlates with a 
measureable alteration in animal behaviour and motor deficits. Gene-based models 
use transgenic overexpression of mutant genes for autosomal-dominant genes such 
as α-synuclein and leucine rich repeat kinase 2 (LRRK2) and knockdown models for 
autosomal-recessive genes such as Parkin, DJ-1, phosphatase and tensin homolog 
(PTEN)-induced novel kinase 1 (PINK1) (Dawson, Ko, & Dawson, 2010). The 
measurement of behavioural changes in rodent models of PD may not draw direct 
parallels with symptoms found in human PD, as the human and rodent motor system 
organizations vary. However, induced-phenotypes or behavioural changes (or 
‘symptoms’) in rodent models must give a measure correlating a relationship between 
the degeneration of nigrostriatal DA neurons and striatal function to be of relevance. 
As rodents do not exhibit typical Parkinsonism as seen in humans, a non-human 
primate model is best suited to accurately study PD motor symptoms (Dauer & 
Przedborski 2003).   
Besides the use of gene-based models to induce SNpc DA neuron degeneration, 
pathologic models which utilize neurotoxins to replicate DA neurone degeneration are 
also well established. The neurotoxins 6-hydroxydopamine (6-OHDA) (Vercammen 
et al. 2006), (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) MPTP (Lee et al. 1992) 
and more recently, the widely used pesticides, paraquat and rotenone have received 
attention due to the positive association of human PD cases in users of these 
pesticides (Tanner et al. 2011). 
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3.3.2. 6-OHDA Parkinson’s Disease Model 
6-OHDA is an organic chemical which accumulates in DAergic (and noradrenergic 
(NAergic) neurons to induce degeneration resulting in loss of motor function in animal 
models of PD (Ungerstedt, U. 1968). Although the 6-OHDA-induced pathology varies 
from that of PD; as a result of DA and NAergic transporter uptake, 6-OHDA has been 
used for over 30 years for its relative selectiveness for monoaminergic neurones 
(Ungerstedt, U. 1968; Luthman et al. 1989). In this chapter we will focus on replicating 
selective SNpc DA neuronal degeneration and the resulting motor-deficits in an in vivo 
6-OHDA unilateral MFB lesion rat model of PD (Simola et al. 2007). Furthermore, we 
will test the efficacy of acyl-ghrelin neuroprotection against 6-OHDA-induced 
neurodegenerative phenotype and motor-deficits ex vivo and in vivo respectively. 
6-OHDA is not permeable to the BBB and therefore must be administered by 
stereotaxic injection into the brain while the animal is under anaesthesia. Stereotaxic 
injection into the subtantia nigra (SN) or medial forebrain bundle brain (MFB) results 
in the initiation of DA neurone degeneration without an apoptotic morphology within 
24hrs (Jeon et al. 1995). The MFB carries ascending DA and serotonergic projections 
to the forebrain. Alternatively, the DA nigrostriatal pathway can be targeted by 
injection into the striatum (Janov et al. 1976). Stereotaxic 6-OHDA injection into the 
striatum results in a prolonged retrograde degeneration of nigrostriatal cells which 
lasts for 1-3 weeks (Sauer & Oertel, 1994; Przedborski et al 1995). In unilateral 
stereotaxic lesions one hemisphere is selectively degenerated, with the contralateral 
hemisphere then serves as a control (Ungerstedt, U. 1971). Unilateral lesioning 
results in an asymmetrical rotation in animals when injected with methamphetamine 
which is proportional to the extent of the nigrostriatal lesion (Przedborski et al 1995). 
The unilateral lesion can be assessed quantitatively by the number of unidirectional 
rotations performed by the animal and by quantifying SNpc cells displaying TH 
immunoreactivity. DA neurone groups in mammalian brains can be identified by 
staining for tyrosine hydroxylase (TH), the enzyme that catalyzes the rate-limiting step 
in the synthesis of dopamine (Björklund & Dunnett, 2007). These measurements can 
be used to assess the success of novel PD treatments such as graft transplantation, 
gene therapy and novel therapeutics in restoring or protecting nigrostriatal DA 
neurones (Jiang et al. 1993; Bjorklund et al. 2002). 
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3.3.3. 6-OHDA Mode of Action to Replicate Progressive Nigrostriatal 
Dopamine Cell Death of PD 
A key pathophysiological hallmark of PD is the progressive degeneration of DA 
neurons of the nigrostriatal pathway- these are the dopamine neurones which have 
their soma residing in the SN and their projections extending to the striatum. The 
nigrostriatal pathway is one of the major dopamine systems in the brain and is part of 
the basal ganglia motor loop which is involved in the production of movement (Dauer 
& Przedborski 2003). Loss of DA neurons in the SNpc results in striatal DA deficits 
and subsequent motor symptoms of PD (Dauer & Przedborski 2003). 
The mode of action and mechanism by which 6-OHDA kills DA neurones is not yet 
fully understood. However, evidence suggests that an amalgamation of many factors 
contributes to 6-OHDA-mediated cell death. Following neurotoxin uptake via 
dopamine transporters (Luthman et al. 1989), 6-OHDA resides in the cytosol of DA 
neurones where it produces reactive oxygen species (ROS) and retards the activity 
of biological macromolecules (i.e. lipids, nucleic acids, and proteins) by the production 
of quinones that attach nucleophilic groups (Dauer & Przedborski 2003). The 
formation of ROS by the autoxidation of 6-OHDA is considered as one of the main 
underlying DA neurotoxicity mechanisms (Kumar et al. 1995; Seto-Otero et al. 2000). 
Recent studies have also implicated extracellular oxidation of 6-OHDA in DAergic cell 
loss and shown high sensitivity of DAergic neurons to oxidative stress which may 
attribute to the relative selectiveness of DA degeneration versus other monoamine 
cell types (Berretta et al. 2005; Hanrott et al. 2006). It has also been suggested that 
6-OHDA elicits mitochondrial complex 1 inhibition in a mechanism similar to 
environmental toxins and MPTP-induced neuron degeneration (Glinka et al. 1996; 
Betarbet et al. 2002; Schober, A. 2004).  
To date, there is no evidence demonstrating that 6-OHDA contributes towards the 
formation of another PD-linked pathology- the intracellular misfolded protein 
aggregates called Lewy Bodies (LBs). 
 
3.3.4. 6-OHDA in Neuroprotection Studies 
6-OHDA has been used extensively to successfully test the efficacy of putative 
neuroprotective agents to prevent PD neurodegeneration.  
For example, resveratrol, curcumin and naringenin are all extracts found in skin of 
grapes, turmeric and grapefruit respectively. Daily doses (10, 20 and 40 mg/Kg) of 
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resveratrol were given to rats for 10 weeks following 6-OHDA lesions. Resveratrol 
alleviated a list of 6-OHDA-induced aberrations, such as chromatin condensation, 
mitochondrial enzyme complex swelling and DA neurone vacuolization in the rat 
SNpc. These results were paralleled with a decrease in mRNA expression of 
inflammatory markers tumour necrosis factor alpha (TNF-alpha) and Cytochrome C 
oxidase subunit 2 (COX2) (Jin et al. 2008). Curcumin and naringenin also attenuated 
the loss of TH+ SNpc neurone and striatal levels of DA by anti-oxidative mechanisms 
(Zbarsky et al 2005). Other food extracts such as polyphenols extracted from green 
tea, which are known to elicit a potent anti-oxidant scavenging, iron chelating and anti-
inflammatory, have been tested against 6-OHDA neurotoxicity in an in-vitro setting. 
Green tea derived polyphenols also showed anti-oxidative mechanisms by inhibiting 
the 6-OHDA-induced iron-dependent inflammatory redox sensitive transcription 
factor, nuclear factor-kB (NF-kB) (Levites et al. 2002). Pharmacological agent, 
edaravone is used to aid neurological recovery following acute brain ischemia and 
cerebral infarction. Edaravone administered to rats 30 minutes following 6-OHDA 
unilateral lesioning attenuated the loss of TH+ cells on the SNpc and striatum along 
with characteristic unidirectional amphetamine-induced rotations. This same study 
observed edaravone exerted anti-apoptotic and anti-oxidative effects on TH+ neurons 
cultured in vitro. And these effects where paralleled with an increase in vitro TH+ 
neuron survival in a dose-dependent manner (Yuan et al. 2008). 
Other treatments shown to attenuate 6-OHDA-induced nigrostriatal lesion include glial 
cell-line derived neurotrophic factor (GDNF) pre-treatments (24hr) and administration 
of statins, atorvastatin and simvastatin (Kearns et al. 1995; Kumar et al. 2012). 
Similarly to edaravone and food extracts the statins’ neuroprotective mechanisms 
involved recovery or attenuation from 6-OHDA-induced inflammation and oxidative 
stress. Atorvastatin and simvastatin also reversed a plethora of both biochemical and 
behavioural changes induced by the 6-OHDA lesion. These included impaired body 
weight, locomotor activity, rota-rod performance, oxidative defence, mitochondrial 
complex activity and increased levels of pro-inflammatory cytokines TNF-alpha and 
interleukin-6 (IL-6) (Kumar et al. 2012). An in vitro experiment utilising resistin, a 
cysteine-rich adipose-derived peptide hormone, has shown that inhibition of 6-OHDA-
induced apoptotic markers also contributes to neuronal survival. Treatment of 
MES23.5 cells with resistin resulted in the attenuation of Bcl-2 degradation, BAX 
expression, PARP degradation and caspase 3 activation whilst decreasing ROS 
production and restoring perturbed mitochondrial membrane potential (Lu et al. 2013). 
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This evidence shows the 6-OHDA lesion to be a reproducible and well established 
method of assessing DA cell neurodegeneration and testing the efficacy of anti-PD 
therapeutics both in-vivo and in-vitro. These findings also reiterate that oxidative 
stress is a key contributor to 6-OHDA induced nigrostriatal DA degeneration. Anti-
apoptotic effect are also mechanisms by which DA cell neuroprotection can be 
achieved. Furthermore, it appears that anti-oxidative and anti-apoptotic effects of 
naturally occurring and pharmacologically developed compounds are sufficient to 
attenuate 6-OHDA-induced aberrations in vivo and in vitro. 
 
3.3.5. Ghrelin in Parkinson’s Disease Models 
The orexigenic stomach hormone, ghrelin, is known to modulate appetite and 
metabolic homeostasis (De Vriese & Delporte, 2007). However, acyl ghrelin (AG) has 
also shown promise as potential neuroprotective agents in models of PD and other 
disease models (reviewed Andrews Z.B. 2011). In the MPTP mouse model of PD, AG 
but not UAG promotes SNpc neuron protection in a GHSR1a-dependanet manner 
(Jiang et al. 2008; Bayliss et al. 2016). AG treatment attenuated an array of pro-
apoptotic markers such as the increasing Bcl-2: BAX ratio and activation of Caspase 
3. AG-mediated neuroprotection in MPTP-mouse model coincides with a decrease in 
glial cell activation, glial fibrillary acidic protein and ionized calcium binding adaptor 
molecule 1 microglia in the SN. No such neuroprotective mechanisms were observed 
with UAG administration (Bayliss et al. 2016). Thus, supporting the importance of the 
AG-activated GHSR1a pathway in ghrelin-mediated neuroprotection of SNpc 
neurons- an effect that is mediated in a mitochondrial uncoupling protein 2 (UCP-2)-
dependant manner (Andrews et al. 2009). In vitro AG neuroprotection against MPTP 
radical metabolite, MPP+, also involved modulation of apoptotic Bcl-2: BAX ratio, anti-
oxidative effects and inhibition of NF-KB translocation (Liu et al. 2010). An in vitro 
experiment by (Beynon et al. 2013) also showed anti-inflammatory properties of AG 
in a lipopolysaccharide (LPS) neuro-inflammatory model using TH and GHSR1a 
immune-reactive SN4741 midbrain derived neurons. Here, AG attenuated the LPS-
mediated release of pro-inflammatory cytokine interleukin-6 (IL-6). An affect which 
was abolished upon pre-treatment with GHSR1a antagonist [D-Lys3]-GHRP-6 
(Beynon et al. 2013). 
Work describing the AG-mediated neuroprotection of DA neurons in vitro and in vivo 
appears to be governed by GHSR1a activation resulting in an array of downstream 
effects involving anti-apoptotic, anti-inflammatory and oxidative mechanisms.  It 
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should be noted, however, that the efficacy of AG as a neuroprotective agent has not 
been tested using the 6-OHDA toxin PD model.  Herein, the rat unilateral MFB 6-
OHDA lesion model was used in order to assess the effectiveness of AG in prohibiting 
neurodegeneration. 
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3.2. Methods and Material 
 
3.2.1. Animal Handling and Stereotaxic 6-OHDA Lesioning 
All in vivo procedures were performed under licence to the Animal (Scientific 
Procedures) Act 1986 by Dr Tim Wells and Dr Mariah Lelos in the School of 
Bioscience, Cardiff University. Male SD rats (weighing 194-241g) were purchased 
from Charles River (Margate, UK) and housed under conditions of 12h light/12h dark 
(lights on at 06.00h) with water available ad libitum. Rats were fed crushed diet (SDS 
801066 RM3(E); 3.64kcal/g) available either ad libitum throughout the 24h period or 
in three 1h periods (at 18.00h, 23.30h and 05.00h) during the dark phase using a 
Comprehensive Lab Animal Monitoring System (CLAMS).   Food intake and body 
weight was monitored daily. On day 0 one cohort of ad libitum-fed rats were surgically 
implanted with osmotic minipumps (Alzet model 2001) primed to deliver acyl-ghrelin 
(Phoenix Pharmaceucitals; 80µg/24µl/day) sub-cutaeneously for 7 days. A control 
group was also monitered where acyl-ghrelin was replaced with saline. 
 
After 1 week on these treatment regimes, rats received an injection of 
desipramine/pargyline (50mg/kg/i.p), were anaesthetised with isolfluorane and 
mounted in a Kopf stereotaxic frame. The skull was exposed and a burr hole was 
drilled to introduce a cannular for a single unilateral medial forebrain bundle (MFB) 
injection of either vehicle (0.2mg/ml ascorbic acid in 0.9% sterile saline; pH5.0) or 6-
OHDA (hydrobromide salt (Sigma Chemicals, UK); 3μg/µl in vehicle). To minimize 
variability due to degradation of the toxin, the 6-OHDA solutions were freshly made, 
kept on ice and protected from exposure to light. The solution was injected into 
the right MFB using the following co-ordinates (relative to bregma) Lateral −1.3; 
Anterior −4.0 and Ventral 7.0.  A total volume of 3μl 6-OHDA was injected at a flow 
rate of 1μl/min, the cannular was left in place for a further 3 min and then slowly 
removed. The rats received an injection of analgesic (Metacam, 150µg/s.c) after the 
skin was sutured and they were allowed to recover before being returned to their 
home cage. 
Rats received injections of BrdU (50mg/kg/i.p) on days 12 and 18 after lesion surgery 
to birth date dividing cells, whilst on days 27 and 35 (i.e. 3 and 4 weeks post lesioning) 
they were subjected to drug-induced rotational testing. On the day of testing rats 
received an injection of methamphetamine (2.5mg/ml/kg/i.p in sterile saline) and 
immediately placed into individual rotometer bowls. Contralateral and ipsilateral 
rotations were recorded using Rotorat software for 90 mins. 
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After rotational testing on day 35 rats were terminally anaesthetised with sodium 
pentobarbital (200mg/ml) (Euthetal, Merial) until total loss of reflex, nose-anus length 
measured, and subjected to thoracotomy. After withdrawal of a terminal blood sample 
by cardiac puncture, rats were killed by transcardial perfusion of 1.5% 
paraformaldehyde (PFA). After perfusion, brains were excised and post-fixed by 
immersion in 1.5% PFA in 0.1M PBS overnight at 4oC. Brains were then cryo-
protected by sinking in 30% sucrose at 4oC until further processing. In addition, 
pituitaries were dissected and weighed, and right femori and tibiae dissected for 
quantification of bone length using a handheld micrometer. 
 
3.2.2. Histology: Tissue preparation for Nickel DAB 
Immunohistochemistry 
Whole rat brains were shipped from Cardiff University to the Institute of  Life Science, 
Swansea University and mounted onto a freezing microtome (Microm HM 450) (-
30◦C) with JUNG-tissue fixing medium® for coronal sectioning (30µm thick). Rat 
brains were sectioned rostro-caudally along the entire brain and sectioned tissue was 
collected 1:6 in a labelled 12-well plate and immersed in PBS+0.2% Sodium Azide 
(Sigma Aldrich). The tissue sections were stored at 4oC prior to immunohistochemical 
preparation.   
 
3.2.3. Tyrosine Hydroxylase DAB Immunohistochemistry 
Immunohistochemistry experiments were carried out in CELLSTAR® 12-well plate 
[665180] (greiner bio-one, UK) at room temperature and with gentle agitation unless 
stated otherwise. Free-floating tissue sections were removed from storage conditions 
washed thoroughly (2 x 10 mins) in PBS (Sigma Aldrich) with gentle rocking/agitation 
at room temperature. PBS was removed prior to permeabilization of tissue sections 
using 0.03% Triton-x100 in PBS (0.03% PBS-T) for 10mins. Following 
permeabilization tissue sections were immersed in 1.5% H2O2 in PBS for 20 mins in 
order to remove endogenous peroxidase activity before being washed for another 2 x 
10 mins in PBS and 1 x 10 mins in 0.03% PBS-T. Tissue sections were then immersed 
in 5% Normal Goat serum (5% NGS) (Sigma Aldrich) in 0.1% PBS-T for 60 min at 
room temperature to block non-specific binding sites. Excess block was then removed 
prior to application of a primary antibody, rabbit anti-TH [ab6211] (1:500, Abcam®, 
UK), diluted in 2% NGS in PBS-T and incubation at 4oC overnight (approx. 16-24hrs). 
Primary antibody stained sections were then washed another 2 x 10 mins in PBS and 
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1 x 10 mins in 0.03% PBS-T before a 70 minute incubation with biotinylated goat Anti-
Rabbit IgG Antibody (Vector Laboratories [BA-1000], with gentle agitation at room 
temperature whilst being protected from light. All steps from here onwards are carried 
out with minimum exposure to light as the sample is now light sensitive until the final 
oxidation reaction occurs and DAB precipitate has formed. Again, the sections were 
washed 2 x 10 mins in PBS and 1 x 10 mins in 0.03% PBS-T prior to incubation with 
VECTASTAIN®Elite® ABC Kit [PK-6100] (Vector laboratories, UK) ABC solution (a 
mix of 0.4% reagent solution A and 0.4% reagent solution B in 0.1% PBS-T). ABC 
solutions A (Avidin DH solution) & B (biotinylated enzyme) were pre-mixed in 0.1% 
PBS-T for 30mins, making-up the ABC solution prior to its addition to sample tissues 
for 90mins. ABC solution was then removed and the tissue sections were washed 2 
x 10mins in PBS before a final wash 10 minute wash in 0.1M sodium acetate pH 6.0. 
Excess sodium acetate solution was then removed prior to initiating the DAB reaction 
by mixing 1ml Nickel DAB solution with 60ul of glucose oxidase solution (5mg/ml) in 
the presence of tissue sections. This reaction was performed by 1ml of Nickel DAB 
solution pipetted into a well of a corner of a weighing boat and 60ul of glucose oxidase 
was pipetted adjacently but were not mixed. A fine-tipped painting bush was used to 
transfer tissue sections into the 1ml of DAB solution immediately prior to the mixing 
with glucose oxidase. The plate was then swirled (3-4 times) to ensure solutions were 
thoroughly mixed prior to gentle rocking/agitation for nickel DAB staining to develop. 
Once sufficient Nickle DAB staining had developed, a paint brush was used carefully 
to transfer tissue sections from the DAB-glucose oxidase reaction solution into PBS 
and washed twice for 10 mins in PBS. 
 
3.2.3.1. Sample Dehydration, Delipidation and Slide Preparation  
Following 2 x PBS washes tissue sections were suspended in a TBS (Sigma Aldrich, 
Gillingham, UK) filled petri dish. The tissue sections were mounted onto 
SuperFrost®Plus slides [25 x 75 x 1.0mm] (VWR International LTD) and allowed to 
dry overnight. Once dry, tissue samples underwent dehydration by submerging the 
slides in increasing concentrations of ethanol (70%, 90%, 100%, and 100 %) for 3 
minutes each. Samples were then de-lipified by submerging slides in Histo-Clear [HS-
200] (National Diagnostics) twice for 3 minutes. Slides were removed from Histo-Clear 
and 50ul of Entellan® [107960](MerckMillipore) was pipetted evenly over the slide 
prior to carefully lowering a MENZEL-GLÄSER 24 x 60mm glass coverslip (Thermo 
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Scientific, Germany) to complete slide preparation. Sample slides were the left to dry 
prior to inspection via light microscopy. 
 
3.2.3.2. Light Microscope Imaging 
Examination and imaging of tissue sections was performed using a Nikon Eclipse 50i 
light microscope. X4 magnification .tif/ format images were acquired for spatial 
orientation and illustration of entire SNpc. 2-3 x10 magnification images (tif format) of 
the SNpc were then acquired per hemisphere in order to perform TH+ cell 
quantification using the open source image analysis software, Image J (Java) 
(Available to download: http://imagej.net/Welcome).  Image J is an image processing 
program for multidimensional image data with a focus on scientific imaging 
(imagej.net/Introduction).  
 
3.2.4. Quantification of Tyrosine Hydroxylase-positive SNpc neurons 
with image J 
The protocol below describes the step-by-step image J protocol used to quantify TH+ 
SNpc neurones from x10 magnification digital images. Each step includes a 
description followed by instructions on how to execute the step in image J software 
(in italic font).  
Step 1: Open x10 magnification raw image with image J software.  
File > Open. Then select the x10 magnification image to be analysed. 
Step 2: Convert raw image to an 8-bit image. 
Image > Type > 8-bit 
Step 3: Enhance the contrast between foreground and background staining. 
Process > Filters > Unsharp Mask. Select 100 radius (sigma); 0.5 mask weight. 
Process > Enhance Contrast. Select saturate pixels: 0.4%. 
Step 4: Outline the SNpc in x10 magnification image using x4 magnification image for 
reference and orientation. 
Set tool as ‘Polygon’. Draw around the SNpc in the x10 image. 
Step 5: Convert image to a masked image where there are only two colours, black 
and white. Then adjust the threshold until only the TH+ SNpc neurons appear black, 
91 
 
and all image background is white. Use original or contrast enhanced images to 
ensure TH+ cells appear black. This is important as threshold values may vary slightly 
between images, therefore slight adjustments are usually required to ensure correct 
cell quantification. To minimise the variation in image intensity, all images of the same 
magnification should be acquired using identical microscope settings (e.g. Acquire all 
x10 images using an identical exposure time, image type and quality output). 
Image > Threshold > Adjust Threshold. Move sliders to ‘correct’ threshold where only 
TH immunoreactive cells are visible in black against a white background. 
Step 6: Quantify the number of TH immunoreactive cells in the outlined SNpc. Once 
this step is executed image J will produce a table of results which includes (cell) 
counts and produce an image of identified cells.  
Analyse > Analyse Particles > Set Particle size: 100- Infinity; Circularity: 0.00-1.00; 
select show: Overlay Masks, select: Display Results and select: Summarise.  
 
Figure 22: Step by Step Illustration of SNpc DA Cell Identification using Image J 
Software 
This figure illustrates the 7 steps described above in the section titled ‘Quantification of 
Tyrosine Hydroxylase-positive SNpc neurons with image J’. 
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3.3. Results 
3.3.1. Acyl-Ghrelin Treatment Attenuated SNpc Dopamine Cell Loss 
Induced by 6-OHDA Lesion  
 
A-J show greyscale x4 magnified rat SNpc-containing midbrain tissue sections 
stained for TH immunoreactivity. (B, D & F) illustrate unlesioned control hemispheres 
and (A, C & E) illustrate sham or 6-OHDA lesioned rat hemispheres. 6-OHDA lesion 
results in loss of TH+ neurones in the SNpc and VTA in ad-lib (C) and meal fed (G) 
rats. AG pre-treatment attenuated TH+ cell loss in rat SNpc and VTA. Meal fed, 
dietary-restricted rats do not prevent 6-OHDA-mediated cell loss. Ad-libitum fed 
sham/lesioned rat (Ad-lib/sham); Ad-libitum fed/lesioned rat (Ad-lib/lesion); Ghrelin 
pre-treated/ad-libitum fed/lesioned rat (Ghr/ad-lib/lesion). Scale bar; 500 μm (A-J). 
 
 
Figure 23: 6-OHDA-Induced SNpc TH+ Neurone Loss is Attenuated in Rats 
Pre-treated with Acyl-Ghrelin. 
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Quantification of TH+ SNpc neurones in sham or lesioned rat hemispheres (left) as a 
percentage of intact control hemisphere (left). Image J quantification of rat SNpc TH+ 
neurones shows 6-OHDA-induced TH+ cell loss in lesioned animals. The number of 
TH+ SNpc neurones ad-lib fed/6-OHDA lesioned rats was reduced. However, TH+ 
SNpc neurone number was protected from 6-OHDA lesioning in acyl-ghrelin pre-
treated ad-lib fed rats. Ad-libitum fed sham lesioned rat (Ad-lib/sham) (n=17); Ad-
libitum fed/lesioned rat (Ad-lib/lesion) (n=19); Meal fed/sham lesioned rat 
(Meal/sham) (n=6); Meal fed/lesioned rat (Ad-lib/lesion) (n=8); Acyl-ghrelin pre-
treated/ad-libitum fed/lesioned rat (Ghr/ad-lib/lesion) (n=10). Statistical analysis was 
carried out with Graph Pad Prism 5.0 using one-way-ANOVA and Bonferroni’s pot-
hoc analysis*, P<0.05; **, P<0.01; ***, P<0.001. 
 
Dietary-restriction (meal –fed) did not protect 6-OHDA-induced dopaminergic cell 
loss. 
 
 
Figure 24: Acyl-Ghrelin Pre-treatment Protects TH+ SNpc Neurones in an In 
Vivo 6-OHDA Parkinson’s Disease Model. 
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3.3.2. Acyl-Ghrelin Treatment Attenuated Amphetamine-Induced 
Rotations in In Vivo 6-OHDA Parkinson’s Disease Model 
 
 
 
Graphs (a) and (b) demonstrate the average net amphetamine-induced rotations 
completed by rats in 90 minutes at week 3 and 4 post-lesion, respectively. Graphs (a) 
and (b) show 6-OHDA-induced unilateral lesion in animals increases the 
amphetamine-induced rotation versus Ad-Lib/Sham lesioned controls. This effect is 
significant (***) at 4 weeks post-lesioning. However, 6-OHDA unilateral lesion-induced 
amphetamine rotation are greatly attenuated in AG-pretreated Ghrelin/Ad-
Lib/Lesioned animals. An effect which is statistically significant 4 weeks post-
lesioning. Ad-libitum fed sham lesioned rat (Ad-lib/sham) (n=17); Ad-libitum 
fed/lesioned rat (Ad-lib/lesion) (n=18); Ghrelin pre-treated/ad-libitum fed/lesioned rat 
(Ghr/ad-lib/lesion) (n=10). Statistical analysis was carried out with Graph Pad Prism 
5.0 using one-way-ANOVA and Bonferroni’s pot-hoc analysis*, P<0.05; **, P<0.01; 
***, P<0.001. 
 
 
3-weeks post lesion 4-weeks post lesion 
Figure 25: Acyl-Ghrelin Pre-treatment Attenuated Amphetamine-Induced 
Rotations in In Vivo 6-OHDA Parkinson’s Disease Model. 
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3.4. Discussion 
The rat in vivo unilateral MFB 6-OHDA lesion is a well-established method used to 
mimic characteristics of PD pathology - that is the preferential degeneration of 
midbrain dopaminergic neurons and induction of motor dysfunctions in animal models 
(Dauer & Przedborski, 2003). Published data suggests the stomach hormone, acyl-
ghrelin, as a potential neuroprotective agent against PD neurodegeneration (Andrews 
et al. 2009). Both in vitro and in vivo studies propose that increased mitochondrial 
function, anti-oxidative effects and anti-inflammatory effects underpin the 
neuroprotective properties of acyl-ghrelin (Lee et al. 2010 & Bayliss et al. 2016). In an 
effort to test acyl-ghrelin-mediated neuroprotection we raised circulating levels of acyl-
ghrelin directly by mini-pump infusion (80ug/kg/day; s.c) and indirectly by subjecting 
rats to 7 days of dietary restriction prior to unilateral injection of 6-OHDA into the MFB. 
As described in previous literature, unilateral 6-OHDA injection into the MFB induced 
degeneration of dopaminergic SNpc neurons (Bagga et al. 2015), thus replicating 
aspects of the DA cell death pathology of PD (Brichta et al. 2014).  However, it must 
be noted that our unilateral injection of 6-OHDA also destroyed TH-immunoreactive 
neurones in the ventral tegmental area (VTA); an area rich in A10 DA neurone sub-
type which show relative resistance to degeneration in PD (Dauer & Przedborski, 
2003; Björklund & Dunnett. 2007). Direct administration of acyl-ghrelin for 7 days via 
mini-pump infusion attenuated the 6-OHDA-induced degradation of TH+ SNpc 
neurones (Figure 24). However, our indirect attempt to increase circulating acyl-
ghrelin levels did not result in dopaminergic cell protection. Acyl-ghrelin has displayed 
efficacy in the neurone protection MPTP models of PD and other CNS lesions (Bayliss 
et al. 2016 & Lee et al. 2010). MPTP and 6-OHDA not only share similar uptake 
mechanisms in DA neurones (Dauer & Przedborski, 2003) but also inhibit 
mitochondrial complex 1, increase oxidative damage by ROS production and 
modulate pro-apoptotic events (e.g. release of mitochondrial cytochrome c, increase 
of Bcl-2: BAX ratio and downstream activation of caspases) (Glinka et al. 1996; Dauer 
& Przedborski, 2003; Andrews et al. 2009; Lu et al. 2013 & Tobón-Velasco et al. 
2013). Since there are similarities in neurotoxic modes of action in DA neurons, it is a 
possibility that the acyl-ghrelin-mediated neuroprotection observed in both toxin 
models are governed by similar mechanisms.   
Comparable to other agents found to protect against 6-OHDA-induced cell loss, acyl-
ghrelin mediated neuroprotection has been attributed to anti-apoptotic (Yuan et al. 
2008), ROS-buffering (Andrews et al. 2009) and anti-inflammatory (Levites et al. 
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2002; Jin et al. 2008) mechanisms. Collectively, the acyl-ghrelin mechanisms could 
be utilised in treating a range of CNS diseases (Andrews Z, B. 2011) which share 
underlying perturbations. In the mouse MPTP-PD models, acyl-ghrelin-mediated 
ROS-buffering (via mitochondrial UCP-2), anti-apoptotic effects (via retention of 
mitochondrial Cytochrome C and decreased caspase activation) and subsequent 
survival of SNpc DA neurones is suggested to be GHSR1a mediated (Jiang et al. 
2008 & Bayliss et al. 2016). Inflammation is also associated with PD progression. The 
beneficial effects of acyl-ghrelin on neuronal survival has been associated with a 
decrease in inflammatory mediators (i.e. microglial activation) (Bayliss et al. 2016) 
which result in release of pro-inflammatory cytokines such as IL1-1B, TNF-alpha and 
IL-6 (Hide et al. 2000; Shigemoto-Mogami et al. 2001 & Clarke et al. 2010). The 
release of the latter (IL-6) was diminished by 4hr acyl-ghrelin pre-treatment on in vitro 
midbrain derived neurons (Beynon et al. 2013). Moreover, upon the addition of ghrelin 
receptor antagonist these anti-inflammatory effects were abolished. Other 
unpublished data by our group shows acyl-ghrelin attenuating the activation of 
microglia-associated protein CD11b. 
This data shows that elevating circulating levels of acyl-ghrelin protects SNpc DA 
neurones from 6-OHDA-induced death and attenuates subsequent amphetamine-
induced rotations. These data suggest that acyl-ghrelin may be able to slow or 
diminish the progression of PD or other diseases that share similar pathological traits. 
Strides must now be made to identify the underpinning mechanisms of acyl-ghrelin-
mediated DA neuroprotection. Elucidation of such mechanisms may aid the 
development of novel PD therapeutics. 
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4.0. Chapter 4: In Vitro Parkinson’s Disease (PD) Model 
4.1. Introduction  
4.1.1. In Vitro PD Models 
In vitro models of PD are used extensively to study the cellular pathology of PD by 
attempting to replicate cellular pathophysiological hallmarks such as DAergic cell 
degeneration and the formation of misfolded protein aggregates that contribute to 
intracellular inclusions (Gundersen, 2010). Genetic models involve inducing over-
expression or under-expression (or knockdown) of key PD-related genes identified 
from genetic studies in familial PD (Kumaran & Cookson, 2015). Since these PD-
related genes are usually associated with a distinct cellular or protein dysfunction, 
these have been used to investigate specific subcellular PD-associated mechanisms 
underpinning PD. 
Chemicals which induce PD-like cellular phenotypes are also commonly used to study 
the cellular mechanisms of PD. Moreover, these studies are utilised to test novel anti-
PD therapeutics. In this chapter, we use an in vitro chemical induced PD model to test 
the potential neuroprotective effects of AG and a synthetic GHSR1a agonist, JMV 
2984. 
 
4.1.2. Chemically Induced PD Models 
A range of chemicals have been used to mimic aspects of PD pathology in vitro. 
Among the most frequently used are 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP)(Langston, Ballard, Tetrud, & Irwin, 1983), 6 hydroxydopamine (6-OHDA) (Y. 
M. Ding, Jaumotte, Signore, & Zigmond, 2004), paraquat (McCarthy, Somayajulu, 
Sikorska, Borowy-Borowski, & Pandey, 2004)  and rotenone (Hao, Li, Duan, & Li, 
2017; Pan, Qiao, & Wen, 2016). The mechanism of actions of these in vitro PD-
inducing chemicals disrupt normal cellular pathways predominantly by increasing 
production of reactive oxygen species (ROS) resulting in oxidative damage, and 
inducing mitochondrial dysfunction that perturbs cellular energy homeostasis. 
 
4.1.2.1. MPTP 
The metabolic product of MPTP, MPP+, is a toxin found to cause severe Parkinsonism 
in humans upon intravenous injection. MPTP is a by-product of the synthesis of 1-
methyl-4-phenyl-4-propionoxy-piperidine (MPPP), a synthetic analogue of the opioid 
99 
 
heroin (Langston, et al., 1983). Once inside the cell the active metabolite, MPP+, 
inhibits ETC complex 1, impairs mitochondrial respiration and function, and increased 
ROS production. Moreover, DAergic neurotransmitter DA is relocated from cellular 
extremities to the cytosol where it becomes oxidised and elicits a further increase in 
ROS and subsequent oxidative damage.  Furthermore, MPP+ inhibits ATP production 
and produces oxidative radicals which damage other cellular proteins. Some of the 
oxidative radicals produced are super oxides, these may react with nitric oxide and 
for peroxynitrite which is known to cause oxidative damage and nitration of selective 
proteins (Cleeter, Cooper, & Schapira, 2001). TH, the rate limiting enzyme in the 
biosynthesis of DA is one such protein. Nitration of TH renders the enzyme inactive 
and thus DA production is decreased. Nitrating agent peroxynitrite also damages 
deoxyribonucleic acid (DNA). Peroxynitrite-induced DNA nicks result in the activation 
of poly-(ADP-ribose)-polymerase (PARP) which itself requires the utilisation ATP. 
This activity further aggravates cell energy levels which is already stressed by other 
MPP+ ETC complex 1 inhibiting mechanisms. Furthermore, there is evidence that 
nitric oxide enhances the MPP+ mediated inhibition of ETC complex 1 (Cleeter, et al., 
2001). These deleterious cascades result in increased ROS and oxidative stress, 
decreased mitochondrial efficiency and respiration and energetic failure (Przedborski 
et al., 2000). Moreover, MPTP mouse models mimic aspects of PD symptoms 
(Przedborski, et al., 2000).   
4.1.2.2. 6-OHDA 
6-hydroxydopamine (6-ODHA, also known as oxidopamine) is a DAergic and 
noradrenergic (NAergic) neurone specific neurotoxin. 6-OHDA is taken up into 
DAergic and NAergic cells via DA and or NA re-uptake transporters. 6-OHDA is 
sometimes administered in conjunction with a NA reuptake transporter inhibitor. This 
ensures the selective uptake and degradation of DA neurones. Once inside neurones 
6-OHDA induces an increase in ROS and catecholamine quinone production. The 
accumulation of 6-OHDA inside the cell results in oxidative stress and cell death. The 
literature is unclear as to whether 6-OHDA-induced-cell death is a result of inhibition 
of the ETC complex I and complex IV (Y. Y. Glinka & Youdim, 1995) or that 6-OHDA 
induces a reduction in cell viability via an increase in ROS production (Storch, Kaftan, 
Burkhardt, & Schwarz, 2000). 
The onset of sporadic PD cases has been linked to farmers working with pesticides 
such as paraquat and rotenone. A study by (Narayan, Liew, Bronstein, & Ritz, 2017) 
showed an increased risk of developing sporadic PD amongst individuals who had 
occupational, residential and household sources of pesticide exposure. An increased 
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risk of PD is observed in users versus non-users of these pesticides (Tanner et al., 
2011). 
4.1.2.3. Paraquat 
Paraquat is commonly used herbicide which also shown to be toxic to animals and 
humans. In vitro use of paraquat has utilised its oxidative stress-inducing property to 
stimulate degeneration of neuronal cells in models of PD. In a model used by (Ravi, 
Narasingappa, Joshi, Girish, & Vincent, 2017) paraquat induced oxidative stress 
which led to lipid peroxidation, DNA damage and apoptosis. 
4.1.2.4. Rotenone 
Rotenone is a highly lipophilic compound commonly used as an insecticide which 
induces PD-like cellular hallmarks including increased oxidative stress, mitochondrial 
dysfunction and alpha synuclein accumulation, and neurotoxicity in in vitro PD 
models. Moreover, rotenone also produces PD-like motor deficits in animal models of 
PD (Cicchetti, Drouin-Ouellet, & Gross, 2009; S. Y. Kang et al., 2017; Pan, et al., 
2016). Rotenone’s link to sporadic PD (Narayan, et al., 2017; Tanner, et al., 2011), in 
vivo  selectivity for DAergic neurone degeneration (Sherer, et al., 2003) and its 
lipophilic properties, which allow it to enter cells directly devoid of transporter 
assistance, make it a robust PD-like inducing chemical (Sherer, et al., 2003; Testa, 
Sherer, & Greenamyre, 2005). In vivo rotenone treatment in animal models of PD 
exert PD-like symptoms and motor deficits, and DAergic SNpc neurone degeneration 
and alpha synuclein and Lewy body proteinous aggregates in both in vitro and in vivo 
models. The major limitation of the rotenone model is its variability. There is a 
variability in terms of the percentage of animals that develop recognizably distinct 
nigrastatial lesions and the extent of those lesions (Cannon et al., 2009). Although 
selective degeneration is observed in SNpc in animal models (Sherer, et al., 2003) 
rotenone's highly lipophilic characteristic allows it to also readily cross the cell 
membrane of many cell types an induce complex 1 inhibition (e.g. hepatocytes) (Heinz 
et al., 2017). Thus, the PD-like effects induced in rotenone models may be the result 
of cumulative cell damage and not specifically the degeneration of nigrostriatal 
neurones.  
PD-like symptoms (e.g. bradykinesias, postural instability and rigidity, loss of TH+ 
substantia nigra neurones and subsequent loss striatal dopamine. Rotenone is known 
to inhibit ETC complex 1, impair mitochondrial respiration and induce an increase in 
ROS production (Q. Zhang et al., 2014), inhibit the removal of damaged proteins by 
impairing proteasomal activity (S. Y. Kang, et al., 2017) and increase neurotoxicity. 
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Besides investigating the neurodegenerative mechanism by which DAergic cells die, 
in vitro models are also used as tools for testing novel anti-PD therapies and 
elucidating their underpinning mechanism of action. The in vitro rotenone PD models 
is one such tool.  
 
4.1.3. Neuroprotection in In Vitro Rotenone PD models 
Published literature identifies the in vitro rotenone PD model as a test for new anti-PD 
therapeutics. Kaempferol inhibits rotenone-induced toxicity by significantly reducing 
ROS and mitochondrial carbonyls in primary neurones and SH-SY5Y cells. Moreover, 
this study shows that kaempferol has anti-apoptotic and antioxidative effect, and 
neuroprotection appears to be related to increased mitochondrial turnover by 
mitophagy (Filomeni et al., 2012). 
Rotenone-induced toxicity was not prevented by quercetin, myricetin and resveratrol 
(Filomeni, et al., 2012). However, a study by (S. Y. Kang, et al., 2017) shows that 
rosuvastatin does indeed exert neuroprotection against rotenone-induced 
neurotoxicity in SH-SY5Y cells. Moreover, rosuvastatin treatment appeared to restore 
lost cell viability and decrease expression of alpha synuclein. This protection is 
thought to be mediated by regulation of autophagy related proteins, mTOR and beclin-
1, and implicates suppressed autophagy in rotenone-induced neurotoxicity. 
The neuroprotective effects of alpha-mangostin on rotenone induced ROS production, 
caspase 3 and 8 activation, mitochondrial dysfunction and alpha synuclein 
aggregation was demonstrated by (Hao, et al., 2017). Moreover, alpha-mangostin 
treated SH-SY5Y cells were protected from the rotenone induced deficit in 
mitochondrial membrane potential (MMP) and cellular ATP levels. 
A study by (Y. Moon, Lee, Park, Geum, & Kim, 2005) showed that pre-treatment of 
primary rat mesencephalon neurones with coenzyme Q10 reverses rotenone-induced 
apoptosis and mitochondrial depolarization. This suggests that loss of MMP may be 
important in rotenone-induced DAergic cell death via apoptosis. In vitro rotenone 
models are commonly used to explore the possible mechanisms behind intracellular 
PD pathology and mechanisms of action of potential neuroprotective chemicals and 
agents. Although AG is cited as being neuroprotective in PD models using MPTP in 
vitro and in vivo, there is no literature surrounding AG neuroprotection against 
rotenone-induced neurotoxicity. 
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4.1.3.1. Acyl-Ghrelin Neuroprotection in Models of PD 
An elegant experiment by (Bayliss, Lemus, Santos, et al., 2016) performed on Ghrelin 
(knockout) KO mice showed that chronic administration of AG attenuated MPTP-
induced loss of nigrostriatal TH+ DAergic neurone number, neurone volume and TH 
protein expression. Moreover, AG administration reduced the increase in glial fibrillary 
acid protein (GFAP) and ionized calcium binding adaptor molecule 1 (Iba1) induced 
by the mouse MPTP PD model. No such effect was observed upon chronic 
administration of exogenous un-acylated form of ghrelin (UAG) in Ghrelin KO mice. 
Of note, injection of exogenous AG also increased levels of plasma UAG. Illustrating 
the un-acylating action of APT-1 in the conversion of AG to UAG. Other studies by 
this group provide evidence that AG neuroprotection is at least partly dependent on 
an integral mitochondrial uncoupling protein, mitochondrial uncoupling protein 2 
(UCP2), buffering of ROS and increased mitochondrial biogenesis (Andrews, et al., 
2009). 
In vitro studies indicate that acylated AG Protects against MPP+-induced neurotoxicity 
in MES 23.5 neuroblastoma cells. In this study ghrelin is seen to reverse a multiplicity 
of pro-cytotoxic events such as induction of malonaldehyde, increased Bax-Bcl2 ratio 
and elevated levels of superoxide dismutase and catalase; suggesting that AG’s in 
vitro protection against MPTP-induced cytotoxicity must be partly governed by anti-
oxidant effects and modulation of cytokines and proinflammatory factors via NF-kB 
(L. Liu, et al., 2010). A short study by (Beynon, et al., 2013) also shows ghrelin 
mediating an anti-inflammatory response in lipopolysaccharide (LPS) treated DAergic 
neurones by inhibiting the release of interleukin-6 (IL-6). This effect was shown to be 
mediated via AG’s endogenous receptor, GHSR1a, which is expressed on these 
neurones, as inhibition of GHSR1a by [D-Lys3]-GHRP-6 (D-Lys3) abolished these 
anti-inflammatory effects. This is consistent with an anti-inflammatory and anti-oxidant 
effect observed in a study showing ghrelin mediated inhibition of pro-inflammatory 
factors including tumour necrosis factor-alpha (TNF-α), interleukin 1-beta (IL-1β) and 
nitrite in in vitro cultured mesencephalon neurones (Moon, et al., 2009). Furthermore, 
an in vivo aspect to this study showed ghrelin mediating the inhibition of MPTP-
induced pro-inflammatory markers and activation of microglia, as well as the 
attenuation of DAergic neurone death in the SNpc. AG inhibited the expression of 
TNF-α, IL-1β, activation of inducible nitric oxide synthase and microglial activation in 
the nigrostriatal pathway. This study states that GHSR1a is not expressed on 
microglia suggesting that AG-mediated effects are not induced directly at microglia. 
Instead it is suggested that inhibition of microglia activation, which is associated with 
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AG neuroprotection (Andrews, 2011), is elicited via the suppression of matrix 
metalloproteinase-3 in DAergic neurones (M. Moon, et al., 2009).   
It has been proposed that AG mediated neuroprotection is the result of GHSR1a 
binding and activation of 5’ adenosine monophosphate activated kinase (AMPK), 
which shifts cellular energy balance from negative to neutral; enhanced removal of 
damaged mitochondria (and proteins) via mitophagy (autophagy of mitochondria), 
which limits the excess production of ROS; and increased mitochondrial biogenesis 
and function, including the buffering of ROS (Bayliss & Andrews, 2013). 
Drawing on insights from the published literature PD-inducing chemicals appear to 
perturb mitochondrial function, increase ROS production, energetic stress, increased 
inflammatory response- leading to cytotoxicity and neurodegeneration. 
Neurodegeneration in animal models manifest in PD-like motor deficits. We propose 
that AG-mediated neuroprotection is the result of binding with its endogenous 
receptor, GHSR1a, triggering downstream signalling pathways via phosphorylation of 
energy homeostasis regulator, AMPK; leading to increased function of the 
mitophagy/autophagy system and mitochondrial biogenesis to attenuate oxidative 
damage sustained by neurotoxins and retain metabolic function. In addition, AG may 
function indirectly as it appears to play an anti-inflammatory role in attenuating the 
release cytokines and inflammatory factors and suppressing microglial activation.  
In this chapter, we aim to: 
• Determine growth kinetics of SN4741 cells in full culture medium and substrate 
restricted medium. 
• Define a concentration of mitochondrial complex-1 inhibitor, Rotenone, which 
results in a decrease of SN4741 cell number and viability and an increase in 
cell cytotoxicity.  
• Test the direct neuroprotective effects of AG and JMV 2894 Pre-treatment 
against Rotenone-induced cell loss. 
• Investigate intracellular mechanisms by which AG treatment protects SN4741 
cells from rotenone.  
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4.2. Methods & Materials 
 
4.2.1. SN4741 Cell Line 
SN4741s are a mouse midbrain derived nigral dopaminergic cell line. Establishment 
of the SN4741 cell line is described fully in (Son et al. 1999) see 
(http://www.jneurosci.org/content/19/1/10.full.pdf+html).  Briefly, DAergic progenitor 
cells where collected by surgically removing butterfly-shaped mesencephalic regions 
from transgenic embryos from embryonic day 13.5 (13.5) TA58-#8.  
Only DA cells from the transgenic embryos would be immortalized and survived in 
successive cultivation steps. Mesencephalic butterfly-shaped regions were triturated 
as described (son et al 1999) and primary pelleted cells were cultured for at least 3-5 
weeks. A pure cell population of transgenic primary embryonic cells was produced by 
repeated passages for 3-4 months. Cloning cylinders were used for cloning purposes. 
Cells of clonal origin were monitored during colony formation and re-confirmed by TH 
and SV40Tag immunostaining. 
4.2.2. SN4741 Culture Medium and Substrate Restricted Medium 
SN4741 cells are routinely cultured in 500mL DMEM without sodium pyruvate 
(Invitrogen, 41965-039) supplemented with 50ml FBS (10106169, Invitrogen), 5mL 
Penicillin/Streptomycin (Pen/Strep) (15140122, Gibco, UK), 5mL L-Glutamine 
(25030081, Gibco, UK) and 15mL 20% Glucose solution, filtered bioultra for molecular 
biology 20% in water (Sigma, 49163-100ml). Substrate restricted SN4741 cell culture 
media was also prepared by diluting the above (termed ‘Full media’) in dilution media 
in the absence of L-Glutamine, FBS and Glucose supplementation. Full media diluted 
in dilution media (DMEM without sodium pyruvate, supplemented with Pen/Strep) to 
prepare a titration of media at various percentages (%). The aim was to mimic caloric 
restriction in vitro as there is growing evidence for the benefits of caloric restriction. 
Research (Andrews et al.2009) also indicates that the neuroprotective effects of AG, 
at least in in vivo rodent models, require a concomitant reduction in caloric intake. 
Using our substrate restricted media we investigated the effects of neurotoxin 
challenge in the presence and absence of GHSR1a agonist pre-treatment. The table 
below lists the volumes of full medium vs dilution medium used to prepare substrate 
restricted (SR) media. 
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Table 13: Volumes of Full Medium and Dilution medium required to Prepare 
50mL of Substrate Restricted (SR) SN4741 Cell Culture Media 
Percentage of Full 
Medium 
Volume of SN4741 Full 
Media (mL) 
Volume of SN4741 
Dilution Media (mL) 
0% 0 50 
20% 10 40 
40% 20 30 
60% 30 20 
80% 40 10 
100% 50 0 
  
SN4741 cells were routinely cultured in full (100%) media. Full media was replaced 
by a chosen SR medium at the initiation of an experimental procedure. SN4741 cells 
were seeded in triplicate into corning 3596 flat bottom multi-well plates. Cells were 
incubated in 0, 20, 40, 60, 80 and 100% of full media for 72hrs. 100µL SN4741 
medium was added to each well every 24hrs. At 72hrs cells were screened for 
cytotoxicity and viability using methods described in ‘Development of a Rotenone-
induced neurotoxicity/cell loss in vitro PD model’.  
 
4.2.3. Routine SN4741 Cell Culture 
Thawing SN4741 cells: SN4741 cells were stored in liquid nitrogen in cryovials. 18ml 
of SN4741 full culture medium was pipetted into a T75 flask and incubated at 37◦C 
(5% CO2) for 30 mins. SN4741 cryovials were then removed from the liquid nitrogen 
and thawed by swirling in 37◦C water bath until only a small amount of ice remains. 
Using a P1000 the contents of the thawed cryovial were placed into the pre-warmed 
18ml of SN4741 full culture medium in a T75 flask(s). The flask was then swirled to 
ensure an even distribution of cells and placed in a cell culture incubator at 37◦C, 5% 
CO2 overnight to adhere. 
Seeding SN4741 cells: the following morning SN4741 cells should be adhered to the 
T75 flask- cells were visualised via a light microscope. The SN4741 cell culture media 
was removed and the cells were washed 1x with 10ml PBS (10010023, Gibco, UK) to 
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remove excess medium. SN4741 cells were then detached from the cell culture vessel 
by adding 4ml of trypsin/EDTA, 0.5% (15400054, Gibco, UK) into the flask and 
incubating (5% CO2; 37◦C) for 5min. The flask was removed from the incubator and 
gently tapped to ensure all cells had detached before neutralising trypsin/EDTA by 
adding 6ml of cell culture medium and resuspending. Using a 10ml pipette, the cell 
solution was gently pipetted up and down 5-10 times to create a single cell 
suspension. Prior to seeding cells, 10 µL of cell suspension was mixed with 10 µL 
Trypan Blue Solution 0.4% (15250061, Gibco, UK) and pipetted onto a Countess™ 
cell counting chamber slide (Invitrogen). The Trypan Blue Solution is a dye exclusion 
test where dead cells take up the dye and viable cells do not. The chamber slide was 
placed into the Countess™ Automated Cell Counter (Invitrogen) and a total cell count, 
a total live cell count and a total dead cell count was obtained (expressed as cells per 
ml). Live cell count values were used to quantity cells destined for seeding or sub-
culturing/passaging. SN4741 cells were then seeded into experiment vessel of choice 
and placed into the incubator (5% CO2; 37◦C) overnight to settle and adhere. 
Sub-Culturing SN4741 cells: Following the re-suspension of a 90% confluent T75 
flask in cell culture medium: 
• Add 0.5ml of SN4741 cell suspension to 19.5ml cell culture medium→90% 
confluent in 4 days. 
• Add 1ml of SN4741 cell suspension to 19ml cell culture medium→ 90% 
Confluent in 3 days 
• Add 2ml of SN4741 cell suspension to 18ml cell culture medium→ 90% 
Confluent in 2 days 
• Add 3ml of SN4741 cell suspension to 17ml cell culture medium→90% 
Confluent in approx. 24hrs. 
Every 2-3 days cell culture medium was removed, cells were washed (PBS) and 
medium was replenished. All culture vessels and experimental plates were labelled 
with name, date, contents and passage number. 
Making cell stocks: Cell culture medium was removed from a 90% confluent T75 
culture flask and SN4741 cells were washed once with 10ml PBS (10010023, Gibco, 
UK). The PBS wash was removed and 4ml of Trypsin/EDTA (15400054, Gibco, UK) 
solution was introduced into the culture vessel before being placed in the incubator 
for 5 minutes whilst SN4741 cells detached. The culture vessel was subsequently 
checked for cell detachment via light microscope and gently tapped to remove 
adhered SN4741 cells if necessary. Using a 10ml sterile pipette add 6ml of fresh cell 
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culture medium to neutralize the trypsin/EDTA solution before pipetting the cell 
suspension up and down (5-10 times) to produce a single cell solution. The cell 
suspension was placed into a 50ml falcon/centrifuge tube and centrifuged at room 
temperature for 300xg for 5 minutes. The supernatant was carefully removed to avoid 
disturbing the cell pellet and the cells were re-suspended in cryopreservation media 
(see table 1 below for contents of cryopreservation medium).  
 
Table 14 Contents of Cryopreservation medium 
Cryopreservation media 
Reagents FBS DMSO SFM (serum free 
medium) 
Volume 12.5ml 5ml 32.5ml 
Ratio 2.5 1 6.5 
 
The resuspension was promptly added to a cryovial and sealed in a NalgeneTM 
(bottom container holds Isopropanol) container and transferred to a -80oC freezer 
overnight (16-24hrs). Cryovials were labelled with cell type, name, date and passage 
number. The frozen cryovial were then submerged in a tanker filled with liquid nitrogen 
and a record was made.  
 
4.2.5. SN4741 Cell Growth Curve 
To estimate the time required to culture sufficient numbers of SN4741 cells for 
downstream experiments 1ml of cell suspension (34,000 cells/ml) was added to 19ml 
of full SN4741 cell culture medium in a T75 flask. Confluency of cells in the T75 was 
recorded by observation via a light microscope and were then detached and quantified 
every 24hrs post-seeding- as described in ‘Seeding SN4741 cells’ section above. A 
complete monolayer of cells covering the culture vessel was referred to as 100% 
confluency and no cells was referred to as 0% confluency. 
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4.2.6. Development of a Rotenone-Induced Neurotoxicity In Vitro PD 
Model  
The loss of SNpc dopamine neurones is a pathological hallmark of PD. Before testing 
the direct neuroprotective effect of AG and GHSR1a agonist compound (JMV 2894), 
SN4741 cells were challenged with a titration of rotenone concentrations over 24hrs. 
Here we aimed to define a minimum dose (concentration) of rotenone which induced 
SN4741 cell loss that parallels an increase in cell cytotoxicity and a decrease in cell 
viability. The optimal dose of rotenone will subsequently be used to test whether AG 
and GHSR1a agonists exert protective effects on rotenone-induced 
neurodegeneration.  
SN4741 cells were seeded at 3000 cells/well on a 96 well plate (Corning 3596 flat 
bottom plate) by pipetting 100µL of 30,000 cell/ml of the stock solution into each well 
(See SN4741 splitting/subculture for details on method). Cell culture plates were left 
to sit on a level surface for 5 minutes before incubation (5% CO2; 37◦C) – this allowed 
the cells to distribute evenly onto the bottom of the wells. Following overnight 
incubation, 100 µL of pre-warmed (37◦C) SN4741 cell culture media was introduced 
to treatment wells before being returned to the incubator for either 1 hr or 24hrs. 
Subsequently, SN4741 cells were treated for 24hrs with final well concentrations of 
rotenone at 0nM (vehicle only), 10nM, 100nM, 1,000nM and 10,000nM. Rotenone 
was prepared at a 3-fold higher concentration (i.e. 0nM, 30nM, 300nM, 3,000nM and 
30,000nM) by thoroughly mixing (vortex) 3 µL of 10mM rotenone stock diluted in 
Dimethyl Sulfoxide (DMSO) into 10ml culture medium producing a 30,000nM 
rotenone solution. 3,000nM, 300nM and 3nM rotenone solutions were prepared by 
performing 1 in 10 dilutions i.e. 100 µL of 30,000nM rotenone solution mixed into 900 
µL of cell medium to produce 1ml of 3,000nM rotenone solution. Vehicle treatment 
was prepared from DMSO using the same dilution method. Finally, 100 µL of 3x 
concentrated rotenone solution was added to treatment wells performing a 1:3 dilution 
which resulted in final well concentrations 0nM, 10nM, 100nM, 1,000nM and 
10,000nM before 24hr incubation (5% CO2; 37◦C).  100 µL of a 50:50 solution of 
DMSO in PBS was used as a positive control to induce cell cytotoxicity. Each 
treatment was performed in triplicate. Cells were then fixed, imaged and analysed as 
described in SN4741 Cell Growth Curve, Image acquisition with In Cell 2000 and 
Image J cell count analysis macro for quantification of rotenone-induced cell loss. 
Rotenone treated cells were also subject to cytotoxicity and viability assessment using 
the CellTox™ Green Cytotoxicity Assay (Promega, #G8741) and the CellTiter-Blue® 
Cell Viability Assay (Promega, #G8080) respectively. 
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4.2.6.1. The CellTox™ Green Cytotoxicity Assay 
The CellTox™ Green Cytotoxicity Assay was used according to user manual for 
endpoint determination of rotenone-induced SN4741 cytotoxicity following 24hr 
treatments. This assay includes a proprietary asymmetric cyanine dye whose 
fluorescence properties are amplified upon binding to DNA. The cyanine dye 
produces no measurable fluorescence intensity in the presence of healthy cells with 
intact cell membranes. When the cell membrane integrity is compromised, such as 
that observed in dead or dying cells, the cyanine dye may then bind with DNA and 
produce appreciably larger fluorescence intensity. The fluorescence intensity 
measured by the binding of the cyanine dye with DNA of dead cells is proportional to 
cytotoxicity. A fluorimeter measures the intensity and wavelength distribution of 
emission spectrum after excitation by a certain spectrum of light. 
During 24hr incubation of cells in the presence of rotenone, the CellTox™ Green 
Cytotoxicity Assay components (CellTox™ Green Dye and Assay Buffer) were 
thoroughly thawed in a 37°C water bath. Kit components were individually mixed 
using a vortex to ensure homogeneity, then collected at the bottom of their tubes using 
a centrifuge. 1 µL CellTox™ Green Dye was added to every 500 µL Assay Buffer, as 
needed, to produce a 1:500 dilution equivalent to a 2x concentrated staining solution. 
Following 24hr cell incubation with rotenone, 200 µL of cell medium was removed 
from each well and 100 µL of 2x concentration of the CellTox™ Green staining 
solution was added to each well. Samples were protected from light and incubated 
(5% CO2; 37◦C) for 15mins before 1 minute of shaking (500-700 RPM). The plate was 
placed into a microplate-reader for fluorescence intensity measurements using an 
excitation wavelength of 485–500nm and emission of 520–530nm. Treatments were 
performed in triplicate. Measurements were exported in a spreadsheet for analysis.  
 
4.2.6.2. CellTiter-Blue® Cell Viability Assay  
The CellTiter-Blue® Cell Viability Assay was used according to user manual for 
endpoint determination of rotenone-induced decrease in SN4741 cell viability 
following 24hr treatments. This assay utilises the ability of viable cells to convert the 
redox dye, resazurin, into a fluorescent end product resorufin. The colour change from 
blue to purple can be observed by eye and therefore the conversion of resazurin to 
resorufin can be quantified using a plate-reader with fluorimeter and 
spectrophotometer capabilities. The production of resorufin is hampered in a 
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population of dead cells as they readily lose metabolic capacity. Thus, the fluorometric 
intensity and spectrophotometric absorbance measured by the production of resorufin 
is proportional to cell viability. A spectrophotometer: measures the number of photons 
(the intensity of light) absorbed after it passes through sample solution. Resazurin is 
permeable to living cell membranes and is reduced to resorufin once inside living 
cells. Studies on hepatic subcellular sections show that resazurin (peak absorbance 
wavelength = 605nm) can be reduced by several redox enzymes found in the cytosol, 
micro soma and mitochondria. Once reduced, resorufin (peak absorbance 
wavelength = 573nm) freely diffuses back into the cell culture medium. 
During the 24hr incubation of cells in the presence of rotenone, the The CellTiter-
Blue® Cell Viability Assay Reagent were thawed in a 37°C water bath. 200 µL of cell 
culture medium was removed from treatment wells and 20 µL of CellTiter-Blue® 
Reagent was added. Sample plates were tapped gently to ensure solution 
homogeneity, before being returned to an incubator (5% CO2; 37◦C) for 30mins. 
Absorbance measurements were collected for 1-4 hrs using an OMEGA microplate-
reader. Treatments were performed in triplicate. Measurements were exported into 
an Excel spreadsheet for analysis.  
4.2.6.3. SN4741 Counterstaining 
To quantify numbers of SN4741 cells following experimental treatments, cells were 
fixed (as described previously) and counterstained with Hoechst. Hoechst is a blue 
fluorescent dye with a high affinity to binding with DNA and so is used to counterstain 
cell nuclei. Following fixation with 4% PFA the fixing solution was removed and a 100 
µL of counterstaining solution, consisting of Hoechst diluted 1: 10,000 in PBS, was 
applied to the cells. The plate was protected from light and incubated for 15 mins at 
room temperature to counterstain SN4741 cell nuclei. The staining solution was then 
removed and cells were washed 2 times in 100 µL PBS before applying a final 100 
µL of PBS to each well. Samples plates were sealed with parafilm and protected from 
light with tin foil. Plates containing counterstained cells were kept refrigerated (4◦C) 
until image acquisition with the In Cell Analyser 2000. 
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Figure 26: 24hr rotenone treatment timelines 
Figure 26 illustrates experimental timeline from seeding SN4741 cells through to 
rotenone administration and fixation at experimental endpoint prior to cell 
counterstaining and image acquisition. (A) Illustrated experimental time lines for 
rotenone treatments in sync with 1hr GHSR1a agonist pre-treatment (A) and 24hr 
GHSR1a agonist pre-treatments (B). 
 
4.2.6.4. Image Acquisition with In Cell 2000 
The In Cell Analyser 2000 is an automated wide-field fluorescence microscope 
capable of 2D and 3D image capture. The In Cell Analyser 2000 contains a range of 
fluorescence and bright-field filters and objective lenses. A number of images were 
acquired per well. These images were termed ‘fields’ or ‘fields of view’. To quantify 
relative numbers of cells per well, the maximum number of fields per well was selected 
so that edges of the 96-well plate were not included. Sample plates were left to 
equilibrate to room temperature before placing into the In Cell Analyser 2000. Images 
were saved in TIF format to a Seagate (2TB) external hard drive for storage. 
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4.2.6.5. Image J Cell Count Analysis and Macro Automation 
The protocol below describes the step-by-step imageJ protocol used to quantify 
SN4741 cell nuclei from x20 magnification digital images. Each step includes a 
description followed by instructions on how to execute the step in image J software  
(in italic font).  
Image J available at (https://imagej.nih.gov/ij/download.html) 
Step 1: Open x20 magnification raw image with image J software.  
File > Open. Select the x20 magnification image to be analysed. 
Step 2: Convert raw image to an 8-bit image and subtract background. 
Image > Type > 8-bit 
Process > Subtract Background > Set Rolling Ball Radius: 70 pixels. 
For rolling ball radius background subtraction method, rolling ball radius must be at 
least as large as the radius of the largest object. The approximate radius size can be 
measured by drawing a straight line through the diameter of the largest object 
(nucleus) using Set tool as ‘Straight’’. Since, Diameter = 2 x Radius; Radius = 
Diameter/2. 
E.g. If the diameter of the largest object (nucleus) measured approximately 120 pixels 
in length. Since Radius = Diameter/ 2; Radius = 120/2 = 70 pixels. And 60 pixels 
should be used as minimum Rolling Ball Radius. 
Step 3: Enhance the contrast between foreground and background staining. 
Process > Enhance Contrast. Select saturate pixels: 0.4%. 
Step 4: Convert image to a masked image where there are only two colours, black 
and white (binary image). Then adjust the threshold until only the SN4741 nuclei 
appear white, and all image background is black. Use original or contrast enhanced 
images to ensure cell nuclei appear white. This is important as threshold values may 
vary slightly between images, therefore images from various treatment groups were 
selected and tested to before defining a set threshold to be applied to the entire 
dataset. Variation in image intensity was minimised by acquiring all x20 magnification 
images using an automated imaging system with identical exposure time and image 
type output. 
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Image > Threshold > Adjust Threshold. Move sliders to ‘correct’ threshold where only 
cell nuclei are visible in white against a black background. 
Step 5: Invert the binary image so that nuclei are black and background is white. 
After moving sliders to ‘correct’ threshold.  Select ‘Apply’ on Thresholding window with 
‘Dark background’ unchecked.  
Step 5i: Shows the red box in step 5 (figure 27) zoomed-in shows a cluster of 3 nuclei 
which would be counted as 1 object by ‘Analyse Particles’ function in Image J. 
Step 6: Separate touching nuclei using the watershed feature. The watershed feature 
finds the centre of each object and calculates a distance map from the object centre 
points to the edges of the objects. The algorithm then fills that "topological map" with 
imaginary water (watershed). A 1 pixel line (dam) is then placed between two objects 
where their water sheds meet. 
Process > Binary > Watershed 
Step 6i: Depicts the red box in step 6 (figure 27), zoomed-in region identifies a cluster 
of 3 nuclei which have been separated using the watershed feature. This cluster of 
nuclei would be counted as 1 object by ‘Analyse Particles’ function in Image J but will 
now be counted as 3 separate nuclei. 
Step 7: Quantify the number of cell nuclei in the image. Once this step is executed 
image J will produce a table of results which includes (cell) counts and produce an 
image of numbered, identified cell nuclei.  
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Analyse > Analyse Particles > Set Particle size: 300- 10,000; Circularity: 0.50-1.00; 
select show: Overlay Outlines, Select: Display Results and select: Summarise.  
 
Steps 2 through 7 can be automated by creating a macro. Once a macro is created, 
image J can execute the image processing steps 2-7 on a single image or a collection 
of images. To create a macro, open one of the images destined for analysis then 
select: Plugins > Macros > Record. When steps 2 to 7 have been completed, click 
‘Create’ macro and save as ‘ijm’ file. To run a macro on an image open an image on 
image J then select Plugins > Macros> Run. Select the previously saved macro and 
steps 2-7 will be executed on a selected image. Selecting and executing a macro for 
100s or 1,000s of images is laborious. Image J possessed a batch processing feature 
which can be utilised to automate the application of an image analysis or image 
processing macro to an entire image set. This can be done by firstly storing all images 
Figure 27: Schematic Illustration of Image J Cell Nucleus Count Protocol Steps 1- 7 
as Described Above in “Image J Cell Count Analysis Macro'' 
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to be analysed into 1 folder. Then select:  Process > Batch > Macro. Select the folder 
containing images to be analysed into ‘Input’ and select a folder to store all Overlay 
Outline images in ‘Output’. ‘Open’ the pre-saved macro containing steps 2-7 and 
select ‘Process’.  
Image J will begin applying the macro in succession to an image set and subsequently 
populate a table of results which includes object (nuclei) counts. Data produced in 
image J was transferred to a Microsoft Excel spreadsheet. SN4741 cell nuclei were 
quantified in 30 fields of view (unless stated otherwise) in each well for each 
treatment. Treatments were performed in triplicate. Statistical analyses were carried 
out using GraphPad Prism 5.0 for PC. 
 
4.2.6.6. Live/Dead Assay 
LIVE/DEAD ® Viability/Cytotoxicity Kit *for mammalian cells* (L3224, Thermo Fisher 
Scientific) was also utilised to measure and validate rotenone-induced cytotoxicity 
across a titration of rotenone concentrations (Vehicle, 0, 10, 100, 1,000 and 
10,000nM) with DMSO treatment serving as a positive control for cell cytotoxicity. The 
LIVE/DEAD ® Viability/Cytotoxicity Kit serve to distinguish viable from cytotoxic cells 
and with the use of two dyes. Both of which express negligible fluorescence before 
interacting with cells. The first dye, Ethidium Homodimer-1 (EthD-1) is used as a 
marker cell cytotoxicity. EthD-1 is impermeable to intact cell membranes. Once 
compromised EthD-1 enters the cell, binds to nucleic acids and undergoes a 40-fold 
enhancement of fluorescence. Thus, producing a bright red fluorescence in dead 
cells. Excitation/emission wavelengths: ~495 nm/~635 nm. Two vials containing 200 
µL of EthD-1 (2 mM) was received in DMSO/H2O 1:4 (v/v). The second dye, Calcein 
AM, is cell permeable and enzymatically converted to the intensity green fluorescent 
dye calcein. The polyanionic dye calcein is formed in the presence of ubiquitous 
intracellular esterase activity which produces an intense uniform green fluorescence 
in live cells. Excitation/emission wavelengths: ~495 nm/~515 nm. Calcein AM (4 mM) 
was received in anhydrous DMSO.  
3,000 SN4741 cell were seeded per well in a 96 well plate and exposed to a titration 
of rotenone concentrations as described (Development of a Rotenone-induced 
neurotoxicity/cell loss in vitro PD model). 1.25 µL Calcein AM (4 mM) and 5 µL EthD-
1 (2 mM) was mixed and vortexed in 5 mL Dulbecco’s phosphate-buffered saline (D-
PBS) (14040133, Gibco) to produce a LIVE/DEAD staining solution (1µM Calcein AM; 
2µM EthD-1). 200 µl of cell culture media was removed and 100µl of staining solution 
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was applied to the cells for 30 minutes at room temperature and protected from light.  
Calcein AM is sensitive to esterase activity and esterase activity may be found in FBS 
supplemented media. Culture media/staining solution was removed and cells were 
gently washed with 200 µL D-PBS to prevent extracellular fluorescence before fixation 
in 4% PFA. SN4741 nuclei were then Hoechst counterstained (see SN4741 
Counterstaining) before 20x objective was used to acquire TexasRed, FITC and DAPI 
images using In Cell Analyser 2000. FITC stain was not retained well post-fixation 
and was omitted from analysis. DAPI images were used to identify nuclei as primary 
objects in the image sets. Mean intensity of nuclear EthD-1 staining in Texas-Red 
channel images was quantified using cell profiler ‘Identify Primary Objects’ and 
‘Measure Object Intensity’ modules following image pre-processing. These steps are 
described fully in chapter 5. Three experimental repeats (n=3) were performed in 
triplicate and 25 images were acquired per well per treatment. Cell Profiler available 
at (http://cellprofiler.org) 
 
4.2.6.7. Detection of Rotenone-Induced Activated Caspase 3/7 in 
SN4741 Neurones 
To determine whether rotenone-induced cell loss was mediated via apoptosis, 
CellEvent™ Caspase-3/7 Green Detection Reagent (Invitrogen, C10423) was applied 
to cells prior to detection with fluorescence microscopy. Caspase 3 activation is an 
essential event in apoptosis. Cell Event™ Caspase-3/7 Green Detection Reagent 
novel fluorogenic substrate for activated caspases 3 and 7. The Caspase-3/7 reagent 
is a cell permeable compound containing a four amino acid peptide (aspartic acid, 
glutamic acid, valine and aspartic acid; DEVD) conjugated to a nuclei acid binding 
dye. In its conjugated form the caspase-3/7 reagent is intrinsically non-fluorescent, 
however activation of caspase-3 or caspase-7 in apoptotic cells leads to cleavage of 
DEVD peptide. Cleavage of DEVD peptide leads to the availability of nuclei acid 
binding dye enabling the dye to bind to DNA and produce a bright green, fluorogenic 
response inside cell nuclei with an absorption/ emission maximum of ~502/530 nm. 
This reagent is applicable for live-cell imaging and fixed (3.7% PFA) cell imaging 
approaches. The dye is well retained post-fixation and detergent permeabilization, 
making the reagent a candidate for potential multiplexing with other kits or 
immunostaining for identification of other proteins of interest. Detection reagent was 
received at 2 mM concentration in DMSO. 
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3,000 SN4741 cells were seeded per well in a multi-well plate prior to being subject 
to 24hrs of 10nM rotenone treatment. Rotenone treatment was prepared and 
administered as described in ‘Development of a Rotenone-induced neurotoxicity/cell 
loss in vitro PD model’. 50:50 DMSO: PBS solution served as a positive control for 
activation of apoptosis and DMSO diluted in culture medium served as vehicle. 
Following 24hrs of 10nM rotenone treatment 0.88 µL of CellEvent™ Caspase-3/7 
Green Detection reagent was added and vortexed in 110 µL complete cell culture 
medium to yield a 16µM stock staining solution (volume was adjusted for number of 
wells required). 200 µL of was removed from cell culture wells and 100 µL 16µM stock 
staining solution was applied to cells for 30mins and incubated at 5% CO2; 37◦C. 
Application of 100 µL 16 µM stock staining solution into 100 µL of medium present 
inside cell culture wells produces a 1:2 dilution resulting in a final well concentration 
of 8 µM Cell Event™ Caspase-3/7 Green Detection reagent. This concentration is 
within the recommended staining concentration described in CellEvent™ Caspase-
3/7 Green Detection reagent user manual, 2 µM - 10 µM. Cell staining solution was 
removed following a 30 minute incubation with staining reagent. Cells were then fixed 
in 3.7% PFA and counterstained with Hoechst as described ‘SN4741 Cell Growth 
Curve’ and ‘SN4741 Counterstaining’. Sample plate was sealed with parafilm, stored 
at 4◦C and imaged using the In Cell Analyser 2000 with 24hrs. 25 x20 magnification 
images were acquired per well using In Cell Analyser 2000 FITC and DAPI filters. 
Treatments were carried out in triplicate for two technical experimental repeats. Total 
cell number (blue Hoechst nuclei) and apoptotic cells (Green Caspase-3/7 Reagent+ 
nuclei) were quantified in Image J image software as described in ‘Image J cell count 
analysis and macro automation’. Data is expressed as the percentage of apoptotic 
cells in the total cell population for each well: 
 
 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑎𝑝𝑜𝑝𝑡𝑜𝑡𝑖𝑐 𝑐𝑒𝑙𝑙𝑠
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
x 100.  
 
Percentage of Caspase 3/7-positive (apoptotic cells) per well(s) was then used in 
Graph Pad Prism v.5 for statistical analysis.  
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4.2.6.8. Direct GHSR1a Agonist Neuroprotection in the Rotenone-
Induced Neurotoxicity In Vitro PD Model 
SN4741 cells cultured in complete medium were treated for 24hrs with 10nM rotenone 
which resulted in a decrease in the number of midbrain cell number (P<0.05) in 
conjunction with decrease cell viability (P<0.01) and increased cytotoxicity (P<0.001), 
as seen in figure 36 (a-c). SN4741 cells cultured in substrate restricted (60% of 
complete cell culture) medium were treated for 24hrs with 10nM rotenone which 
resulted in a decrease in the number of midbrain cell number (P<0.01) in conjunction 
with decrease cell viability (P<0.05) but no increased cytotoxicity (P>0.05), as seen 
in figure 36 (d-f). 10nM concentration of rotenone was selected to model PD 
neurodegeneration in our assay due to its efficacy in inducing the loss of SN4741 cells 
following a 24hr incubation period. To test the potential direct neuroprotective effects 
of AG and synthetic GHSR1a agonist (JMV 2894) SN4741 cells were treated prior to 
rotenone challenge. This experiment was carried out on SN4741 cells cultured in 60, 
80 and 100% of complete full culture medium. Graphs of results showing significant 
protection will be displayed in the results section.  
SN4741 cells underwent 1hr and 24hr pre-treatment with a titration of AG and JMV 
2894 prior to 10nM rotenone challenge. 3,000 SN4741 cells in 100 µL cell culture 
media were seeded per well and incubated overnight under normal growth conditions 
(37◦C; 5% CO2) to adhere. 2x concentrated stocks of AG and JMV 2894 was diluted 
in cell culture media. 100 µL 2x concentrated AG or JMV 2894 (IC50=0.5+/-0.3nM; 
EC50=0.6+/-0nM) is applied to treatment wells, performing a 1:2 dilution. Following 
the addition of 100 µL 2x concentrated stock solutions, final well concentrations of AG 
pre-treatments were: vehicle (H2O), 1nM, 10nM, 100nM, 1,000nM. 1mg of lyophilized 
AG (Tocris, #1465) was reconstituted in 6.0335mL H2O (Nuclease-Free Water, 
Ambion® Nuclease-Free Water) producing a 50 µM solution which was stored in 
single-use aliquots at -20◦C. 40 µL of 50 µM AG stock was mixed with cell culture 
medium to produce 1mL of 2µM (2,000nM) AG treatment solution. 1 in 10 serial 
dilutions were performed to produce the remaining 2x concentrated AG treatment 
solutions (200nM, 20nM and 2nM) e.g. 100µL of subsequent AG treatment solution 
was added into 900 µL culture medium. 
Final well concentrations of JMV 2894 pre-treatment: vehicle (H2O), 0.6nM, 6nM, 
60nM, 600nM. 4.47mg of lyophilized JMV 2894 (molecular weight= 745.79; 10.08mg 
vial of compound 41 was received from Æterna Zentaris, Germany) was reconstituted 
in 998.94 µL H2O (Nuclease-Free Water, Ambion® Nuclease-Free Water) producing 
a 6mM solution which was aliquoted and stored at -20◦C. 6mM JMV 2894 was then 
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diluted 1 in 100 (10 µL into 990 µL) in cell culture media to obtain a 600µM JMV 2894 
solution. 0.6 µM (600 nM) JMV 2894 stock solution was prepared by mixing 1 µL into 
1 mL cell culture medium. 1 in 10 dilutions were performed in cell culture medium to 
obtain the remaining 2x concentrated JMV 2894 solutions (60nM, 6nM and 0.6nM). 
SN4741 cells underwent 1hr and 24hr pre-treatment with GHSR1a agonists prior to 
24hr rotenone challenge (10nM).  Addition of rotenone was as described in 
‘Development of a rotenone-induced neurotoxicity/cell loss in vitro PD model’. Cells 
were subsequently fixed (4% PFA; room temperature for 15mins) and prepared for In 
Cell Analysis of cell numbers by Hoechst nuclear counterstaining.  
Figure 28 illustrates experimental timeline from seeding SN4741 cells and GHSR1a 
agonist pre-treatments through to rotenone administration and fixation at 
experimental endpoint prior to cell counterstaining and image acquisition for 1hr 
GHSR1a agonist pre-treatments (A) and 24hr GHSR1a agonist pre-treatments (B). 
 
 
 
 
 
Figure 28: 1hr & 24hr GHSR1a Agonist Pre-treatment Timelines 
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4.2.6.9. Measurement of Ghrelin-Induced SN4741 Cell Proliferation 
using EdU (5-Ethynyl-2´-Deoxyuridine) Click-iT Assay  
Using our in-vitro PD model, we have shown that acyl-ghrelin pre-treatment 
attenuates rotenone-induced SN4741 cell loss. To ensure the increase in cell number 
observed at the endpoint of our assay is the result of AG-neuroprotection and not the 
result of AG-induced cell proliferation, we employed Click-iT® EdU AlexaFluor®488 
HCS Assay (C10351, Invitrogen) to investigate proliferation status of SN4741 cells. 
The most accurate method of evaluating proliferation is measurement of DNA 
synthesis. 5-ethynyl-2´-deoxyuridine (EdU) is a thymidine analogue which is readily 
incorporated into DNA during DNA synthesis occurring in S-Phase of the cell cycle. 
Detection of EdU is based on a copper-catalysed covalent reaction between an Alexa 
Fluor® dye which contains azide and an alkyne contained in EdU. EdU has an 
advantage over BrDU (also a thymidine analogue) as an efficient detection of the 
incorporated EdU is possible using standard aldehyde-fixation and detergent 
permeabilization (e.g. Triton®-X100).  The Click-iT® EdU assay is also compatible 
with nuclear counterstaining (blue fluorescent Hoechst 33342) and multiplexing with 
immunocytochemistry protocols to identify other cell surface or intracellular markers. 
Conversely, BrdU detection often requires harsher preparations such as DNA 
denaturation to expose BrdU antigens for detection via a anti-BrdU antibody. DNA 
denaturation may disrupt integrity of double-stranded DNA and subsequent nuclear 
counterstaining. DNA denaturation may also affect cell morphology and affect 
antigenicity. BrdU antibodies can also exhitbit non-specific binding. This final problem 
is overcome with the Click-iT® EdU assay using biologically unique (biorthogonal) 
moieties to ensure minimal background noise and high EdU detection sensitivity.      
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Figure 29 illustrates experimental timeline from seeding SN4741 cells and GHSR1a 
agonist pre-treatments through to rotenone administration and addition of EdU at 
71hrs. Following 1hr incubation, thymidine analogue (EdU) is incorporated into cells 
undergoing DNA synthesis. At experimental endpoint (72hrs), cells are fixed before 
the addition of Click-iT detection reagents containing AlexaFluor 488® (AF488) and 
Hoechst 33342 nuclear counterstain. Images of fluorescently labelled cells are then 
acquired using the In Cell Analyser 2000. 
 
 
 
We selected the following treatments to investigate potential proliferative effects of 
1µM AG on SN4741 cells: Vehicle (including water and DMSO diluted accordingly); 
1µM AG (diluted in vehicle) and cells exposed to 10nM rotenone in the presence and 
absence of a 24hr 1 µM AG pre-treatment. Treatments were performed in 100% full 
culture media and 60% of full culture media. We propose that 1µM AG pre-treatment 
(24hr) promoted direct neuroprotection from 10nM rotenone-induced cell loss seen in 
our previous neurotoxicity assay/PD model. Vehicle treated cells and 1µM AG treated 
cells were inspected to establish whether direct AG promoted proliferation in the 
absence of neurotoxin challenge. 20µM EdU-media mix was omitted from negative 
control wells to ensure green EdU fluorescence signal originated from EdU-DNA 
binding and was not a product of the reaction cocktail alone. All treatments were 
performed in triplicate for 2 technical repeats (n=2).  
 
Figure 29:Click-iT EdU Assay Experimental Timeline. 
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SN4741 cells were seeded before undergoing experimental procedure for 24hr 1µM 
AG pre-treatment. See: ‘Direct GHSR1a agonist neuroprotection versus rotenone-
induced SN4741 cell loss’; for full description. A 2x concentrated (20µM) EdU staining 
solution was prepared in cell culture medium. At 71hrs, 200µL of cell culture medium 
was removed from wells and replaced with 100µL EdU (20µM) staining solution. 
SN4741 cells were incubated for 1 hr under standard culture conditions (37◦C; 5% 
CO2) in EdU (10µM) containing media. Cell medium was removed and cells were fixed 
(3.7% PFA; room temperature; 15 mins) (see figure 29 for experimental timeline). 
Fixative was discarded and cells were washed twice in 3% Bovine serum albumin 
(BSA) (A2153-100G, Sigma) in PBS. Cells were permeabilized in 0.5% Triton® X-100 
(X100-500ML, Sigma) in PBS for 20 minutes at room temperature. Fresh 1x Click-iT® 
EdU buffer additive and Click-iT® reaction cocktail was prepared according to user 
manual. For optimal results reaction buffer was used within 15 minutes of preparation 
from kit components: 1X Click-iT® reaction buffer, CuSO4 (Component E), Alexa 
Fluor® azide and Reaction buffer additive. Permeabilization solution was removed 
and cells were washed a further 2 times with 100µL 3% BSA in PBS. Click-iT® 
reaction cocktail was then distributed (50 µL) into each well. Sample plates were 
protected from light and gently rocked at room temperature for a 30 minute incubation 
step. All steps were then carried out with minimal direct exposure to light. Reaction 
cocktail was removed and cells were washed once in 100µL 3% BSA in PBS and 
once in 100µL PBS. SN4741 cell nuclei were then counterstained by incubation with 
100µL of Hoechst 33342 diluted (1:2,000; 5µg/mL) in PBS. Cells were protected from 
light and incubated for 30 minutes at room temperature. Cells were washed twice in 
PBS before imaging and analysis using the In Cell Analyser 2000. 25 fields of view 
(images) were acquired within each well at x20 magnification and 12 images per well 
were acquired at x40 magnification (for illustrative purposes). Images were acquired 
for both (blue) Hoechst 33342 and (green) and Click-iT® EdU AlexaFluor®488 
fluorescence signals. Approximate fluorescence excitation/emission maxima for 
AlexaFluor®488 and Hoechst 33342 bound to DNA are 495nm/519nm and 
350nm/461nm, respectively. The total number of cells (Blue Hoechst nuclei) and 
number of actively proliferating cells (Green AlexaFluor®488) in 25 fields of view were 
quantified using the batch macro process in image J analysis software. Later, datasets 
were also analysed using Cell Profiler image analysis software to compare data 
outputs. Higher magnification (x40) images were also analysed by both software. 
Statistical analysis was carried out in Graph Pad Prism V.5. 
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This figure illustrates the step-by-step method use to quantify the percentage of 
EdU+ve cells. Using the In Cell Analyser (a), images of Hoechst and EdU stained 
nuclei were acquired (Blue and green respectively) (b). Automated Image J cell 
scoring was employed to quantify nuclei in both image channels. (C) Illustrates binary 
masks of scored nuclei, whilst (d) represents numbered nuclei in a zoomed section 
(red box) of a x20 magnification image (c). Total number (e) and number of EdU+ve 
nuclei (f) are quantified. These data are used to calculate the percentage of EdU+ve 
nuclei (g). 
 
 
 
 
 
Figure 30: Work Flow Through of EdU Assay and Analysis. 
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4.2.6.10. Ghrelin Receptor (GHSR1a) Antagonist versus Acyl-Ghrelin 
Neuroprotection 
Acyl- Ghrelin (AG) pre-treatment (24hr) significantly attenuates the loss of SN4741 
cells in our in-vitro rotenone assay. The proposed mechanism of action by which AG 
exerts neuro-protection is thought to begin extracellularly with the binding of AG to its 
endogenous receptor, GHSR1a. 
Here, we use two known GHSR1a antagonists in order to establish whether AG (1uM) 
attenuation of SN4741 cell loss during rotenone (10nM) challenge is dependent on 
GHSR1a. We have previously demonstrated that the SN4741 cell line expresses 
GHSR1a along with some key ghrelin axis proteins; APT1 and GOAT. 
In an attempt to inhibit GHSR1a signalling we pre-incubated (30mins) SN4741s with 
GHSR1a antagonists at a range of concentrations (10, 100, 1000 and 10,000nM) prior 
to AG pre-treatment (24hrs) and subsequent rotenone challenge (24hr). D-Lys3 -
GHRP-6 (D-Lys3) (500µg, Phoenix Pharmaceuticles, 031-22) is a peptide inhibitor of 
GHSR1a (IC50= 0.9μM). 500µg D-Lys3 was reconstituted in 10.75mL water to 
produce 50 µM D-Lys3 solution which was aliquoted and frozen (-20◦C).  
Antagonist D-Lys3 stock solutions were added to culture medium in order to prepare 
30,000nM antagonist solutions- see table 15 for volumes. This antagonist solution 
was diluted 1:10 to achieve 30,000, 3000, 300 and 30nM antagonist concentrations. 
50µL of each of these were added to cells bathing in 100µL of media (a 1:3 dilution) 
resulting in final well concentrations of 10,000, 1000, 100, 10nM. 
Table 15: Preparation of 30µM GHSR1a Antagonist Solutions 
Antagonist Volume of 
Antagonist 
Volume of 
Medium 
Final volume 
D-Lys3 1200ul 800ul 2ml 
Vehicle solutions were prepared by adding a volume of water corresponding ‘Volume 
of Antagonist’ to full medium. 
 
Antagonists were then added to respective wells and incubated under normal growth 
conditions (37◦C; 5% CO2) for 30mins. In this period 4µM (4000nM) AG was prepared 
from frozen stock (at 50µM) by the addition of 152µL of stock AG into 1748µL of 
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media. 50µL of this was added to the wells resulting in a 1:4 dilution and a final well 
concentration of 1000nM AG. SN4741 cells were then incubated under normal culture 
conditions for 24hrs prior to rotenone challenge (previously described). Cells were 
fixed, counter stained and analysed as previously described. 25 2-D de-convoluted 
fluorescence images per well were acquired on the 20x magnification objective of the 
In Cell Analyser 2000 using the DAPI filters- 100% autofocus; 0.5 second exposure. 
SN4741 nuclei counts were measured using Cell Profiler image analysis software. 
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4.2.6.11. 5' Adenosine Monophosphate-activated Protein Kinase (AMPK) 
Antagonist and Acyl-Ghrelin Neuroprotection 
Here we use Compound C (171260, EMD MILLIPORE), a known inhibitor of AMPK, 
to establish whether AG (1uM) attenuation of SN4741 cell loss during rotenone 
(10nM) challenge is dependent on the cellular energy homeostasis regulator, AMPK. 
The phosphorylation of AMPK regulates mitochondrial biogenesis which is thought to 
result in cellular protection (Reznick & Shulman, 2006). 
First, 10mM Compound C stock solution was prepared by dissolving 1mg of powder 
in 250uL DMSO, aliquoted and stored at 4°C. SN4741 cells were cultured for 48hr in 
a titration of Compound C concentrations. This was performed in sync with the 24hr 
AG pre-treatment neurotoxicity experiment, also described in GHSR1a antagonist 
section, to find a concentration which would not result in SN4741 cell loss. The results 
of initial test was used to determine the concentration to be used to determine whether 
AG-mediated neuroprotection is pAMPK dependents.  
Compound C Titration: 3,000 SN4741 cells in 100µL of medium were seeded in into 
a 96-well plate and incubated overnight under standard conditions. On the day of 
Compound C and AG treatment, 1µL of 10mM Compound C stock was mixed into 
1mL of medium producing a 10 µM working stock solution. This working solution was 
then diluted in 100% or 60% of complete medium to produce 3x concentrated 
Compound C solutions to apply to cells. The final 1:3 dilution consisted of adding 50µL 
of 3x concentrated treatments to each well containing 100µL of medium. The final well 
treatment concentrations were 0nM (vehicle), and 20nM, 40nM, 60nM, 80nM, 100nM, 
1000nM Compound C for 30 minutes prior to the addition of 50µL of cell culture 
medium to simulate the addition of AG treatment in the subsequent neurotoxicity 
assay. Table below details the volumes of Compound C working solution and medium 
used to produce concentrated treatments.  
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Table 16: Preparation of Compound C Solutions. 
Compound C 
Final well 
Concentration (nM) 
Compound C 
3x Concentration 
Solution (nM) 
Volume of 10 µM 
Compound C 
Working Stock 
Solution (µL) 
Volume of Cell 
Culture Medium  
(µL)  
0 0 0.00 500.00 
25 75 3.75 496.25 
50 150 7.50 492.50 
75 225 11.25 488.75 
100 300 15.00 485.00 
250 750 37.50 462.5 
20 60 0 500 
40 120 6 494 
60 180 9 491 
80 240 12 488 
100 300 15 485 
1000 3000 150 350 
 
Following a 30 minute incubation with Compound C, 50µL cell culture medium was 
added to each well before returning the culture plate to incubate under standard 
conditions for 24hrs. 100µL of additional medium was then added for the final 24hr 
prior to fixing, counterstaining and analysis of SN4741 cell nuclei. Treatments were 
carried out in quadruplicate for 2 experimental repeats (n=2) in both complete (100%) 
and substrate restricted (60% of complete) medium. 
Compound C in neurotoxicity assay: Titration experiment showed that 100nM of 
potent AMPK phosphorylation inhibitor Compound C did not result in a significant 
decrease in cell number, as observed in figure 51 (a & b) (P>0.05). This concentration 
was used to test AG-mediated neuroprotection. 3,000 SN4741 cells in 100µL of 
medium were seeded in a 96-well plate and incubated overnight under standard 
conditions. Following a 30 minute incubation with 100nM Compound C, 50uL of 4x 
concentrated AG was applied to SN4741 cells 24hrs prior to rotenone (10nM) 
challenge (24hr). Cells were then fixed and counterstained for cell count analysis.  
Image acquisition: 25 2-D de-convoluted fluorescence images per well were then 
acquired on the 20x magnification objective of the In Cell Analyser 2000 using the 
DAPI filters- 100% autofocus; 0.5 second exposure. SN4741 nuclei counts, 
128 
 
corresponding to cell counts, were acquired using a nucleus identifying pipeline in 
Cell Profiler image analysis software. 
 
The effects of Acyl Ghrelin on SN4741 intracellular metabolic signalling 
pathways 
We propose that the neuroprotection observed in AG pre-treated SN4741 cells is the 
result of a switch in metabolite utilisation from glucose derivatives to fatty acid 
derivatives. AG pre-treatment also led to a greater attenuation of rotenone-induced 
cell loss in substrate restricted (SR) media (60% of full medium) (P<0.001) as 
opposed to 100% medium (P<0.01), shown in figure 43 (a-c).  Thus, we also queried 
whether this proposed switch in metabolic regulation was enhanced in SN4741 cells 
cultured in SR medium. 
To investigate the role of metabolic sensor AMPK and fatty acid synthesis and 
degradation regulator protein, ACC, we collected SN4741 protein lysates from our in 
vitro neurotoxicity PD assay. 24hr AG pre-treatment neurotoxicity timeline (see figure 
28 B) was replicated in T25 cell culture flasks with modifications to scale. 
1x106 SN4741 cells were seeded into T25 cell culture flasks (CLS430639, Sigma) in 
10mL of cell culture medium and incubated overnight (16-24hr) under normal culture 
conditions. 5mL of cell culture medium was then removed and replaced with 5mL of 
fresh medium in the presence of 2µM AG resulting in a 1:2 dilution and a final vessel 
AG medium concentration of 1µM. AG was omitted from vehicle flasks and replaced 
with equivalent volumes of H2O. SN4741 cells were cultured in AG for 24hr prior to 
the removal of 5mL of culture medium. 5mL of culture medium was subsequently 
replaced with medium containing 20nM concentration of rotenone resulting in SN4741 
cells being cultured in 10nM rotenone. SN4741 in the presence and absence of 
rotenone were incubated under normal conditions for a further 24hrs. Rotenone was 
omitted from vehicle flasks and replaced with an equivalent volume of DMSO. SN4741 
cell protein lysates were collected from flasks at 24hr intervals prior to the addition of 
subsequent treatment agents. This allowed us to investigate intracellular targets of 
interest, step-by-step along our assay timeline, in the presence and absence of AG 
and rotenone treatments.   
At relevant time points, cell culture medium was removed from T25 flasks and cells 
were washed twice in 10mL of cold PBS (on ice). 250µL of lysis buffer [consisting of 
91% deionised H2O; 150mM Tris HCl, pH7.5; 150mM NaCl; 1% IGEPAL® CA-630; 
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0.5% sodium deoxycholate (DOC); 0.1% Sodium dodecyl sulfate (SDS); including 1% 
protease inhibitor and 1% phosphatase inhibitor] was then pipetted onto cells in a T25 
flask. Flasks were swirled gently to ensure total coverage of adhered cells in culture 
vessel before being placed on ice. Cells were scraped from the culture flasks using 
Greiner cell scrapers (C5981, Sigma) and lysates were transferred to 0.6mL 
microcentrifuge tubes (E1405-0610, StarLab). Cell lysate was passed 10 times 
through a 25G needle to mechanically sheared contents and placed on ice for 15 
minutes. Following this incubation stage cell lysates were then centrifuged at 14,000 
revolutions per minute (RPM) at 4◦C for 10 minutes. Centrifugation ensures that 
cellular debris is pelleted below protein containing supernatant. Supernatant was 
transferred into fresh microcentrifuge tubes for estimation of protein concentration and 
downstream Western blot (described in chapter 2). Cellular debris was discarded. 
See experimental timeline (figure 31) and table (table 17) below: 
 
Figure 31:Experimental Timeline for SN4741 Protein Extraction 
SN4741 cells were lysed at 24, 48 and 72hour time points post seeding 1x106 SN4741 
cells into T25 cell culture flasks. 
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Table 17: List of Treatment Conditions and Time of SN4741 Protein Extraction 
Time point /Day  24hr / Day 1 48hr / Day 2 72hr / Day 3 
SN4741 cell  
treatment(s) 
• No Treatment • Vehicle  
• 24hr 1µM AG 
• Vehicle 
• 24hr 10nM 
Rotenone  
• 24hr 1µM AG pre-
treatment & 24hr 
10nM Rotenone  
• 24hr 100nM 
Rotenone 
 
 
Relative expression levels of intracellular signalling proteins AMPK and ACC of each 
treatment group was expressed as a ratio- phosphorylated:non-phosphorylated 
AMPK (pAMPK:AMPK) and phosphorylated:non-phosphorylated ACC (pACC:ACC). 
The table below lists details of the primary and secondary antibodies used. 
 
As previously described (Chapter 2: 2.3.4), blots were incubated overnight with 
primary antibody before the addition of complimentary secondary antibody and 
subsequent visualisation of chemiluminescence signal using ChemiDoc XRS (Biorad) 
and Quantity One® 1-D analysis software. 2-D Raw images were transformed using 
the auto-scale within the Quantity One® software using the transform function and 
exported. Blot analysis was carried out in Image J software. Data analysis was carried 
out in Microsoft Excel. Data points were plotted and statistical analysis was carried 
out in Graph Pad Prims version 5. 
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Table 18:  Primary and Secondary Antibodies Utilised in AMPK/pAMPK & 
ACC/pACC Western Blot 
Target protein Description Primary 
antibody 
concentration 
Secondary 
Antibody 
Concentration  
Molecular 
weight kDa 
Phospho-
AMPKα (Thr172) 
(40H9) Rabbit 
mAb. Cell 
Signalling 
Technology 
#2535 
Detects 
endogenous 
AMPKα only 
when 
phosphorylated 
at threonine 
172. The 
antibody 
detects both α1 
and α2 isoforms 
of the catalytic 
subunit. Does 
not detect the 
regulatory β or 
γ subunits. 
1:1000 in 5% w/v 
BSA, 1X TBS, 0.1% 
Tween® 20 
Anti-Rabbit IgG, 
HRP-linked 
Antibody (7074S, 
Cell Signalling 
Technology).  
1:2500 in 5% w/v 
NFM, 1X TBS, 0.1% 
Tween® 20 
62 
AMPKα (D63G4) 
Rabbit mAb. Cell 
Signalling 
Technology 
#5832 
Detects 
endogenous 
levels of total 
AMPKα protein. 
1:1000 in 5% w/v 
BSA, 1X TBS, 0.1% 
Tween® 20 
Anti-Rabbit IgG, 
HRP-linked 
Antibody (7074S, 
Cell Signalling 
Technology).  
1:2500 in 5% w/v 
NFM, 1X TBS, 0.1% 
Tween® 20 
62 
Phospho-Acetyl-
CoA Carboxylase 
(Ser79) 
Antibody. Cell 
Signalling 
Technology 
#3661 
Detects 
endogenous 
levels of ACC 
only when 
phosphorylated 
at serine 79. 
Antibody 
recognizes both 
ACC alpha and 
ACC beta. 
1:1000 in 5% w/v 
BSA, 1X TBS, 0.1% 
Tween® 20 
Anti-Rabbit IgG, 
HRP-linked 
Antibody (7074S, 
Cell Signalling 
Technology).  
1:2500 in 5% w/v 
NFM, 1X TBS, 0.1% 
Tween® 20 
280 
Acetyl-CoA 
Carboxylase 
Antibody. Cell 
Signalling 
Technology 
#3662 
Detects 
endogenous 
levels of all 
isoforms of 
acetyl CoA 
carboxylase 
protein. 
 
1:1000 in 5% w/v 
BSA, 1X TBS, 0.1% 
Tween® 20 
Anti-Rabbit IgG, 
HRP-linked 
Antibody (7074S, 
Cell Signalling 
Technology).  
1:2500 in 5% w/v 
NFM, 1X TBS, 0.1% 
Tween® 20 
280 
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4.3. Results 
4.3.1. SN4741 Cell Growth Curves 
To estimate the amount of time required to grow SN4741 cells to a quantity desired 
to carry out an experiment, confluency and cell concentrations (cells/mL) were 
measure at 0, 24, 48, 72 and 96 hours post seeding 34,000 SN4741 cells into a T75 
culture flask containing 19ml of cell culture medium. 
 
 
 
 
34,000 SN4741 cells were seeded into full culture medium and cultured in a T75 flask. 
Confluency (%) and cell count (Cells/mL) measurements were taken at 0, 24, 48, 72 
and 96 hours (A). These measurements (A) are plotted in a graph (B) using MS Excel 
2013. SN4741 cell doubling time was quantified by inputting the initial (34,000 
cells/ml) and final (610,600 cells/ml) cell concentrations into equation (C). SN474 
doubling time calculated as 23.04 hours. Cell doubling equation acquired from Roth 
Figure 32: SN4741 growth rate in full culture medium. 
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V. 2006 Doubling Time Computing, Available from: http://www.doubling-
time.com/compute.php. 
This method of calculating SN4741 cell doubling time in (figure 32) utilises 2 data 
points. Next, in order to generate a cell doubling time using all data points listed in 
figure 32a,  a curve fitting equation to fit my data points to a theoretical curve 
described here : http://mathworld.wolfram.com/LeastSquaresFittingExponential.html 
was used. This second method applies least square fitting method directly to a dataset 
and weighs all data points equally.  
All data points from figure 33a were imputed to a doubling time generator which 
computes Doubling Time with several data points accessed at: http://www.doubling-
time.com/compute_more.php. The online generator generated an exponential curve 
fitting of all data points (A) and calculated an SN4741 cell doubling time of 25.71 hours 
(B). This method is with reference to Weisstein, Eric W. "Least Squares Fitting--
Exponential." From MathWorld--A Wolfram Web Resource. 
Figure 33: SN4741 Growth Rate in Full Culture Medium Using All Data 
Points 
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Both methods of calculating SN4741 cell doubling time yield slightly different times. 
The first method utilises initial and final SN4741 cell concentration and does not 
consider other data points.  This method may misrepresent SN4741 cell doubling time 
as the rate of cell growth may alter during the period between the initial and final time 
points. The second method fits all data points to a theoretical curve. However, in doing 
so, alters the initial SN4741 concentration from 34,000 to 53,028.8176 cells/mL. Both 
methods misrepresent the dataset and a 2.67 hour difference is found between both 
cell doubling times. SN4741 cell doubling time was approximated by calculating the 
mean of both values. Mean SN4741 doubling time = 24.375 hours; standard deviation 
(std.dev) = 1.88798; population std.dev = 1.335). 
Finding an approximate population doubling time for SN471 cells is important for 
experimental design. It will allow us to approximate the time taken for a culture vessel 
to become confluent and ready for sub-culturing, and avoid over-confluency during 
cell culture. Changes in the rate of routine SN4741 growth may also indicate a 
problem within the cell culture system. 
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4.3.2. Development of a Rotenone-Induced Neurotoxicity/Cell Loss In 
Vitro PD Model  
To define a minimum dose (concentration) of rotenone which replicated the cell loss 
observed in PD. SN4741 cell line was incubated for 24hr in rotenone of concentrations 
0nM, 10nM, 100nM, 1,000nM and 10,000nM. SN4741 cells under the same 
treatments were assessed for an increase in cell cytotoxicity and a decrease in cell 
viability. A concentration which replicated DAergic SN4741 cell loss and resulted in 
increase in cell cytotoxicity and a decrease in cell viability will be selected to test 
neuroprotective effects of 1hr AG and JMV 2894 pre-treatments. 
 
24hr rotenone challenge exerts a dose dependant SN4741 cell loss. Rotenone 
neurotoxicity assay treatments were performed in quadruplicate for each 
experimental repeat; data shown from 4 experimental repeats (n=4). Statistical 
analysis was performed by One-way ANOVA with Dunnett’s post-hoc analysis, with 
P<0.05 (*), P<0.01 (**), P<0.001 (***) considered significant when compared to control 
(0nM Rotenone). 
 
Figure 34: 24hr Rotenone Treatment Causes SN4741 Cell Loss. 
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SN4741 cells in sync with 1hr GHSR1a agonist pre-treatment timeline seen in Figure 
26a were challenged with a titration of rotenone concentrations.  24h challenge results 
in a significant (**) SN4741 cell loss (P<0.01) (figure 34) at 10nM rotenone 
concentration and a dose-dependent decrease in cell number at concentrations 
thereafter. Next, SN4741cells in sync with 24hr GHSR1a pre-treatment timeline as 
seen in Figure 26b were subjected to rotenone challenge. 
 
Rotenone challenge exerts a dose dependant SN4741 cell loss as illustrated. 
Rotenone neurotoxicity assay treatments were performed as described in timeline 
figure26b in quadruplicate for each experimental repeat; data shown from 4 
experimental repeats (n=4). Statistical analysis was performed by One-way ANOVA 
with Dunnett’s post-hoc analysis on graph pad prism 5 software, with P<0.05 (*), 
P<0.01 (**), P<0.001 (***) considered significant when compared to treatment control 
(0nM Rotenone). 
 
 
Figure 35: 24hr Rotenone Treatment Causes SN4741 Cell Loss 
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SN4741 cells were challenged with a titration of rotenone concentrations for 24hrs in 
sync with 24hr GHSR1a agonist pre-treatment timeline as seen in Figure 26b. Results 
show a dose-dependent decrease in SN4741 cell number and a significant (***) cell 
loss at 10nM rotenone concentration (graphed in figure 35).  
We have established that 10nM rotenone is sufficient to ensure a significant and 
reproducible decrease in SN4741 cell number cultured in 100% of full medium 
following a 24hr incubation. We will use 10nM rotenone to assess SN4741 cell viability 
and cytotoxicity.  
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4.3.3. The CellTox™ Green Cytotoxicity & CellTiter-Blue® Cell Viability 
Assays 
SN4741 cells in 100% and 60% of full medium were assessed for cell numbers, 
cytotoxicity and cell viability following 24hr rotenone treatment (in sync with 24hr 
GHSR1a pre-treatment). Hoechst counterstained nuclei were quantified using In Cell 
Analyser 2000 whilst cytotoxicity and viability measurements were carried out on 
POLARstar® Omega (BMG Labtech) microplate reader. 
Figure 36 (a), (b) and (c) represent SN4741 cell count, viability and cytotoxicity data 
respectively from cells cultured in complete (100% of full) culture medium. Figure 36 
(d), (e) and (f) represent SN4741 cell count, viability and cytotoxicity data respectively 
from cells cultured in 60% of full culture medium. Rotenone exerts a dose dependant 
decrease in SN4741 cells in both complete (100%) and substrate restricted (60% of 
full) cell culture medium, (a) and (d) respectively. A dose dependant decrease in cell 
viability is observed in rotenone treated SN4741 cells cultured in complete (b) and 
substrate restricted medium (e).10nM,1000nM and 10,000nM rotenone treatment 
induces a significant increase in cell cytotoxicity in complete medium (c). No 
significant increase in cell cytotoxicity was observed in rotenone challenged SN4741 
cells cultured in substrate restricted medium (f). SN4741 cell count data (a & d) 
expressed as mean cell count from cells treated in triplicate for 4 experimental repeats 
(n=4). SN4741 cell viability (b and e) and cytotoxicity (c and f) data represents data 
from treatments performed in triplicate for 3 experimental repeats (n=3) and is 
Figure 36: 24hr Rotenone Treatment Cell Loss, Decreases Viability and 
Increases SN4741 Cell Cytotoxicity. 
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expressed as percentage of control (0nM). Statistical analysis Statistical analysis was 
performed by One-way ANOVA with Bonferroni’s post-hoc analysis (a and d) and with 
Dunnett’s post-hoc analysis (in b, e, c and f) on graph pad prism 5 software, with 
P<0.05 (*), P<0.01 (**), P<0.001 (***) considered significant when compared to 
treatment control (0nM Rotenone). 
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4.3.4. SN4741 Counterstaining and Quantification 
In order to speed up the tedious task of manual scoring of nuclei, images of SN4741 
nuclei were run through image analysis software Image J or Cell Profiler to automate 
cell counting. This short section aims to i) validate that automated cell counting 
accurately quantifies nucleus (cell) numbers versus manual scoring and ii) ensure 
transferability in nuclei counting between Image J and Cell Profiler. The accurate 
identification of nuclei is not only integral for correct quantification of cell number; it 
also provides a ‘seed’ (digital coordinates) which can be utilised as a primary object 
to build image analysis protocols to extract quantitative data on changes in 
morphology of the nucleus or other fluorescently (or non-fluorescently) probed cellular 
organelles. The construction of an image analysis protocol to measure several cellular 
features will be discussed further in chapter 4.  
141 
 
 
142 
 
12 x20 magnification images of Hoechst stained SN4741 nuclei were selected from a 
dataset to compare manual versus automated nucleus scoring. Nucleus size (area in 
Pixel2) was also acquired via automated approaches. Image 1-6 represent nuclei 
following 24hr incubation 0, 1, 10, 100, 1000 & 10,000nM rotenone treatment cultured 
in full (100%) culture medium. Image 7-12 represent nuclei following 24hr incubation 
0, 1, 10, 100, 1000 & 10,000nM rotenone treatment cultured in SR (60%) culture 
medium. Tiles (a) represent raw images used for manual counting (scoring) of 
SN4741 nuclei. (b) And (c) represent masked images of automated computer 
software scored nuclei from raw images (a) using Image J and Cell Profiler 
respectively. Graphs: (d) displays nuclei counts scored per image by manual and 
automated Image J method; (e) displays nuclei counts per image scored by manual 
versus automated Cell Profiler methods; (f) compares nuclei counts per image for 
both automated approaches- Image J versus Cell Profiler; (g) compares nuclei counts 
per image for all 3 scoring methods. Graph (h) displays a comparison of the mean 
nucleus area per image measured using automated methods, Image J and Cell 
Profiler. Data is graphed using MS Excel 2013. Mean values, standard deviation 
(STDEV) and standard error of means (SEM) were calculated for each comparison 
(d-h). Means, STDEV and SEM for each comparison (d-h) is displayed in form of 
tables (i-m). 
Figure 37: Validating Transferability of Manual vs Automated Nuclei Scoring. 
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4.3.5. Live/Dead Assay 
 
 (a) & (b) Represent merged x20 magnification images of EthD-1 and Hoechst stained 
SN4741 cells following 0nM and 1,000nM rotenone challenge (24hrs). These images 
clearly illustrate an increase in nuclear EthD-1 staining intensity upon rotenone 
challenge (1,000nM). Images (a) and (b) were acquired by In Cell Analyser 2000. 
White and red arrows delineate nuclei containing low and high EthD-1 fluorescence 
intensity, respectively. Nuclei were identified by Hoechst counterstaining and mean 
EthD-1 fluorescence was measure in each nucleus using Cell Profiler image analysis 
software. 
 
 
EthD-1 / Hoechst EthD-1 / Hoechst 
Figure 38: Ethidium homodimer-1 & Hoechst stained SN4741 cells. 
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24hr rotenone challenge induces an increase in cell death measure by an increase in 
nuclear EthD-1 fluorescence intensity (AU). Pooled mean nuclear EthD-1 
fluorescence intensity of 100 images per treatment group. Treatments were 
performed in quadruplicate per technical repeat. Technical repeats 1, 2 & 3 (n=3) are 
represent by (a), (b) & (c). EthD-1 fluorescence intensity was calculated as a 
percentage of control (0nM rotenone) for each dataset (a-c). Percentage of control for 
all 3 technical repeats were plotted in (d). Statistical analysis was performed by One-
way ANOVA with Dunnett’s post-hoc analysis on graph pad prism 5 software, with 
P<0.05 (*), P<0.01 (**), P<0.001 (***) considered significant when compared to control 
(0nM Rotenone). 
 
Figure 39: 24hr Rotenone Challenge Induces Cell Death Measured by EthD-1 
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4.3.6. Detection of Rotenone-Induced Activated Caspase 3/7 in SN4741 
Neurones 
We have established that treating SN4741 cells for 24hrs with 10nM rotenone induces 
an increase in cell cytotoxicity, a decrease in cell viability and cell loss. Published 
literature shows rotenone mediated cell death is possible via caspase 3/7-dependant 
pathways (N. Li et al., 2003). In this section we aim to investigate whether challenging 
SN4741 cells with 10nM rotenone for 24hrs results in increased caspase 3/7 
expression. As seen in figure 40 (a), there is no detectable increase in caspase 3/7 
fluorescence intensity in SN4741 nuclei following 24hr incubation with 10nM 
rotenone, when compared to control. Conversely, DMSO treated cells exhibit a large 
increase in nuclear fluorescence intensity.  
As expected, wells where Caspase-3/7 Green Detection Reagent was omitted- 
Caspase 3/7 positive nuclei were not detectable by visual inspection (not shown), nor 
via software analysis. Caspase 3/7-positive nuclei counts, acquired by automation of 
Image J software, show a significant increase in percentage of Caspase 3/7-positive 
cells following DMSO treatment; however, no increase is observed following 
treatment with 10nM rotenone. This indicates that the loss of SN4741 cells is not the 
result of Caspase 3/7 activation and therefore must be attributed to an alternative cell 
death pathway. 
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Graph a) shows the number of Caspase 3/7-positive SN4741 nuclei as a percentage 
of total nuclei counterstained with Hoechst. Statistical analysis was performed by 
One-way ANOVA with Dunnett’s post-hoc analysis on graph pad prism 5 software, 
with P<0.05 (*), P<0.01 (**), P<0.001 (***) considered significant when compared to 
control (0nM Rotenone). An intensity histogram of nuclear SN4741 Caspase 3/7 
fluorescence intensities b). 10,000 nuclei were selected per well and measured for 
Caspase 3/7 fluorescence intensity. Merged DAPI (blue) and FITC (green) channel 
images c), d) and e) represent 0nM rotenone (control), 10nM rotenone and DMSO 
treated SN4741 cells (as labelled) stained with Hoechst and Caspase-3/7 Green 
Detection Reagent. White arrows indicate examples of Caspase 3/7-postive nuclei (c-
e). 
 
 
 
Figure 40:Rotenone (10nM) Does Not Increase Active Caspase 3/7 Activity in 
SN4741s Cells 
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4.3.7. GHSR1a Agonists Protect Against Rotenone-Induced SN4741 Cell 
Loss 
SN4741 cells incubated for 24hr in 10nM rotenone results in a significant cell loss, an 
increase in cytotoxicity and a decrease in cell viability with respect to controls. Here 
we aim to test the effectiveness of 1hr and 24hr GHSR1a agonist pre-treatment in 
reversing the observed SN4741 cell loss. Cells were treated directly with a titration of 
known GHSR1a agonists acyl-ghrelin and JMV-2894 for 1hr or 24hr prior to 10nM 
rotenone challenge (24hrs). Here we also investigate whether ghrelin-mediated 
neuroprotection is enhanced or diminished in SN4741 cell growing and treated in 0, 
20, 40, 60, 80 and 100% of full (complete) medium.   
 SN4741 cells were cultured in 100%, 80% or 60% of full medium. Cells were grown 
in respective media before 1hr AG pre-treatments followed by a 24hr rotenone (10nM) 
challenge. (a) In 100% of full medium, 1hr pre-treatment with 100nM AG prevented 
rotenone (10nM) induced dopamine cell loss; (b) In 80% of full medium, 1hr pre-
treatment with 10nM, 100nM and 1000nM AG prevented rotenone (10nM) induced 
dopamine cell loss; (c) in 60% of full media 1hr pre-treatment with 100nM and 1000nM 
AG prevented rotenone (10nM) induced dopamine cell loss. Statistical analysis was 
performed by One-way ANOVA with Dunnett’s post-hoc analysis on Graph Pad Prism 
5 software, with P<0.05 (*), P<0.01 (**), P<0.001 (***) considered significant 
compared to control (0nM). Ghr-/rot- signifies cells treated with neither AG nor 
rotenone. Ghr+/rot- signifies cells treated with 1,000nM AG without rotenone 
challenge. Red bar above graph indicates 24hr 10nM rotenone treatments. 
 
 
Figure 41: 1hr Acyl-Ghrelin Pre-treatment Attenuates Rotenone-Induced 
SN4741 Cell Loss. 
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As shown in figure 41a we see that in cells cultured in 100% medium 100nM AG pre-
treatment for 1hr attenuates rotenone-induced cell loss significantly with P<0.05. 
Figure 41b shows that in cells cultured in 80% of full medium 10nM, 100nM and 
100nM AG pre-treatment for 1h attenuates rotenone-induced cell loss significantly 
with P<0.05. We see in Figure 41c that in cells cultured in 60% of full medium 100nM 
and 1000nM AG attenuates rotenone-cell loss significantly with P<0.05. This suggests 
that our crude substrate restriction (80% and 60% of complete cell culture media) 
increases the efficacy of AG neuroprotection against rotenone-induced cell loss. 
 
 SN4741 cells were seeded into respective 100%, or 80% and 60% of complete media 
to simulate substrate restriction prior to 1hr pre-treatments with GHSR-agonist 
(JMV2984) followed by rotenone (10nM) challenge. 1hr pre-treatment with JMV2984 
did not prevent rotenone (10nM) induced dopamine cell loss in full media (a), 80% 
media (b) or 60% media (c). Treatments were performed in triplicate and in three 
separate experiments. Statistical analysis was performed by One-way ANOVA with 
Dunnett’s post-hoc analysis on Graph Pad Prism 5 software, with P<0.05 (*), P<0.01 
(**), P<0.001 (***) considered significant when compared to control (0nM). JMV-/rot- 
signifies cells treated with neither JMV2894 nor rotenone. JMV+/rot- signifies cells 
treated with 600nM JMV2894 only. Red bar above graph indicates treatments 
including 24hr 10nM rotenone. 
 
As seen in Figure 42 (a-c), none of the JMV 2894 pre-treatments resulted in 
attenuation of rotenone-induced cell loss in cells cultured in 100%, 80% or 60% media 
(P>0.05).   
 
Figure 42: 1hr JMV2894 Pre-Treatment Does Not Significantly Attenuate 
Rotenone-Induced SN4741 Cell Loss. 
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SN4741 cells were cultured in 100%, 80% or 60% of full medium. Cells were grown 
in respective media before 24hr AG pre-treatments followed by a 24hr rotenone 
(10nM) challenge. (a) In 100% of full medium, 24hr pre-treatment with 100nM and 
1000nM AG prevented rotenone (10nM) induced dopamine cell loss; (b) In 80% of full 
medium, 24hr pre-treatment with 10nM, 100nM and 1000nM AG prevented rotenone 
(10nM) induced dopamine cell loss; (c) in 60% of full media 24hr pre-treatment with 
1nM, 10nM, 100nM and 1000nM AG prevented rotenone (10nM) induced dopamine 
cell loss. Treatments were performed in triplicate and in three separate experiments. 
Statistical analysis was performed by One-way ANOVA with Dunnett’s post-hoc 
analysis on Graph Pad Prism 5 software, with P<0.05 (*), P<0.01 (**), P<0.001 (***) 
considered significant compared to control. Ghr-/rot- signifies cells treated with neither 
AG nor rotenone. Ghr+/rot- signifies cells treated with 1000nM AG without rotenone 
challenge. Red bar above graph indicates treatments including 24hr 10nM rotenone. 
 
As observed in Figure 43a, cells cultured in 100% medium 100nM AG attenuates 
rotenone-induced cell loss significantly with P<0.05 and 100nM attenuates AG more 
significantly with P<0.01.  Figure 43b shows that in cells cultured in 80% media, 10nM 
AG attenuates rotenone-induced cell loss significantly with P<0.05 and 100nM AG 
and 1000nM AG do so more significantly with P<0.01. As seen in Figure 43c, in cells 
cultured in 60% medium 1nM, 10nM, 100nM and 1000nM AG all attenuated rotenone-
induced cell loss very significantly with P<0.001. This further proves that our crude 
substrate restriction increases the efficacy of AG neuroprotection against rotenone-
induced cell loss.  
Figure 43: 24hr Acyl-Ghrelin Pre-Treatment Attenuates Rotenone-Induced 
SN4741 Cell Loss. 
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SN4741 cells were cultured in 100%, 80% or 60% of full medium. Cells were grown 
in respective media before 24hr JMV 2894 pre-treatments followed by a 24hr rotenone 
(10nM) challenge. (a) In 100% of full medium, 24hr pre-treatment with JMV 2894 did 
not prevented rotenone (10nM) induced dopamine cell loss; (b) In 80% of full medium, 
24hr pre-treatment with 0.6nM and 6nM JMV 2894 prevented rotenone (10nM) 
induced dopamine cell loss; (c) in 60% of full media 24hr pre-treatment with 0.6nM, 
6nM and 60nM JMV 2894 prevented rotenone (10nM) induced dopamine cell loss. 
Treatments were performed in triplicate and in three separate experiments. Statistical 
analysis was performed by One-way ANOVA with Dunnett’s post-hoc analysis on 
Graph Pad Prism 5 software, with P<0.05 (*), P<0.01 (**), P<0.001 (***) considered 
significant when compared to control (0nM). JMV-/rot- signifies cells treated with 
neither JMV-2894 nor rotenone. JMV+/rot- signifies cells treated with 600nM JMV-
2894 without rotenone challenge. Red bar above graph indicates treatments including 
24hr 10nM rotenone. 
 
Figure 44a shows that cells cultured in 100% medium for 24hrs showed no significant 
attenuation in cell loss.  As seen in Figure 44b, in cells cultured in 80% medium 0.6nM 
and 6nM JMV 2894 significantly attenuated rotenone-induced cell loss with P<0.05. 
Figure 44c shows that in cells cultured in 60% medium, 0.6nM JMV 2894 attenuated 
rotenone-induced cell loss more significantly with P<0.01 and 6nm and 60nm JMV 
2894 attenuated rotenone-induced cell loss less significantly with P<0.05.   This 
suggests that our crude substrate restriction increases efficacy of JMV 2894 
neuroprotection against rotenone-induced cell loss, with the most significant 
protection with 0.6nM in 60% medium. 
Figure 44: 24hr JMV2894 Pre-Treatment Attenuates Rotenone-Induced SN4741 
Cell Loss 
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4.3.8. Acyl-Ghrelin Does Not Induce SN4741 Cell Proliferation  
AG pre-treatment attenuates rotenone-induced SN4741 cell loss in-vitro. The mode 
of AG’s neuroprotective mechanism is yet to be fully elucidated with this cell line. Prior 
to investigating the potential molecular mechanisms underpinning AG-mediated 
neuroprotection, it is necessary to establish that the observed protection of SN4741 
cell number is not the result of an AG-mediated increase in cell proliferation. Ghrelin 
is reported as an inducer of cell proliferation (e.g. cardiomyocytes) (Pettersson et al., 
2002), but also an inhibitor of cell proliferation in other cells (e.g. mouse T 
lymphocytes) (Pettersson, et al., 2002; Q. Xia et al., 2004). To determine whether the 
attenuation of cell loss is a result of increased cell proliferation, SN4741 cells were 
incubated in the presence of thymidine analogue EdU which was incorporated in to 
actively dividing cells, giving us a relative measure of cell proliferation.  
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Image tiles (Figure 45 a and b) illustrate Hoechst (blue) and EdU-Click-iT (green) 
stained SN4741 nuclei of treated in full media and 60% media, respectively. From left 
to right (in tile panels a and b), image tiles represent the nuclei of vehicle, 1µM AG, 
10nM rotenone and 1µM AG+10nM rotenone treated SN4741 cells, as labelled. (c) 
Shows zoomed-in examples of Hoechst and EdU stained nuclei, as labelled. White 
arrows on zoomed image tile (c) indicate examples of EdU+ neurones. 
 
 
 
 
 
 
 
a 
b 
c 
Hoechst Merge EdU 
Figure 45: Hoechst and EdU as an Indicator of SN4741 Cell Proliferation 
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The percentage of proliferating (EdU-positive) nuclei per total nucleus count for 
SN4741 cells challenged with 10nM rotenone in the presence and absence of 24hr 
1µM AG pre-treatment. 10nM rotenone was omitted from AG control treatment where 
cells were incubated with 1µM AG only. EdU was omitted from EdU-ve well and no 
EdU-positive nuclei were detected upon image analysis. Treatments were carried out 
on cells seeded in 100% and 60% of full media and percentage of proliferating cells 
are shown in graphs (a) and (b) respectively.  24hr Rotenone challenge induces a 
significant decrease in cell proliferation in both presence and absence of 24hr 1µM 
AG pre-treatment in SN4741 cells cultured in complete medium (a). This is not 
observed in SN4741 cells cultured in SR (60%) media (b). Treatments were 
performed in triplicate and in two separate experiments. Statistical analysis was 
performed by One-way ANOVA with Dunnett’s post-hoc analysis on Graph Pad Prism 
5 software, with P<0.05 (*), P<0.01 (**), P<0.001 (***) considered significant when 
compared to rotenone (10nM). 
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Figure 46:Rotenone Reduces SN4741 Proliferation in Full Media but Not in 
Substrate Restricted Media. 
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Graph (a) compares the proliferation of vehicle treated SN4741 cells seeded in 100% 
and 60% of full media; (b) compares proliferation of 1µM AG treated SN4741 cells 
cultured in 100% and 60% of full media.  Graph (c) compares proliferation of SN4741 
cells seeded in 100% and 60% of full media followed by 10nM rotenone challenge. 
Graph (d) and (e) compare the proliferation of SN4741cells treated with 1µM AG 
versus vehicle treatment following cell seeding in 100% and 60% of full media 
respectively. Graph (f) and (g) compare the proliferation of SN4741cells treated with 
10nM rotenone versus vehicle treatment following cell seeding in 100% and 60% full 
media, respectively. Statistical analysis was performed by unpaired one-tailed t-test 
on Graph Pad Prism 5 software, with P<0.05 (*), P<0.01 (**), P<0.001 (***) considered 
statistically significant. 
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Figure 47: Substrate Restriction (SR) (60% of full medium) and Rotenone 
Challenge Reduces SN4741 Cell Proliferation Whilst AG Does Not Effect Cell 
Proliferation. 
155 
 
In each treatment group, the percentage of EdU-positive (indicated with white arrows, 
figure 45c) per total nuclei was calculated. The proliferation of SN4741 cells seeded 
in full media was significantly reduced following 10nM rotenone challenge (figure 
46a), an effect which was not observed in SN4741 cells seeded in SR (60%) media 
(figure 46b). Moreover, 24hr pre-treatment with 1µM AG did not result in increased 
SN4741 cell proliferation in full or SR media in the presence or absence of rotenone 
(figure 46a and b). Results shown in figure 47(a-c) shows a decrease in SN4741 cell 
proliferation in vehicle (a), AG only (b) and rotenone (c) treated cells cultured in SR 
media compared to full media. Data shown in graphs (figures 47 d & e) illustrate no 
significant increase in SN4741 cell proliferation following 1µM AG treatment. Data 
represented in graphs (figure 47 f & g) show a significant decrease in SN4741 cell 
proliferation following rotenone challenge in both full media (figure 47 f) and SR media 
(figure 47g). A significant decrease in cell proliferation was observed in vehicle treated 
SN4741 cells cultured in SR media compared to full media (figure 47a); 
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4.3.9. GHSR1a Antagonist Inhibits Ghrelin-Mediated Neuroprotection 
 
 
Graph (a) shows SN4741 cell counts at endpoint in each treatment group acquired by 
automated cell counting. Graph (b) illustrates CellTox™ Green fluorescence intensity 
(FI) captured at experimental endpoint. FI intensity is normalised to cells per well. 
Graph (a & b) shows that 1,100 and 1000nM of D-Lys3 attenuated 1µM AG-mediated 
cell survival and decrease in cell viability. Statistical analysis was performed by One-
way ANOVA with Dunnett’s post-hoc analysis on Graph Pad Prism 5 software, with 
P<0.05 (*), P<0.01 (**), P<0.001 (***) considered significant when compared to 
rotenone (10nM). Each treatment was performed in triplicate for two experimental 
repeats (n=2). 
 
 
 
 
Figure 48: GHSR1a Antagonist D-Lys3 Inhibits Acyl-Ghrelin’s Effect on 
Rotenone-Induced Cell Loss and Cytotoxicity in Full Medium 
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Graph shows that 1,100 and 1000nM D-Lys3 attenuated 1µM AG-mediated cell 
survival. Statistical analysis was performed by One-way ANOVA with Dunnett’s post-
hoc analysis on Graph Pad Prism 5 software, with P<0.05 (*), P<0.01 (**), P<0.001 
(***) considered significant when compared to rotenone (10nM). Each treatment was 
performed in triplicate for two experimental repeats (n=2). 
 
 
 
 
 
 
 
 
 
Figure 49: GHSR1a Antagonist D-Lys3 Inhibits Acyl-Ghrelin’s Effect on 
Rotenone-Induced Cell Loss in SR (60% of Full) Media. 
10nM Rotenone  
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4.3.10 Is AG-Mediated Neuroprotection Dependent on AMPK? 
Optimisation of Compound C concentration: as shown in figure 50a, no reduction in 
SN4741 cell number was observed following Compound C treatment at 0nM, 20nM, 
40nM, 60nM, 80nM, 100nM and 1000nM in 100% medium in compound C 
optimisation. However, a decrease in SN4741 cell number was observed following 
1000nM (P<0.001) Compound C treatment. Moreover, in Figure 50b no reduction in 
SN4741 cell number was observed following Compound C treatment at 20nM, 40nM, 
60nM, 80nM and 100nM (P>0.05) in substrate restricted (60% of full cell culture) 
medium. However, a decrease in SN4741 cell number was observed following 
1000Nm (P<0.001) compound C treatment. Treatments were carried out in 
quadruplicate for 2 experimental repeats (n=2) in each media. 
Compound C decreases SN4741 cell number following 48hr incubation. Treatment 
with Compound C at the initial concentration of 1000nM resulted in a significant loss 
of SN4741 cells cultured in 100% (a) and 60% (b) of full culture media. Treatments 
were carried out in quadruplicate across two experimental repeats (n=2) for cells 
cultured in complete and SR media. Mean cell number was quantified in each 
replicate (n=2) and expressed in graphs (a) and (b). Statistical analysis was 
performed by One-Way-ANOVA with Dennett’s post-hoc test in Graph Pad Prism 5, 
with P<0.05 (*), P<0.01 (**), P<0.001 (***) considered statistically significant.  
 
 
Figure 50: 1000nM AMPK Phosphorylation Inhibitor Compound C Produces SN4741 
Cell Loss. 
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In both full and SR (60% of full cell) culture media, 100nM Compound C was the 
highest concentration that did not significantly reduce SN4741 cell number. This 
concentration of compound C was used to pre-treat SN4741 cells prior to AG-pre-
treatment and rotenone challenge.  
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Compound C in neurotoxicity assay: SN4741 cells seeded in complete and SR media 
were incubated with 100nM and 200nM Compound C for 30mins prior to 24hr AG 
(1µM) treatment and subsequent 24 hr 10nM rotenone challenge. 
 (a) Graph showing the SN4741 cell counts expressed as percentage of the control 
(vehicle treated cells) in 100% media. This graph shows that a significant rotenone-
induced SN4741 cell loss is not observed in cells cultured in full medium in n=2 
experimental trials. (b) Graph showing the SN4741 cell counts expressed as 
percentage of the control (vehicle treated cells) in SR (60%) media. This graph shows 
that significant rotenone-induced SN4741 cell loss was not observed in cells cultured 
in complete medium in n=2 experimental trials. Therefore, AG-mediated 
neuroprotection was not observed. Treatments were performed in triplicate and in two 
separate experiments. Statistical analysis was performed by One-way ANOVA with 
Dunnett’s post-hoc analysis on Graph Pad Prism 5 software, with P<0.05 (*), P<0.01 
(**), P<0.001 (***) considered significant when compared to rotenone (10nM).   
 
SN4741 cell loss was not induced by rotenone and therefore, we were not able to test 
the efficacy of Compound C as an inhibitor to the neuroprotective effects of AG. 
Figure 51:  SN4741 Cell Number Does Not Decrease with Rotenone Treatment 
in Neurotoxicity Assay. 
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4.3.11 The effects of Acyl Ghrelin on SN4741 Metabolic Signalling 
Pathways 
Protein lysate was collected from SN4741 cells at 5 minutes and 24h post-AG and 
JMV2894 agonist treatment as described in the method. Expression of 
phosphorylated versus non-phosphorylate AMPK and ACC was determined. 
 
4.3.11.1. AG and GHSR1a agonist (JMV2894) phosphorylates the 
cellular energy sensor AMPK and catalytic enzyme ACC at 5 minutes. 
 
 
(A) & (B) Immunoblot data shows that 5-minute treatment with both acyl-ghrelin (AG) 
(1uM) and GHSR1a agonist JMV2894 (0.6nM) induced phosphorylation of metabolic 
sensor AMPK (P<0.01), (P<0.001). (C) & (D) Immunoblot data shows that 5-minute 
treatment with (C) AG (1uM) induced phosphorylation of fatty acid biosynthesis 
regulator ACC (P<0.01) whilst (D) GHSR agonist JMV2894 (0.6nM) decreased 
phosphorylation of ACC (P<0.05). These data demonstrate that SN4741 cells are 
responsive to ghrelin-GHSR1a signalling. 
Figure 52: Acyl-Ghrelin and GHSR1a Agonist JMV2894 Induce 
Phosphorylation of Metabolic Sensor AMPK & Inhibits Phosphorylation of 
ACC 
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4.3.11.2. Phosphorylation of cellular energy sensor AMPK and catalytic 
enzyme ACC during neurotoxicity experiment following treatment with 
GHSR1a agonist AG. 
 
 
 
(a) Immunoblot data shows that 24 hr treatment of SN4741 cells with AG (1uM) 
induced phosphorylation of metabolic sensor AMPK (P<0.001). (b) Immunoblot data 
shows that AG (1uM) induced phosphorylation of AMPK does not persist to 
experimental endpoint. SN4741 cells in the presence of rotenone (10nM and 100nM) 
showed an increase in pAMPK at experimental endpoint. However, the increase was 
not statistically significant. Graphed data represents the mean fold change of 
phosphorylated AMPK versus non-phosphorylated AMPK for 3 technical experimental 
repeats. Statistical analysis was carried out using Graph Pad Prism version 5 using 
an unpaired Two-tailed T-test for (a) and one-way ANOVA with Bonferroni's Multiple 
Comparison Test for (b).  
Experimental paradigm for the protein extractions above is illustrated in Figure 31 & 
table 17. 
Figure 53: Phosphorylation of Metabolic Sensor AMPK During Neurotoxicity 
Experiment. 
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4.3.11.3. Phosphorylation of catalytic enzyme ACC during neurotoxicity 
experiment following treatment with GHSR1a agonist AG. 
 
(A) & (B) Immunoblot data shows that AG (1uM) induced phosphorylation of ACC is 
not retained at 24hr post treatment. (b) Analysis of SN4741 cell protein lysates from 
experimental endpoint shows that cells treated with 10nM rotenone, AG and 10nM 
rotenone, and 100nM rotenone all expressed significantly higher levels of 
phosphorylated ACC compared to vehicle. Graphed data represents the mean fold 
change of phosphorylated ACC versus non-phosphorylated ACC for 3 technical 
experimental repeats. Statistical analysis was carried out using Graph Pad Prism 
version 5 using an unpaired two-tailed t-test for (a) and one-way ANOVA with 
Bonferroni's Multiple Comparison Test for (b).  
Experimental paradigm for the protein extractions above is illustrated in Figure 31 & 
table 17. 
 
 
Figure 54: Phosphorylation of Fatty Acid Biosynthesis Enzyme ACC During 
Neurotoxicity Experiment. 
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4.4 Discussion  
In this chapter, we show that Girk2-positive mouse SN derived DAergic neurones are 
sensitive to rotenone-induced cell loss and cytotoxicity. The origin of the SN4741 cell 
line is important as the nigrostriatal subpopulation DAergic neurones show a selective 
degeneration in in-vitro (Y. M. Ding, et al., 2004) and in vivo models (Andrews, et al., 
2009) of PD that attempt to mimic the degeneration observed in human PD (Damier, 
et al., 1999a). We find that treatment of SN4741 cells for 24hr with rotenone (10nM) 
results in a significant decrease in cell number which parallels an increase in 
cytotoxicity and loss of viability. These data suggest that SN4741 cells are particularly 
sensitive to the mitochondrial perturbing effects of ETC complex 1 inhibition.  
The rotenone-induced cell loss was observed in SN4741 cells cultured in full media 
and SR (60% of complete) media. SN4741 cells cultured in SR media solely did not 
show increased tolerance to 10nM rotenone challenge. This may have been expected 
as caloric restriction in a range of organisms shows there to be evolutionarily 
conserved mechanisms seen in bacteria, flies and mammals which increase life span, 
longevity and the ability to overcome the effects of cellular stressors in both healthy 
and diseased conditions (Longo & Mattson, 2014). It is possible that depletion of a 
particular substrate, and not the total restriction of cell nutrients used in this chapter 
may result in enhanced cellular resilience. This may be an avenue for further 
investigation. However, restriction of cellular substrates did enhance the 
neuroprotective effects of AG at lower concentration, suggesting that SR in SN4741 
cells may, at least partly, act as a mechanism to prime cells to buffer cell stress. The 
mechanism of rotenone induced cell loss did not appear to be mediated via caspase 
3/7 activation, which has been linked to cytotoxicity, mitochondrial dysfunction and 
oxidative stress (Balakrishnan et al., 2018). 
SN4741 neurones pre-treated with a titration of AG concentrations (0, 10, 100, 
1000nM) for 24hr in full cell culture media showed attenuated rotenone induced cell 
loss with 1000nM AG. However, SN4741 cells cultured in SR media showed a 
significant increase in cell survival following AG pre-treatments at lower 
concentrations. Similar effects were observed in SN4741 cells following 24hr pre-
treatment with the GHSR1a agonist JMV2894. The period of pre-treatment may also 
play an important role in the mechanism of SN4741 neuroprotection. 1hr pre-
treatment with AG resulted in less pronounced AG-mediated SN4741 protection 
compared to those pre-treated for 24hr. Moreover, unlike the 24hr JMV2894 pre-
treatment, no neuroprotection was observed following 1hr pre-treatment. Therefore, 
it is possible that the resulting intracellular signalling events induced via GHSR1a 
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agonism by AG and JMV2894 requires more than 1hr to substantiate changes in 
cellular phenotype to enhance resilience to mitochondrial toxins. 
Furthermore, our data suggests that AG neuroprotection in our assay was GHSR1a-
mediated. This is consistent with data by (Beynon, et al., 2013), who show that 
ghrelin’s effects are at least partly mediated via it’s endogenous receptor, GHSR1a. 
The study also utilised SN4741 cells and showed that the inhibition of GHSR1a 
receptor abolished pro-inflammatory IL-6 production. Here, we show that inhibition of 
GHSR1a by D-Lys3 abolishes the AG-mediated SN4741 cell survival and decrease 
in cytotoxicity in full and SR media. Further studies should be performed to determine 
whether the JMV2894-mediated neuroprotection was GHSR1a-dependent. 
The changes observed in SN4741 cell number could be the result of alterations to cell 
proliferation rates. Indeed, AG has been reported to increase cell proliferation in beta-
cells and T-cells) (Bando et al., 2013; Granata et al., 2007; J. H. Lee et al., 2014). 
However, our results show no significant increase in cell proliferation (EdU+) following 
AG treatment. Rotenone treatment attenuated cell proliferation in cells cultured in both 
full and SR media. Interestingly, a significant increase in proliferation was observed 
in SN4741 cells cultured in full media when compared with cells cultured in SR media. 
This suggests that reduced availability of nutrients in SR media results in cells 
preserving nutrients for survival/growth rather than utilise them in mitosis. Moreover, 
these data suggest that 40% depletion of total culture nutrients is sufficient to induce 
changes in SN4741 cell growth and division kinetics.  
Recent work in a mouse MPTP-model of PD demonstrated that ghrelin-mediated 
neuroprotection was dependent on activation of the cellular energy homeostasis 
regulator AMPK (Bayliss, Lemus, Stark, et al., 2016).  Since SN4741 treated with 1µM 
AG showed a rapid increase in AMPK activation at 5 mins, which was still observed 
at the 24hr time point, it is reasonable to suggest that the AG effects observed in our 
model may also be attributed to a molecular pathway involving AMPK activation. 
Studies of PD link AMPK with increased mitochondrial function and mitophagy as 
contributors to the maintenance of cellular homeostasis and survival under stressed 
conditions. For a comprehensive review see (Bayliss & Andrews, 2013) ; (Andrews, 
2011).  
We also investigate the phosphorylation of ACC along the time course of our 
neurotoxicity assay. ACC is one of many downstream substrates of 
activated/phosphorylated-AMPK (Berg, Tymoczko, & Stryer, 2002). When active, 
ACC increases utilisation of fatty acid stores as an energy source (Berg, et al., 2002). 
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ACC becomes phosphorylated 5 minutes post-AG treatment, suggesting that pAMPK 
is active. As pACC is increased at the experimental endpoint in all treatment groups 
we cannot define pACC phosphorylation as a contributor to AG-mediated 
neuroprotection. However, since expression of pACC appears to be greater in 
SN4741 cells treated with 100nM rotenone versus 10nM rotenone, with and without 
AG, the phosphorylation of ACC might be a molecular response to cellular stressors. 
Further experiments are required to elucidate the role of ACC in AG-mediated 
neuroprotection. These might involve studies of AMPK and ACC phosphorylation 
events in conjunction with the use AMPK-phosphorylation inhibitors such as 
compound C/dorsomorphin (Vucicevic et al., 2011). As shown in figure 51 (a-b) 
100nM and 200nM compound C did not prevent the expected AG-mediated 
neuroprotection in full or SR media, respectively. Although in full medium (a), there 
appears to be an attenuation of SN4741 cell loss in AG & rotenone treated cells, the 
rotenone induced SN4741 cell loss was not significant. 
Importantly, our data does not elucidate whether compound C inhibits the 
neuroprotective effects of AG as rotenone did not induce a significant reduction in 
SN4741 cell number, possibly due to decreased efficacy as a result of oxidation of 
rotenone stocks. Therefore, we can conclude that AG-mediated neuroprotection in 
SN4741 cells treated with rotenone is GHSR1a-dependant. However, we cannot 
conclude whether this effect is AMPK-dependent. 
Phosphorylation of AMPK is linked to neuroprotective events involving mitochondrial 
function and dynamics. The next chapter in this thesis will investigate AG-mediated 
neuroprotection using our in vitro rotenone assay in the context of mitochondrial 
health and function. 
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5.0. Chapter 5: Investigating Mitochondrial Dynamics using 
Automated Cell Profiler Image Analysis Pipeline and Electron 
Microscopy 
 
5.1. Introduction 
5.1.1. Mitochondrial Dynamic: Fission, Fusion and Motility  
In healthy cells and tissues mitochondria are an essential organelle which generate 
adenosine triphosphate (ATP) through metabolic reactions that convert nutrients such 
as glucose, fatty acids and amino acids into biochemical energy (ATP) and waste 
products. The emphasis placed on their metabolic activity relies heavily on the type 
of tissue the mitochondria reside in (Wai & Langer, 2016). Mitochondria, commonly 
referred to as the powerhouse of the cells, are dynamic cellular organelles which are 
continuously undergoing morphological changes depending on cellular demands and 
environment. Mitochondrial dynamics including mitochondrial fusion and fission and 
mitochondrial motility are integral to the regulation of mitochondrial morphology, 
quality, apoptosis regulation, thermogenesis and homeostasis to ultimately ensure 
cell survival (Detmer & Chan, 2007; Okamoto & Shaw, 2005; Yamashita & Kanki, 
2017) The quality of mitochondria is tightly regulated by pathways designed to retain 
healthy subset of these organelle whilst segregating the dysfunctional subset for 
degradation (Yamashita & Kanki, 2017).  
There appear to be 6 main mechanisms by which mitochondria regulate homeostasis. 
First, mitochondria have their own proteolytic system which degrades misfolded or 
oxidatively damaged dysfunctional mitochondrial proteins to avoid mitochondrial 
disruption (Anand, Langer, & Baker, 2013; Marcillat, Zhang, Lin, & Davies, 1988). 
Second, mitochondrial proteins found on the outer membrane (OM) of the 
mitochondrion can be degraded via the proteasome (Karbowski & Youle, 2011). Third, 
during oxidative stress parts of the mitochondria may bud-off and form mitochondrial-
derived vesicles (MDV) which are subsequently fused with digestive enzyme 
containing lysosomes that degrade the oxidised mitochondrial material contained in 
the MDVs (Soubannier et al., 2012). Fourth, mitochondrial spheroids can form under 
certain conditions. These spheroids are tagged with lysosomal markers suggesting 
that this may be an alternative removal pathway for damaged mitochondria (Cook, 
Soto-Pantoja, Jin, Abu-Asab, & Clarke, 2014). The fifth mechanism, as mentioned 
previously, is the continuous mitochondrial fission-fusion dynamics which attempt to 
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repair damaged mitochondrial components. Fission results in the segregation of 
damaged mitochondria, whilst fission allows for the inter-mitochondrial exchange of 
healthy mitochondrial components. These dynamic mitochondrial events are broadly 
integral to ensure cell survival, cell growth, adaptation to changes in conditions and 
overcome mitochondrial disruption during differentiation (Ni, Williams, & Ding, 2015). 
And finally, another mode by which dysfunctional mitochondria are cleared for 
degradation is by a mitochondrial specific autophagy pathway, named mitophagy (H. 
Chen & Chan, 2009). The presence of damaged mitochondria along with deficits and 
genetic mutations in the cellular machinery orchestrating the clearance of sub-optimal 
mitochondria for degradation have been associated with neurodegenerative diseases 
such as Alzheimer’s (Moreira, Carvalho, Zhu, Smith, & Perry, 2010), Huntington’s 
(Quintanilla & Johnson, 2009)  and Parkinson’s disease (Sha, Chin, & Li, 2010). 
 
5.1.2. Mitochondrial Fusion 
Fusion is a coordinated event which entails the merger of two outer membranes and 
two inner membranes of two separate mitochondria. In mammals, three large 
GTPases are required for this function. The first two are mitofusins (Mfns), Mfn1 and 
Mfn2, which are integral outer-membrane proteins with most of their polypeptide chain 
facing the cytoplasm. Mfn1 and Mfn2 can form protein complexes with themselves or 
each other (H. Chen et al., 2003). This interaction between the Mfns on fusing 
mitochondria physically tethers the outer membranes of merging mitochondria 
(Koshiba et al., 2004) and if the Mfns are omitted, fusion of the outer-membrane fusion 
nor inner-membrane fusion does not occur (Song, Ghochani, McCaffery, Frey, & 
Chan, 2009). The presence of GTPase domains in Mfns suggests that they actively 
promote membrane merger via GTP hydrolysis (H. Chen & Chan, 2010). The third 
integral in mammalian mitochondrial fusion is a dynamin-related guanosine 
triphosphatase mutated in dominant optic atrophy, OPA1 (Song, Chen, Fiket, 
Alexander, & Chan, 2007; Song, et al., 2009). In mice and humans, the 
posttranslational proteolytic cleavage by peptidase produces long isoforms of OPA1 
from eight messenger RNA (mRNA) splice variants- integral inner-membrane proteins 
which transverse the membrane once (Del Dotto et al., 2017). The long form of OPA1 
becomes destabilised upon the loss of mitochondrial membrane potential which 
enhances cleavage at two protease sites. Cleavage at S1 and S2 protease sites 
generates short forms of OPA1- short isoforms reside in the intermembrane space 
and are thought to be peripherally associated with the inner membrane (Del Dotto, et 
al., 2017). Individually, the long and short forms of OPA1 substantiate little 
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mitochondrial fusion activity. However, co-expression of short and long OPA1 
isoforms complement each other’s fusion activity. These results from (Song, et al., 
2007) suggest that mammalian cells have multiple pathways to control mitochondrial 
fusion by the processing of OPA1 variants that are regulated by mRNA splicing, 
membrane potential, and Yme1L (a ATPase Associated with diverse cellular Activity, 
a i-AAA protease) (Song, et al., 2007). 
In mammals, these three major proteins are necessary for mitochondrial fusion of the 
outer mitochondrial membrane (Meeusen et al., 2006) and the inner mitochondrial 
membrane (Song, et al., 2009). The importance of these proteins is highlighted by the 
mitochondrial dysfunction and embryonic lethality observed in mice containing 
knockouts of each of these three genes (Alavi et al., 2007; H. Chen, et al., 2003; 
Davies et al., 2007). 
 
5.1.3. Mitochondrial Fission 
Mitochondrial fission involves the recruitment of a dynamin-related protein 1 (DRP1), 
a member of the dynamin superfamily of GTPases. Although DRP1 an integral 
regulatory protein in the process of mitochondrial fission it is also involved in a range 
of other cellular functions inclusive of vesicle and organelle fission, viral resistance, 
and intracellular trafficking (Praefcke & McMahon, 2004). 
In mammalian cells DRP1 is an important driver in the change observed in 
mitochondrial morphology, peroxisomal fission and mitochondrial fission  (Koch, 
Yoon, Bonekamp, McNiven, & Schrader, 2005; Mishra & Chan, 2014; Taguchi, 
Ishihara, Jofuku, Oka, & Mihara, 2007). During mitochondrial fission, DRP1, which 
usually resides in the cytoplasm, utilises power from GTP hydrolysis to facilitate its 
translocation to four protein receptors on the outer mitochondrial surface (Cribbs & 
Strack, 2007). Four mitochondrial outer membrane receptor proteins are associated 
with DRP1 include fisson 1 (Fis1), mitochondria fission (Mff), mitochondrial dynamics 
protein of 49 kDa (MID49) and mitochondrial dynamics protein of 51 kDa (MID51) 
(Westermann, 2010). These act as tethers for DRP1 during the scission (the cutting) 
of mitochondria (Mishra & Chan, 2014).  
DRP1 is recruited to the mitochondrial membrane to facilitate in the segmentation of 
mitochondrial structure by constriction of the mitochondrial membranes which 
eventually results in two separate organelle. In mammals, the DRP1- Mff (Gandre-
Babbe & van der Bliek, 2008; Otera et al., 2010), DRP1-MiD49 and DRP1-
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MiD51interactions (Palmer et al., 2011) appear to play a more prominent role in fission 
than that of the interaction between DRP1- Fis1 which plays a minor role (Loson, 
Song, Chen, & Chan, 2013; Westermann, 2010). Moreover, DRP1 is also known to 
localize at the close contact site between the endoplasmic reticulum (ER) and 
mitochondria, suggesting that ER might contribute to mitochondrial fission (Friedman 
et al., 2011). 
Studies in yeast cells suggest that during fission, DRP1 molecules self-assemble on 
the mitochondrial outer membrane in a multimeric ring-like spiral structure 
surrounding an area on the mitochondria destined for fission (Knott & Bossy-Wetzel, 
2008; Knott, Perkins, Schwarzenbacher, & Bossy-Wetzel, 2008). This process is also 
thought to be conserved in mammalian cells (Smirnova, Griparic, Shurland, & van der 
Bliek, 2001) and is an important step in apoptosis, as well as normal cell growth and 
development. These cellular events which rely on mitochondrial fission and are 
regulated by the phosphorylation of DPR1 at Serine 616 (Ser616) and at Serine 637 
(Ser637). Ser616 and Ser637 are phosphorylated by Cdk1/cyclin B and protein kinase 
A (PKA), respectively (Knott, et al., 2008; Taguchi, et al., 2007). The phosphorylation 
of DPR1 at Ser616 during mitosis leads to increased mitochondrial fission. However, 
mitochondrial fission is inhibited upon Ser637 phosphorylation (Knott, et al., 2008). 
Interestingly, this is an effect which can be reversed by dephosphorylation of Ser637 
by a calcium and calmodulin dependent serine/threonine protein phosphatase, 
calcineurin (Cereghetti et al., 2008). Moreover, a mitochondrial E3 ubiquitin ligase, 
MARCH5, has also been identified as a critical regulatory switch of mitochondrial 
fission as MARCH5 RING mutants and MARCH5 RNA interference induced 
elongated and interconnection mitochondrial morphology synonymous of an inhibition 
of mitochondrial fission in HeLa cells (Karbowski, Neutzner, & Youle, 2007). In 
addition to phosphorylation, sumoylation of DRP1 by SUMO-1 is also an enhancer of 
mitochondrial fission (Zunino, Schauss, Rippstein, Andrade-Navarro, & McBride, 
2007).  
 
5.1.4. Mitochondrial Motility  
Mitochondria are dynamic and mobile organelle. The movement of mitochondria is 
supported by the intracellular cytoskeleton and is essential for mitochondrial 
distribution/localization and turnover (Kislin et al., 2017). Mitochondrial 
motility/transport is facilitated by microtubules, consisting of (+) plus and minus (-) 
ends, and motored by kinesin and dynamic protein motors. Kinesis interacts with 
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adaptor protein Milton (also called TRAK1/2) which binds with the E-F hand motifs of 
Miro (Mitochondrial Rho GTPase, also called RhoT1/2), a protein associated with the 
mitochondrial OM which forms a mitochondrial motor/adaptor complex (Schwarz, 
2013). There is an important interaction between the outer membrane associated 
proteins Mfn1 and Mfn 2 with both Miro and Milton during mitochondrial motility. Such 
that, the knockout of Mfn2 in neuronal cultures results in interrupted mitochondrial 
motility/transport which is also observed in Mfn2 knockout mice (Misko, Jiang, 
Wegorzewska, Milbrandt, & Baloh, 2010). The mitochondrial motility complex 
involving kinesis is like that involving dynein. Dynein and kinesin differ in their direction 
of mitochondrial motility. Dynein aids in the transport of mitochondria towards the 
minus microtubule end (that is towards the centre of the cell); whilst kinesin motors 
mitochondria towards the positive end of microtubule (that is away from the centre of 
the cell) under the regulation of a series of mitochondrial adaptor proteins (Schwarz, 
2013). In neurons, the localisation of mitochondria is integral as they produce ATP 
and Ca2+ for synaptic transmission homeostasis at synapses (J. S. Kang et al., 2008; 
Tang & Zucker, 1997). 
Studies on mouse axons have shown that most mitochondria are fixed to kinesin by 
the static axonal mitochondrial specific anchor, syntaphilin (SNPH) (Y. M. Chen, 
Gerwin, & Sheng, 2009). An increase in calcium ions (Ca2+) leads to the release of 
kinesin from the Miro resulting in increased axonal mitochondrial motility. 
Mitochondrial movement is then stalled at axonal SNPH sites. Mouse neurons 
containing mutant SNPH show a marked increase in axonal mitochondrial motility and 
a reduced mitochondrial density. SNPH has been suggested to be part of a ‘stop-start 
engine’ mechanism which propels mitochondria along microtubules. Studies suggest 
that elevated levels of Ca2+ induce the release of Kinesin from tethering with adaptor 
protein Miro of the mitochondrial OM which releases the ‘brakes’ on the mitochondria 
allowing for mobility along a microtubule. Miro subsequently interacts with SNPH to 
inhibit mobilisation (Y. Chen & Sheng, 2013; Y. M. Chen, et al., 2009; J. S. Kang, et 
al., 2008). Mitochondrial motility can also be stalled by the effects of an increase in 
extracellular glucose. Studies in neurones that O-GlcNAc Transferase-mediated 
GlcNAcylation of adaptor protein Milton results in decreased mitochondrial motility 
and therefore tailors mitochondrial dynamics based on nutrient availability 
(Pekkurnaz, Trinidad, Wang, Kong, & Schwarz, 2014). 
The balancing of fission, fusion and motility events which are essential for proper 
mitochondrial function appear to be tightly regulated by intracellular signals to 
maintain proper cellular function. Research studies have demonstrated mitochondrial 
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defects in a variety of neurodegenerative diseases including Alzheimer’s disease, 
Parkinson’s disease, and Huntington’s disease (Knott, et al., 2008).  A greater 
understanding of the subcellular implications of perturbation and mutations in key 
proteins regulating mitochondrial dynamics and function could highlight therapeutic 
pathways.  
 
5.1.5. Mitochondrial Quality Control and Degradation 
Oxidative stress, the imbalance between the production of free radicals, such as 
Reactive Oxygen Species (ROS) and the ability to neutralise them to avoid damage 
to mitochondria (or other cellular organelles). The overproduction of ROS, which are 
produced as a by-product of ATP synthesis, are implicated in several 
neurodegenerative diseases, including Huntington’s, Alzheimer's and Parkinson's 
disease (Hwang, 2013; Manoharan et al., 2016).  
Mild mitochondrial damage triggers a proteolytic mediated process resulting in the 
inactivation of OPA1 (Alavi & Fuhrmann, 2013), resulting in a decrease in inner-
mitochondrial membrane fusion without effecting fusion of the OM. As the OM fusion 
is associated with Mfn1 and Mfn2. Severe mitochondrial damage may lead to events 
which are dependent on a mitochondrial serine/threonine-protein kinase encoded for 
by gene PINK1, PTEN-induced putative kinase 1 (Pink1) and Parkin (Shimura et al., 
2000). The protein Parkin is encoded for by gene PARK2 and is a component of a E3 
ubiquitin ligase complex which plays an integral part of the ubiquitin-proteasome 
system (Pickrell & Youle, 2015). In the event of mitochondrial damage Pink1 activity 
causes the parkin protein to bind to outer membrane of the depolarized mitochondria 
and induces a mitophagy which ultimately leads to its degradation. Initiation of Pink1-
Parkin events can trigger the degradation of Mfn1 and Mfn2 via pathways involving 
the proteasome or ubiquitination resulting in mitophagy (Alavi & Fuhrmann, 2013). 
Although, fragmentation of mitochondria is key for processing damaged mitochondria 
towards mitophagy, as engulfment my autophagosome is easier, evidence shows that 
mitochondrial fission is not the lone factor in the initiation of mitophagy (Yamashita & 
Kanki, 2017). Mitochondrial fragments must also be depolarised and autophagy 
adaptor protein must also be assembled. Of note, the overexpression of Parkin and 
Pink1 proteins can lead to increased ubiquitination and degeneration of adaptor 
protein Miro- linking the adaptor protein with a role in regulation of Pink1-Parkin 
mediated mitophagy (Twig et al., 2008). For example, the loss of Miro in in-vitro HeLa 
cells results in increased clustering of mitochondria in the area immediately 
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surrounding the nucleus- the peri-nuclear area- and mitophagy (S. Liu et al., 2012). 
The exact role of Miro in mitophagy is yet to be fully elucidated. However, the role of 
Miro in mitophagy is postulated to involve two mechanisms. The first is that Miro-
tethering acts as a process of inhibiting the mitochondria to the fate of mitophagy by 
the tethering of mitochondria to microtubule (via Mitochondria-Miro-Milton-Kinesin-
Microtubule) (S. Liu, et al., 2012). The other is that Miro acts as a mitophagy receptor, 
attracting mito/autophagy associated proteins to mitochondria destined for 
degradation (X. Wang et al., 2011). 
Oxidative stress can result in mitochondrial DNA mutations, damage to the 
mitochondrial respiratory chain, permeabilise mitochondrial membranes and alter 
Ca2+ homeostasis. It is these perturbations which has seen oxidative stress being 
implicated in the development of these neurodegenerative diseases, mediating or 
amplifying neuronal dysfunction and triggering or exacerbating neurodegeneration 
(Guo, Sun, Chen, & Zhang, 2013).  
 
5.1.6. Parkin-Dependant Mitophagy 
Mitophagy can occur in a Parkin-dependent or independent manner (Grenier, 
McLelland, & Fon, 2013). Upon mitochondrial insult in the context of Parkin-
dependent mitophagy, the mitochondrial membrane becomes depolarised and Parkin 
translocates from cytosolic position to the mitochondrial OM and is regulated by Pink1. 
Pink1 is stabilised on the depolarised mitochondrial membrane due to the inactivation 
of mitochondrial protease, Presenilins-associated rhomboid-like protein (PARL) which 
resides in the inner mitochondrial membrane. Upon mitochondrial damage Pink1 is 
also stabilized by the outer mitochondrial membrane protein, Translocase of the Outer 
Mitochondrial Membrane 7 (TOMM7) and de-stabilised by another resident 
mitochondrial protein SIAH3 (siah E3 ubiquitin protein ligase family member 3) which 
inhibits Pink1 accumulation (Hasson et al., 2013).  
Pink1 is thought to regulate Parkin by either directly phosphorylating Parkin or 
phosphorylating ubiquitin to promote translocation or ligase activity. The translocation 
of Parkin to Pink1 from the cytosol is also regulated by two cytosolic proteins- HSPA1L 
(Heat Shock Protein, 70KDa, A1L) and BAG4 (BAG family molecular chaperone 
regulator 4) (Takayama, Xie, & Reed, 1999). HSPA1L promotes and BAG4 inhibits 
parkin translocation. Once Parkin is bound to Pink1 at the mitochondria (Parkin-
Pink1), selective Parkin-dependent mitophagy is promoted by mitochondrial 
ubiquitination and subsequent recruitment of autophagy receptor proteins (e.g. p62 
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and optineurin) which in turn recruits Microtubule-associated protein 1A/1B-light chain 
3-positive (LC3+ve) autophagosomes to engulf targeted mitochondrial cargo (Tanida, 
Ueno, & Kominami, 2008). 
 
5.1.7. Parkin- Independent Mitophagy 
Mitophagy can also be initiated in the absence of Parkin translocation. In the absence 
of Parkin recruitment, a range of autophagy receptor proteins can localise on the 
mitochondria which tether directly to LC3 to recruit autophagosomes to orchestrate 
engulfment of the damaged organelle. These LC3 binding proteins include BNIP3, 
NIX, FUNDC1 and Cardiolipin (Shi et al., 2014; Tagaya & Arasaki, 2017; Yuan et al., 
2017). Autophagosomes may also be recruited to the mitochondria via mitochondrial 
OM associated E3 ligase, MUL1 (J. Li et al., 2015) and cytosolic E3 ligase smurf1 
promotes ubiquitination of mitochondria and recruitment of autophagy receptor 
protein P62 which targets the mitochondria for mitophagy (Orvedahl et al., 2011). 
 
5.1.8. Mitochondrial-Derived Vesicles and Spheroids 
Other mechanism by which damaged mitochondria are degraded include the 
formation of Mitochondrial-Derived Vesicles (MDV) and Spheroids. During MDV 
formation, small vesicles containing subsets of damaged mitochondrial proteins are 
formed. Pink1 and Parkin mediate the segregation of dysfunctional components and 
encapsulates them into MDVs. MDVs subsequently fuse with late-endosomes and 
the cargo/contents are delivered to the lysosome for degradation (McLelland, 
Soubannier, Chen, McBride, & Fon, 2014). Thus, reinforcing the importance of Pink1 
and Parkin proteins in the regulation of mitochondrial quality and trafficking of cargo-
filled vesicles for degradation. Mitochondrial spheroid formation is regulated by 
mitofusins and ROS (W. X. Ding et al., 2012). Here, Parkin acts as a reversible switch 
to mitochondrial spheroid formation. Spheroid formation can occur in the absence of 
Parkin which is demonstrated in cells treated with a reversible mitochondrial un-
coupler, carbonyl cyanide m-chlorophenylhydrazone (CCCP). CCCP triggers a 
unique form of mitochondrial dynamic process involving the subsequent acquisition 
of lysosomal markers (W. X. Ding, et al., 2012). The formation of the mitochondrial 
spheroids and MDV are pathways independent of the canonical autophagy pathway 
(McLelland, et al., 2014; Samardzic & Rodgers, 2017). 
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The fission-fusion dynamics and clearance mechanisms surrounding mitochondrial 
homeostasis has implications in quality control to maintain a healthy intra-cellular 
mitochondrial network. Fission works to segregate and exclude regions of the 
mitochondria with a collapsed/low mitochondrial membrane potential (MMP) which is 
associated with damaged or unhealthy mitochondria. Alternatively, fusion works to 
preserve healthy mitochondria and its components that typically form organelles with 
a high MMP. Thus, changes in MMP are associated with cell health and the resulting 
perturbations are manifested in a range of diseases such as cancer, cardiovascular 
diseases, diabetes, and various neurodegenerative diseases (Pieczenik & Neustadt, 
2007). As such, MMP is used as a measure for mitochondrial toxicity, cell health and 
apoptosis (Sakamuru, Attene-Ramos, & Xia, 2016), making MMP a key parameter for 
evaluating mitochondrial function. 
 
5.1.9. Mitochondrial Dynamics in Parkinson’s Disease 
The cell types with the greatest demand for mitochondrial metabolism are particularly 
sensitive to mitochondrial dysfunction as this results in decreased function and 
concomitant ROS production and damage. Moreover, the dynamic mitochondrial 
fission-fusion interplay facilitates effective motility of mitochondria to their cellular 
destinations such as dendrites or axons via polarised microtubules. The abnormal 
inhibition of mitochondrial fission, fusion or motility are suggested to contribute to 
occur as early events during the neuro-pathogenesis of many neurodegenerative 
diseases (H. Chen & Chan, 2009). 
Approximately 10% of PD cases are thought to be the result of genetic inheritance of 
mutations in genes including SNCA (PARK1-4) (Polymeropoulos et al., 1997), LRRK2 
(PARK 8) (Brice, 2005), DJ-1 (PARK7) (Pankratz et al., 2006), ATP13A2 (PARK9) 
(Ramirez et al., 2006), as well as Parkin (PARK2) (Lucking et al., 2000) and PINK1 
(PARK6) (Bonifati et al., 2005), which are important for the maintenance of 
mitochondrial integrity (Dodson & Guo, 2007).  
There has been a lack of success in replication of common PD symptoms (such as a 
reduced lifespan, dysfunction of brainstem and sympathetic nerves, visible 
aggregates of alpha synuclein-positive Lewy bodies or nigrostriatal neuronal 
degradation) in PINK1 and Parkin knockout mouse studies. These techniques are 
adequate to produce potential underlying causes of the common PD symptoms. 
These genetic mutants resulted in symptoms including increased mitochondrial 
dysfunction (Gautier, Kitada, & Shen, 2008), decreased respiration and ATP 
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production, and an increased sensitivity to oxidative stress (Gautier, et al., 2008), 
decreased DA neurotransmitter firing and synaptic plasticity in the nigrostriatal circuit 
(Kitada et al., 2009; Kitada et al., 2007) (Gispert et al., 2009). Although the loss of 
DAergic neurons was not directly observed, these perturbations may be a precursor 
to nigrostriatal neurodegeneration. 
In vitro studies using mouse-derived primary neuronal cultures and human DAergic 
neuron cultures show that loss of protein PINK1 induces, oxidative stress, alterations 
to mitochondrial morphology and a decrease in long-term cell viability (Wood-
Kaczmar et al., 2008). Genetic manipulation studies in drosophila and mammal 
derived cell lines show that an overexpression of Pink1 promotes fission which is 
possibly facilitated by Fis1 acting as the intermediator between Pink1 and the fission 
promoting action of Drp1 (Y. Yang et al., 2008).  
In HeLa cells, RNA interference induced downregulation of PINK1 leads to 
dysfunctional mitochondrial morphology and abnormal membrane potential. These 
observations are reversed upon reintroduction of wildtype PINK1. Furthermore, 
primary human patient-derived fibroblasts containing two different PINK1 mutants 
partly mirrored these observation in mitochondrial morphology. Interestingly, human 
Parkin rescued this altered morphology, which is associated with cellular stress, in 
the human cells; an effect which was not seen with PD-associated mutants. This study 
also suggests that the induced abnormal mitochondrial phenotype may be rescued 
by increased expression of parkin (Exner et al., 2007).  
Fragmented mitochondrial morphology is associated with cells derived from PD 
patients (Exner, et al., 2007). The importance of Pink1 in replication of PD-like 
mitochondrial morphology has been shown in studies using HeLa and SH-SY5Y 
human cell lines as the knockout of Pink1 leads to a fragmented mitochondrial 
morphology (Dagda et al., 2009; Exner, et al., 2007). Moreover, the overexpression 
of wild-type Pink1 in SH-SY5Y cells increased mitochondrial interconnecting networks 
and attenuated toxin-induced mitophagy. In this context mitophagy serves a 
neuroprotective role by limiting cell death. (Dagda, et al., 2009). 
Whereas mouse Parkin and Pink1 loss of function mutants show a very mild 
phenotype, studies show that drosophila mutants express a more pronounced 
phenotype inclusive of multi-tissue mitochondrial dysfunction, DAergic neurone and 
flight muscle degeneration (Y. Yang et al., 2006). This severe phenotype derived from 
mutant Pink1 flies can be rescued by overexpression of Parkin (Park et al., 2006). 
Drosophila mutant studies also show that mitochondrial morphology is regulated by a 
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balance between fusion, which is regulated by Mitofusin (mfn) and opa1, and fission, 
which is regulated by drp1. Interestingly the severe phenotypes observed in Pink1 
and Parkin mutant flies can be ameliorated by the knockdown of mfn or opa1 or 
overexpression of drp1. The Pink/Parkin pathway is thought to promote the 
fragmentation of mitochondria via promotion of fission or inhibition of fusion by the 
positive regulation of drp1 and negative regulation of fusion proteins mfn and opa1. 
These results implicate Pink1 and Parkin in a common pathway that regulates 
mitochondrial physiology and cell survival in drosophila via regulation of mitochondrial 
fission and fusion (Y. Yang, et al., 2006). However, mitochondrial morphology and 
phenotypes of Pink1 and Parkin mutant flies are unique from the mitochondrial 
phenotypes from drp1 mutant flies. Moreover, flies containing heterozygous mutation 
in drp1 enhance the severity of the Pink1-knockout phenotype, resulting in lethality. 
These results suggest that Pink1 and Parkin are probably chief constituents of the 
drp1-mediated mitochondrial fission machinery (Deng, Dodson, Huang, & Guo, 2008). 
Together this suggests that Pink1/Parkin regulation of mitochondrial fission and fusion 
dynamics is not a straightforward linear pathway. Although Pink1 and Parkin appear 
to promote mitochondrial fission and/or inhibition of fusion, other fusion and fission 
machinery play their own integral roles. An RNAi experiment which screened 719 
genes predicted to code for mitochondrial proteins were screened for alterations in 
Caenorhabditis elegans mitochondrial morphology. The knockdown of over 80% of 
the targets resulted in altered mitochondrial morphologies such as abnormal 
mitochondrial fragmentation and elongation. This study implies that maintenance of 
normal tubular/networked mitochondrial morphology and fission/fusion dynamics is 
dependent on a range of fundamental mitochondria functions including oxidative 
phosphorylation and metabolism (Ichishita et al., 2008). 
Cell health can be evaluated by investigating mitochondrial health, a marker of which 
is MMP. Of note, mitochondria in smaller fragmented networks are preferentially 
chosen for degradation if they also possess a collapsed mitochondrial membrane 
potential (Pieczenik & Neustadt, 2007). 
In this chapter, we investigate the effect of complex-1 inhibitor, rotenone challenge on 
mitochondrial health by measuring mitochondrial membrane potential and 
fragmentation as markers of cell health. Furthermore, we study whether AG pre-
treatment attenuates rotenone SN4741 neurone loss and ameliorates impairment in 
MMP and fragmentation. For ease of use and replicability the open-source image 
analysis software, Cell Profiler was employed to measure mitochondrial health and 
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fragmentation. Cell Profiler is used to extract meaningful quantitative measurements 
in an automated pipeline of pre-set computer algorithms for 100s of multi-channel 
images and export data in the form of a user-friendly spreadsheet format (e.g. MS 
Excel). We will also utilise Transmission Electron Microscopy (TEM) to investigate the 
effects of our AG-rotenone neurotoxicity assay to provide greater morphological 
detail. 
 
5.1.10. Cell Profiler:  a High Throughput Image Analysis Software 
The examination of cellular function has long been carried out by visual analysis and 
microscopy following appropriate cellular staining.  However, the mid-1990s saw the 
advancement of technology towards automation of light and fluorescence microscopy 
hardware. This provided the researcher with a method of rapidly capturing 1000s of 
high quality images for analysis. The result was a bottleneck in the experimental 
protocol between image capture and data acquisition due to the laborious and time-
consuming task of manual image analysis. Now, both open-source and commercial 
software is available to decrease the time required for high-quality image acquisition, 
image analysis and subsequent output of results. Cell Profiler is an example of an 
open-source software streamline the experimental process. 
Cell Profiler: Cell Profiler is a free open-source modular image analysis software 
capable of handling hundreds of thousands of images (Carpenter et al., 2006).The 
Cell Profile Project was developed by a collaboration between the ‘Broad Institute’ 
and MIT (www.cellprofiler.org/about/). The software is available for download at: 
http://cellprofiler.org/. The Cell Profiler software was developed to allow biologists to 
investigate cellular phenotypes of interest using a user-friendly, module-based 
interface. Although some tweaking of Cell Profiler modules is necessary, there is no 
requirement for the user to have previous experience in computer vision or computer 
programming in order to successfully construct a Cell Profiler image analysis pipeline 
(a string of modules) (Carpenter, et al., 2006). Pre-developed modules (algorithms 
developed by computer scientists) cover a range of features for image analysis 
including image pre-processing, object segmentation and a list of data exportation 
options to suit downstream quantitative data management and statistical analysis 
(Kamentsky et al., 2011). 
The automated nature of this software enables the extraction of quantitative data on 
a large, high-throughput scale, making it an ideal tool for the investigation of multiple 
parameters within a large image dataset. The Cell Profiler project and software is 
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bridging the gap between advanced image analysis algorithms and scientists who 
lack knowledge in computer science. Moreover, carefully designed strings of 
algorithms and features, named pipelines, can be saved and re-used by the individual 
or by colleagues running the same experiment 
Why use Cell Profiler? Microscopy has long been the go-to method for trained 
biologists to observe and analyse cellular events and phenotypes. Manual microscopy 
is a feasible method for imaging small sample sizes. The subsequent qualitative or 
quantitative manual analysis of a small sample sizes are relatively practical and non-
labour intensive. However, recent years (mid-1990s) have seen the development of 
more sophisticated and automated microscope technologies to analyse samples on 
a larger scale (Shariff, Kangas, Coelho, Quinn, & Murphy, 2010). The automation of 
light, wide-field and confocal fluorescence microscope systems allows for the 
possibility of large scale image acquisition without the laborious task of constant 
manual user input (e.g. re-focusing microscope between images and manual 
adjustment of microscope to subsequent samples etc.). 
Although, these automated high content analysis (HCA) systems allow scientists to 
acquire vast image datasets sufficient for robust statistical analysis across a range of 
samples and treatments, a common bottleneck in the experimental pipeline often 
occurs during image analysis and data acquisition (Carpenter, et al., 2006; Shariff, et 
al., 2010).  
The automation of image analysis steps which allows the screening of chemical 
libraries to identify perturbants useful as research tools or drugs (T. R. Jones et al., 
2009) can both facilitate and build on the knowledge of a researcher by providing 
quantitative data outputs which are not possible by eye- even by a trained and 
experienced cell biologist. 
 
 
 
Example uses of Cell Profiler: 
As the demand for experimental process automation and High Content Screening and 
analysis grows (for example in drug discovery and RNA interference screens), the 
use of image analysis software capable of extracting quantitative data and scoring 
cellular events from image datasets is increasing. In the 4 years following its 
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publication, Cell Profiler has been cited in over 250 articles (Kamentsky, et al., 2011) 
and is used in a variety of methods to extract data from image datasets.  
Cell Profiler can be used at many levels of complexity, from simply identifying primary 
objects such as nuclei for cell counting (see chapter 4), to segmentation of cellular 
compartments of interest to extract cell-by-cell quantitative information, to more 
complex methods including particle tracking and the use of machine learning to score 
specific cell phenotypes (T. R. Jones, et al., 2009). Cited research papers show the 
application of Cell Profiler in the analysis of a variety of in-vitro and ex-vivo 
experiments. 
In this research chapter we focus on identifying cellular compartments, a method 
commonly termed segmentation. This method involves designating groups of pixels 
in a 2-dimentional (2D) image as cellular compartments of interest, such as nuclei, 
cell bodies and cytoplasm. Once these areas of interest have been identified, 
information in the form of quantitative data is easily extracted using Cell Profiler’s 
intuitive user interface, object measurement features and variety of data output tools. 
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5.2. Methods and Materials 
5.2.1 SN4741 Mitochondrial Health Analysis  
SN4741 cells were seeded and treated in a neurotoxicity assay as described in 
chapter 4 (see figure 28 B for experimental timeline). Following incubation in test 
compounds for a designated period of time under normal cell culture conditions, 175 
µL was removed from each well resulting in 125 µL remaining. 
As described in the HCS Mitochondrial Health Kit (Invitrogen, Cat.No #H10295) 
(referred from here on as MitoHealth Kit) protocol manual, a 50 µL mixture of 
MitoHealth stain and Image-iT® DEAD Green™ viability stain in complete medium 
should be added and incubated under normal condition for 30 mins at this point. 
Although both stains included in this kit are well retained following formaldehyde 
fixation and detergent permeablization, for our application Image-iT® DEAD Green™ 
viability stain was omitted as we have explored SN4741 cell cytotoxicity in this context 
and we were now predominantly focussing on mitochondrial health and 
fragmentation. Mitohealth staining solution was prepared by the addition of 2 µL of 
Mitohealth stain into 650 µL of cell culture medium (1:350 dilution) as required. 
Following 30 minute incubation with Mitohealth stain, the medium was removed and 
100 µL of counterstain/fixation solution was added to each well. Cells were protected 
from direct light using tin foil and incubated for 15 minutes at room temperature to 
ensure fixation and counterstaining of SN4741 cells and nuclei. The counterstain/ 
fixative solution was prepared by adding 3 mL 16% paraformaldehyde (PFA) and 6 
µL of Hoechst 33342 (included in HCS Mitochondrial Health Kit) to 9 mL PBS. This 
ratio of counterstain/fixation solution (PFA: Hoechst 33342: PBS) was prepared fresh 
in the ratio of 1mL PFA: 2 µL Hoechst 33342: 3 mL PBS as required prior to addition 
to cells. SN4741 cells were then washed once in 100 µL PBS before the addition of 
200 µL PBS to each well and stored overnight at 4°C (protected from light) or 
proceeding directly to imaging and analysis.  
5.2.2. HCS Mitochondrial Health Kit 
The MMP, Δψm, is a feature of healthy mitochondria. The Δψm is essential for 
generation and detoxification of reactive oxygen species (ROS), the uptake and 
storage of Ca2+, and synthesizing ATP by oxidative phosphorylation (Nicholls, 2004). 
Since the retention of a Δψm is a good indicator of mitochondrial health and its 
depolarization is a good indicator of mitochondrial dysfunction, it is utilised as a 
measurable parameter in high-content analysis cytotoxicity assays (Abraham, Towne, 
Waring, Warrior, & Burns, 2008). 
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In recent years, fluorescent dyes for measuring the MMP (Δψm) have become 
commonly used tools for monitoring changes in this important physiologic 
mitochondrial parameter as it relates to cells’ capacity to generate ATP by oxidative 
phosphorylation (Perry, Norman, Barbieri, Brown, & Gelbard, 2011). To assess the 
effects of treatments on SN4741 cell mitochondrial health the MitoHealth Kit was 
employed. The MitoHealth kit consists of two stains which can be used can be used 
to quantitatively assess two cell health parameters: Mitotoxicity (or Mitochondrial 
Health) and cytotoxicity. HCS Mitochondrial Health Kit also includes Hoechst 33342 
DNA counterstain. 
The MitoHealth stain, accumulates in functional mitochondria proportional to 
mitochondrial membrane potential.  The fluorescence intensity (FI) staining observed 
with the MitoHealth stain corresponds to MMP and gives a measure of mitochondrial 
health (mitotoxicity) i.e. The FI observed in healthy mitochondrial is greater than that 
observed in damaged mitochondria because they have a higher MMP. 
Hoechst 33342 is a fluorescent DNA counterstain which can be applied to live and 
dead cells. Approximate fluorescence excitation/emission maxima: Hoechst 33342: 
350/461 nm bound to DNA; Image-iT® DEAD Green™ viability stain: 488/515 nm; 
MitoHealth stain: 550/580 nm. All dyes included in this kit are applicable for live cell 
imaging and have sufficient FI retention following formaldehyde fixation and 
permeablization for endpoint assays. 
Image acquisition was carried out using the InCell Analyser 2000 (GE Healthcare) to 
capture 52 x40 magnification tiff format images from each well. Treatments were 
carried out in duplicate for 5 experimental repeats (n=5). Treatments included vehicle, 
1µM AG-treatment, 10nM rotenone challenge, 1µM AG-treatment prior to 10nM 
rotenone challenge, 100nM rotenone challenge and DMSO. Treatments were carried 
out in full medium in synchronicity with the 24hr neurotoxicity assay, as described in 
Chapter 4. A Cell Profiler pipeline was developed to i) identify cell nucleus from 
Hoechst 33342 staining intensity; ii) measure MitoHealth staining intensity in each cell 
peri-nuclear region (area surrounding the nucleus) and iii) quantify extent if 
mitochondrial fragmentation by counting and measuring areas of Mitohealth stained 
mitochondrial fragments. 
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5.2.3. CellProfiler Protocol for the Identification of Cell Nuclei, 
measurement of Mitochondrial Membrane Potential and Mitochondrial 
Fragmentation. 
A variety of example image analysis pipelines and tutorials are available at: 
CellProfiler.org. These include pipelines for various levels of image analysis 
complexity and purpose. Basic Cell Profiler pipelines see relevant application in the 
analysis of human cells, fruit fly cells, tumours and comet assays.  
More Advanced Pipelines include examples which can be applied to Human 
cytoplasm-nucleus translocation assays, Speckle Counting, Object Tracking and 
Metadata Management, and Sequencing RNA molecules in situ.  
Although CellProfiler software and corresponding website does contain pre-made 
computer algorithms (modules) and example analysis pipelines respectively, this 
does not mean that Cell Profiler is a simple out-of-the-box, plug-and-play image 
analysis software.  Rather, these pre-made modules and example pipelines are used 
to teach the everyday biologist, with little computer programming or macro script 
writing experience, how to design and assemble an image analysis pipeline to fit the 
specific needs of their experimental question. Interestingly, CellProfiler also allows for 
ImageJ (NIH) software input of macro scripts to aid image analysis. Taken together, 
CellProfiler is relatively flexible, user-friendly platform on which to conduct image 
analysis.  
The protocol below describes the step-by-step Cell Profiler pipeline for the 
identification of nuclei, measurement of MitoHealth staining intensity and 
quantification of mitochondrial fragmentation protocol used to quantify SN4741 cell 
mitochondrial measurements from x40 magnification digital images. This protocol was 
developed by optimising a range of modules and example protocols. Each step 
includes a description, Cell Profiler-derived notes and rationale followed by 
instructions on how to execute the step in Cell Profiler software (in italic font). ‘Notes’ 
are heavily reference from CellProfiler.org/manuals. 
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Cell Profiler Pipeline: Measuring MMP. 
The fluorescence intensity of the mitochondrial health stain corresponds with MMP. 
The fluorescence intensity was measured in the area/ ring around the nucleus of each 
identified SN4741 cell, as is described in the HCS Mitochondrial Health Kit [H10295, 
Molecular Probes]. The area of the ring surrounding the nucleus is also calculated.  
Here we describe a step-by-step method used to segment this area of interest from 
the remainder of the image to extract measurements. 
 
Step 1: Upload Image set, Image Sorting and Image Pre-processing and Illumination 
Correction 
First, it is necessary to open Cell Profiler Software and select the experimental image 
set. 
Open Cell Profiler Pipeline > Select ‘Images’ in ‘Input Module’ window > Right click 
inside empty ’File list’ window > Browse and select image set. 
Here, our image set is composed of two channels, Cy3 and DAPI, which account for 
x40 magnification images containing MitoHealth stained mitochondria and Hoechst 
stained nuclei of SN4741 cells respectively (see figure 55). To filter the images 
according to filename: 
Select ‘Names and Types’ in pipeline Input modules > Select ‘Images Matching Rules’ 
then select ‘File’, ‘Does’, ‘Contain’ from dropdown box selections > Type ‘DAPI’ into 
input box to group DAPI channel images. 
Select ‘Add another image’ and repeat the process with exception to entering ‘Cy3’ 
into input box to group Cy3 channel images. Assign a (user-defined) name for 
grouped files > Select ‘Update’. 
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This diagram illustrates an image set containing DAPI and Cy3 images being 
separated into groups (DAPI and Cy3) based on their file names. Cropped image tile 
labelled DAPI/Cy3 represents a pseudo-coloured composite of both channels. Blue 
arrows illustrate the separation of DAPI and Cy3 channels based on contents of their 
file names. Example image filenames are given on pseudo-coloured DAPI and Cy3 
images. DAPI, merged and Cy3 x40 magnification images scale bar 40µm. Each 
pseudo-coloured image has a representative Zoomed image for graphical purposes. 
MitoHealth-stained mitochondrial networks are visible in Zoom Cy3 image.  
 
Note: Care must be taken when filtering image sets by common phrases in filenames, 
such as ‘DAPI’ and ‘Cy3’, as phrases are case-sensitive. Inconsistency in spelling or 
case-sensitivity results in failure to identify files and sub-group images. Experimental 
image set should now be grouped in two file lists under user-defined group titles e.g. 
DAPI and Cy3 and ranked in numerical order. 
During the analysis of images taken with a fluorescence microscope it is common for 
the images to be pre-processed prior to analysis. The most common reason for this 
is uneven illumination across a field of view as the light source does not evenly 
Figure 55: Images are Filtered into Groups by File Names. 
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illuminate across the entire area. This results in areas with greater illumination than 
other areas, usually the corners of the image. 
A limitation of many High-Content Screening (HCS) platforms, such as the InCell 
Analyser 2000, is that a flat field correction (FFC) function cannot easily be 
implemented into the imaging process. There is the option to modify the images taken 
during a post-processing stage; however, this leaves the quality control of the FFC to 
the imaging software without any further input or quality control from the end user.  
Without a FFC application we can see that the intensity of an images varies widely 
from the centre to its edges (illustrated in figure 56). This spread of illumination 
intensity within an image will deter the accuracy of downstream image analysis. For 
example, regions of a cell body may appear shaded and therefore segmentation of 
image into biologically-relevant compartments (i.e. identification of cell body 
boundary) may be deterred. 
The illumination pattern will change if a different staining reagent(s) is used for a batch 
of samples or if there is a change in the components or setting in the optical path of 
the microscope. For example, the illumination pattern may change throughout the 
same day or analysis as the lamp changes temperature. Therefore, in this protocol 
illumination is measured and correction applied for each image channel- that is 
Hoechst and Cy3.This illumination pattern must be corrected to ensure correct and 
comparable measurements in intra and inter image analysis.  Cell Profiler software 
has built-in modules to deal with these issues. The CorrectIlluminationCalculate 
module is used to measure the intensity pattern of a single or set of images and 
produces an intensity function which is to be applied across the entire image set.  The 
CorrectIlluminationApply module then applies the calculated intensity function to 
the images prior to analysis. Correction of intensities can be important for 
segmentation and intensity measurement functions. In this method of illumination 
correction, we create and save an illumination function and apply this correction to 
images before segmentation. This can be performed using a separate Cell Profiler 
pipeline to create an ‘average’ illumination function for a specific fluorescence channel 
in a data set. Alternatively, as it is performed in this instance, the pre-processing 
(illumination correction) can be implemented at the start of an image analysis pipeline. 
This illumination function is saved as an image and is applied to the entire data set. 
The drawback of implementing illumination correction as part of a working pipeline, 
especially when dealing with large quantities of image files, is that calculation of the 
illumination function can add a considerable amount of time to the automated analysis 
process. 
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Cell Profiler users recommend calculating different Illumination correction for each 
multi-well experiment and for each wavelength measured within the experiments as 
there is variability in illumination between experimental plates and samples. 
 
 
 
Figure 56: Cy3 Image and DAPI Channel Images Before and After Illumination 
Correction. 
 Figure 56 (a) and (c) show representative x40 magnification greyscale images 
acquired using In Cell 2000 Cy3 filters before (OrigCy3) and after (CorrCy3) 
illumination correction via, respectively. (Figure 56 b) illustrates the Illumination 
function (IllumCy3) produced from entire Cy3 image set. Figure 56 d & f show 
representative x40 magnification greyscale images acquired using In Cell 2000 DAPI 
filters before (OrigBlue) and after (CorrBlue) illumination correction, respectively. 
Figure 56 e (IllumBlue) illustrates the Illumination function produced from entire image 
set This illumination correction is carried out by Cell Profiler modules 
CorrectIlluminationCalculate and CorrectIlluminationApply Images (a-f) are micro 
pictograms acquired and saved from the Cell Profiler Software. 
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To calculate correct illumination function: 
Select Correct Illumination Calculate module > Select input image (name assigned 
from Names and Types) 
Insert a (user-defined) Name the Output Image e.g. ‘IllumCy3’  
Select ‘Regular’ option in How the illumination function is calculated. 
Note: The option ‘Regular’ is selected if stained objects (e.g. cell bodies, nuclei) are 
evenly dispersed across your image(s) and cover most of the image. This is true in 
the case of Cy3 and DAPI channel images. Regular intensities make the illumination 
function based on the intensity at each pixel of the image (or group of images if you 
are in All mode) and applied by division using Correct Illumination Apply module. 
Select ‘Median Filter’ > Select ‘Manual’ method to calculate filter size > input 
smoothing filter size ‘325’. 
Note: Illumination function was calculated across the entire image set prior to initiation 
of object identification and subsequent data measurements. 
To apply the illumination function calculated by Correct Illumination Calculate: 
Select Correct Illumination Apply module 
Input > a user defined name into ‘Name the output image’ box e.g. ‘CorrCy3‘ 
Select illumination function from drop down box (as defined in Correct Illumination 
Calculate module e.g. IllumCy3) 
Select ‘Divide’ as method for how the illumination function is applied 
Note: Divide is the recommended method of illumination function application by Cell 
Profiler users if the illumination correction function was created using ‘Regular’ in the 
Correct Illumination Calculate module. 
Figure 56 illustrates the shading seen on edges of Cy3 and DAPI channel images 
acquired images before and after application of illumination function as described 
above.  
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Step 2: Identification of Nuclei  
Here we identify cell nuclei (a feature) based on their high contrast background to 
foreground staining intensity. In Cell Profiler software, a primary object is defined as 
an object or feature (usually a cellular sub-compartment e.g. nucleus) which can be  
Nuclei are commonly selected as the primary object (or the seed) of an image analysis 
pipeline due to their relatively uniform morphology and high background to foreground 
staining intensity ratio which makes them easily identifiable.  
Select > ‘Identify Primary Objects’ module  
Input > (user named illumination corrected) DAPI image(s)  
Input > Typical Nucleus diameter range (pixels). Min: 50 and Max: 135  
Discard objects outside the diameter range > Yes 
Discard objects touching the border of the image > Yes 
Note: Estimate nucleus diameter using Cell Profiler by selecting a DAPI image by 
‘Right click’ on DAPI image and selecting ‘Show Selected Image’; and selecting ‘Tools 
> Measure length’. 
For thresholding select ‘Global’ Thresholding Strategy with ‘Otsu’ method and ‘Two 
Classes’ thresholding. Set threshold correction factor of ‘1.0’; and lower and upper 
bounds to ‘0.0’ and ‘1.0’, respectively. 
Note: Global thresholding strategy uses the pixel intensities in each un-masked 
image to calculate a single threshold value to classify pixels as foreground 
(brighter/more intense than threshold value) or background (with intensity below the 
threshold value). This thresholding strategy is fast and robust and commonly applied 
to images that have a uniformly illuminated background. Since foreground-to-
background pixels are easily distinguishable using Hoechst, DAPI channel images 
showing counterstained SN4741 cell nuclei, this ‘Global’ thresholding strategy is a 
sensible choice for this primary object identification. Otsu is a method of automatically 
finding thresholds by splitting image pixels into two (foreground and background) or 
three classes (foreground, mid-level and background) by minimizing the variance 
within each class. Lower bounds on threshold can be set at 0.0 as there is an object 
(Nucleus) in each image. Otherwise, an empirically determined lower threshold bound 
as automatic methods of thresholding may miss-assign pixels in a blank image to the 
foreground class, potentially yielding false-positive results. 
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Select > ‘Shape’ for de-clumping of primary object which are touching or in close 
proximity and ‘Shape’ for drawing dividing lines between objects. 
Select > ‘Yes’ to ‘Automatically calculate size of smoothing filter for de-clumping’ 
Select > ‘Yes’ to ‘Automatically calculate minimum allowed distance between local 
maxima’  
Select > ‘No’ to ‘Retain outlines of the identified objects 
Fill in identified objects > ‘After both thresholding and de-clumping’ 
Note: By selecting ‘shape’ for de-clumping method, cases in which there are definite 
indentations separating objects. The image is converted to a binary (black and white) 
image and the resulting shape determines whether clumped objects will be 
distinguished.  
 
Figure 57: Identify Nuclei as Primary Objects. 
Figure 57(a) shows a representative illumination corrected x 40 magnification image 
of Hoechst counter-stained nuclei acquired using In Cell Analyser 2000 DAPI channel 
filters. (b) illustrates identified primary objects using object coloured masks. (c) shows 
nuclei fitting to protocol input criteria (outlined in green); nuclei filtered out by size 
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criteria (outlined in magenta); and nuclei filtered out for touching the image border 
(outlined in yellow). Dashed white line shows zoomed area (d). (d) shows the Zoomed 
area with white arrows indicate indentations used to de-clump objects (nuclei). 
Images (a-d) are micro pictograms acquired and saved from Cell Profiler. 
 
Step 3: Identify Secondary Objects: Ring shaped Cell Body  
The next module in Cell Profiler pipeline is Identify Secondary Objects. This module 
identifies objects by using the object identified by another module as a starting point. 
In this example, the primary object (nuclei) identified in the Identify Primary Object will 
act as the seed for the identification of SN4741 peri-nuclear area (doughnut shaped 
ring around the nucleus) in the corresponding Cy3 images. This will be executed by 
dilation of the previously identified nuclei- this dilated nucleus area is named ‘Full 
Doughnut’ in figure 58 (c) A subsequent module in this pipeline will remove the 
nucleus, and a ring like object will be remaining (a doughnut shaped-perinuclear 
region). This is referred to as ‘True Doughnut’ in figure 59 (f).  Other modules will the 
collect measurements such as area and intensity of peri-nuclear regions. 
To expand nucleus and create ‘Full Doughnut’ shape: 
Select > ‘Identify Secondary Object’ module  
Input > Illumination function corrected Cy3 image ‘’CorrCy3’ 
Input (primary) objects > Select ‘Nuclei’. These were identified by Identify Primary 
Object module. 
Insert the name of objects to be identified > ‘FullDoughnut’ 
Select > ‘Distance- B’ as method to identify the secondary objects 
Note: By selecting Distance as the method to identify the secondary objects (‘Full 
Doughnut’) the primary object (nucleus) is expanded to identify a ‘doughnut’ (or 
‘annulus’) shaped region in the cell, usually in the cytoplasm. Cell Profiler provides 
two methods of identifying the secondary object. The first, ‘Distance-N’ does not utilise 
staining intensity in the image of the second stain- in this instance Cy3. This entails 
expanding the nucleus a set distance. However, this may include areas of image 
background as well as cell cytoplasm. Our protocol on the other hand utilises 
‘Distance- B’ method. This second ‘Distance’ method expands the nucleus a set 
distance however, this method uses the thresholding of the secondary staining image 
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to eliminate background regions. Thus, the nucleus is only expanded in to areas of 
foreground staining intensity to identify Full Doughnut secondary object without 
including background image regions. 
Select > ‘Automatic’ threshold method. 
Input > ‘25’ as number of pixels to expand the primary object (nucleus) 
Fill holes > Select ‘Yes’ 
Discard Objects touching the border of the image > Select ‘Yes’. 
Retain outlines of the identified secondary objects > Select ‘No’ 
Note: the ‘Automatic’ thresholding method is the default setting in Cell Profiler and is 
robust. As this strategy is automatic it does not allow user to select the threshold 
algorithm or to apply additional corrections to the threshold. The ‘Automatic’ strategy 
calculated the threshold using maximum correlation thresholding (MCT) for the whole 
image. The threshold is then applied to the image and smoothed with a Gaussian filter 
with a sigma of 1, this blurs or obscures smaller than an entered diameter and spreads 
bright or dim features larger than the entered diameter. The MCT method is described 
by (Padmanabhan, Eddy, & Crowley, 2010) as computationally efficient and accurate 
without relying on assumptions of the statistics of the image. This algorithm has been 
trialled and tested on neuroscience images in the presence and absence of 
illumination correction to accurately aid in automated image analysis. 
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Figure 58a shows the Illumination Corrected Cy3 image (a); the result of a 25-pixel 
distance dilation in nucleus size with respect to Cy3 image staining intensity 
thresholding. Identified secondary objects/Full Doughnuts are illustrated in the form 
of coloured masked objects. Dashed white line boxes in (a), (c) and (e) highlight the 
area(s) which are zoomed-in and illustrated in (b), (d) and (f) respectively. Zoomed 
images show the image segmentation more clearly. Image (g) is a larger version on 
(f), illustrating the nuclear area/primary object with a green outline and the edges of 
the Full Doughnut/secondary object with a magenta outline. Images (a-g) are micro 
pictograms acquired and saved from the Cell Profiler Software. 
 
 
 
 
 
Figure 58: Identification of Secondary Object- Full Doughnut 
196 
 
Step 4: Identify Tertiary Objects: Cell Cytoplasm or True Doughnut 
Following the identification of the ‘Full Doughnuts’ (secondary objects), the Identify 
Tertiary Objects module is then used to remove the smaller objects (nuclei) from the 
larger secondary objects (Full Doughnuts) to leave a ring shape around the nucleus, 
referred to here as ‘True Doughnut’. 
Images (a), (c) and (f) illustrate the masked image result of sequential steps/modules 
from identification of primary object (Nuclei), identification of secondary object (Full 
Doughnut) and tertiary object (True Doughnut), respectively. The ring shaped True 
Doughnut is the result of removing the Nuclei areas from the areas of Full Doughnuts. 
Micro-pictograph (g) highlights the outlines of the resulting True Doughnut. Dashed 
white boxed in images (a), (c), (e) and (g) indicated the areas which have been 
zoomed-in for illustrative purposes and are represented by images (b), (d), (f) and (h) 
respectively. Images (a-h) are micro pictograms acquired and saved from the Cell 
Profiler Software. 
To identify tertiary objects (ring shaped ‘True Doughnuts’): 
Select > ‘Identify Tertiary Objects’ module 
Select > ‘FullDoughnut’ as larger identified objects (output from Identify Secondary 
Object module) 
Select > ‘Nuclei’ as smaller identified objects (Output from Identify Primary Object) 
Select > ‘Yes’ to shrink smaller object prior to subtraction. 
Figure 59: Identify Tertiary Objects 
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Note: Nuclei will now be subtracted from Full Doughnut area to produce a ring shaped 
‘True Doughnut’ in the peri-nuclear region of the identified SN4741 cells. By selecting 
‘Yes’ to shrink the smaller object the nucleus is shrunk by 1 pixel before subtracting 
the objects. This ensures a tertiary object is produced. Measurements such as area 
and fluorescence intensity of the segmented area can be acquired subsequently.  
 
Cell Profiler Pipeline: Measure SN4741 Mitochondrial Fragmentation 
Abnormal fragmentation of mitochondria is a trait observed in cells derived from 
patients afflicted with neurodegenerative diseases such as PD (Pieczenik & Neustadt, 
2007). Pesticides such as rotenone are commonly used to generate PD models (Knott 
& Bossy-Wetzel, 2008). In in-vivo rat models, systemic exposure to rotenone induces 
neurochemical, behavioural and neuropathological features of PD. These PD-like 
features are inclusive of nigrostriatal dopaminergic degeneration which is associated 
with the behavioural traits of hypokinesia and rigidity. The systemic exposure of 
rotenone in this rat model also resulted in other PD-associated neurochemical 
hallmarks such as the accumulation of ubiquitin and alpha-synuclein containing 
cytoplasmic inclusions (Betarbet et al., 2000). Moreover, evidence shows that cells 
exposed to rotenone, a mitochondrial Electron Transport Chain (ETC) complex-I 
inhibitor, results in a fragmented mitochondrial morphology in-vitro. An affect which is 
appears to be dependent on metabolic energy sensor, AMPK  (Toyama et al., 2016). 
Here we describe a protocol variation on the ‘Cell Profiler Pipeline: Measuring MMP’, 
previously described, which allows for identification of entire mitochondria in SN4741 
cell body and subsequent quantification of mitochondrial fragments and measurement 
of fragment size. This Cell Profiler pipeline utilises aspects of the Cell Profiler 
website’s ‘Speckle Counting’ example pipeline with alterations to complement the 
analysis of x40 magnification image of SN4741 cells for mitochondrial fragments 
stained by the mitochondrial health stain. The basic pipeline is similar to that 
described above, however, there are adjustments at i) ‘step 3’ as Cell Profiler software 
is tweaked to identify SN4741 cell body; and ii) ‘step 4’ as the edges of entire SN4741 
cell cytoplasm are identified as opposed to only the ring shaped ‘True Doughnut’ in 
the peri-nuclear region of the cell. Alterations are described in a step-by-step method 
below. 
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Step 3: Identify Secondary Objects: SN4741 Cell Body  
Following the identification of SN4741 nuclei using Identify Primary Object module 
the Identify Secondary Object module is used again. However, this time the module 
and method must find the edge of SN4741 cell bodies as secondary objects using cell 
body-specific Cy3 staining intensity. Again, this module involves a thresholding step 
which assigns pixels in the input image to foreground and background. To identify cell 
body: 
Select > ‘Identify Secondary Objects’ module 
Input Image > Selects ‘CorrCy3’ 
Select > Input Objects ‘nuclei’ (identified in Identify Primary Object module) 
Input > 'CellBody’ as name for identified objects 
Select > ‘Propagation’ as method to identify secondary objects 
Select > ‘Automatic’ as threshold method 
Input > ‘0.00’ as regularization factor. 
Select > ‘No’ to fill holes in identified objects 
Select > ‘Yes’ to discard objects touching the image border 
Select > ‘Yes’ to discard associated primary objects  
Select > ‘No’ to retain the outlines of the identified secondary objects 
Note: This module uses ‘propagation’ as the method to identify dividing lines between 
clumped cell bodies (secondary objects) where there is a local change in staining 
intensity (i.e. cell bodies having different staining intensities; and foreground and 
background have different staining intensities). This algorithm varies from the 
watershed method (used in Image J macro) as the dividing lines between objects (cell 
bodies) are determined by both the changes in local image intensity (intensity 
gradient) and distance to the nearest primary object (nucleus). Dividing lines are 
placed in the image where the images local intensity changes perpendicular to the 
boundary (T. R. C. Jones, A. Golland, P., 2005). Therefore, this method is considered 
an improved method of object segmentation. Since ‘propagation’ is selected a 
regularization factor (given the symbol λ) must be user-defined to inform the execution 
of the propagation algorithm. Propagation takes 1) the distance to nearest primary 
object and 2) intensity of the secondary object image into account when defining the 
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dividing lines between objects.  The regularization factor is used to decide the balance 
and weight placed on each factor during propagation and can be anywhere in the 
range 0 to infinity. If a regularization value >1 is selected, the image intensity is almost 
completely ignored. Whilst selecting a regularization value of 0, means that the 
distance to the nearest primary object is ignored and propagation relies on image 
intensity. The larger the regularization value the more image intensity is ignored and 
dividing lines drawn become more reliant on distance to the nearest primary object. 
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Figure 60 (a) shows the input Illumination Corrected x40 magnification Cy3 channel 
image; (C) Illustrated the result of propagation method of identifying cell (body) edge 
with respect to Cy3 image staining intensity thresholding. Identified secondary 
objects/Cell bodies are illustrated in the form of coloured masked objects. Image (e) 
shows the input Cy3 channel image with identified cell body outlines in magenta and 
nuclei outlines in green. Dashed white line box in (e) highlights the area zoomed to 
produce image (f). White box in image (f) indicates area which is zoomed in to produce 
image (g). Zoomed in images (f) and (g) were generated to illustrate image 
segmentation. Dashed white line boxes in (a) and (c) highlight the area(s) which are 
zoomed and illustrated in (b) and (d) respectively. Images (a-g) are micro pictograms 
acquired and saved from the Cell Profiler Software. 
 
 
 
 
 
  
 
 
 
Figure 60: Identify SN4741 Cell Body as Secondary Object 
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Step 4: Identify Tertiary Objects: SN4741 Cytoplasm 
Similarly, to that described in ‘Step 4’ of MMP Protocol, the Identify Tertiary Objects 
module subtracts the shape of the smaller object (nucleus) from that of the larger 
identified object (i.e. cell body). Once removed the segmented area identified is the 
cell cytoplasm. 
To identify Mitohealth stained SN4741 cytoplasm using Cell Profiler modules:  
Select > Identify Tertiary Objects module 
Select > ‘Cell Body’ as input for larger identified objects 
Select > ‘Nuclei’ as input for smaller identified objects 
Input > ‘Cytoplasm’ as name for tertiary objects to be identified 
Select > ‘Yes’ to shrink smaller object. Ensuring a cytoplasm is created for each 
nucleus 
Select > ‘No’ to Retain outlines of tertiary objects as these will not be utilised 
downstream 
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Images (a), (c) and (f) illustrate the masked image result of sequential steps/modules 
from identification of primary object a (Nuclei), identification of secondary object c (cell 
body) and tertiary object f (cell cytoplasm), respectively. SN4741 cytoplasm is the 
result of removing the Nuclei areas from the areas of entire cell bodies. Micro-
pictograph (g) highlights the outlines of the resulting SN4741 cell cytoplasm. Dashed 
white boxed in images (a), (c), (e) and (g) indicated the areas which have been 
zoomed-in for illustrative purposes and are represented by images (b), (d), (f) and (h) 
respectively. Images (a-h) are micro-pictograms acquired and saved from the Cell 
Profiler Software. 
 
 
 
 
 
 
 
 
 
 
Figure 61: Identify SN4741 Cytoplasm as Tertiary Object 
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Step 5: Enhance Mitochondrial Speckles 
The Enhance Or Suppress Feature module is a Cell Profiler module that suppresses 
or enhances selected image features such as speckles, ring shapes and neurites) to 
improve the subsequent object identification by an Identify module. In this case it is 
used to make the punctate mitochondrial staining pop out by applying image 
processing filters to the input image and giving a grayscale image output. Following 
the execution of this module the Identify Primary Object module is used again to 
identify mitochondrial puncta. 
Select > ‘CorrCy3’ as input image (image is illumination function corrected) 
Input > ‘FilteredRed’ (or other user-defined name) for output grayscale image 
Select > ‘Enhance’ as operation type 
Select > ‘Speckles’ as feature type to be ‘Enhanced’ 
Input > ‘20’ as feature size. 
 
Note: The enhance operation is used to create an output image which predominantly 
contains user defined features. In this pipeline, the module produces a grayscale 
image largely composed of mitochondrial puncta. Feature size was determined by 
measurement of mitochondrial puncta using the Tools > Measure length Cell Profiler 
function. Cell Profiler suggests that when enhancing (or subtracting) the largest 
feature size in the image(s) should be selected. In these MitoHealth stained x40 
magnification images the largest mitochondrial puncta measured were approximately 
20 pixels in diameter. Speckle feature type was selected to enhance mitochondrial 
puncta in image. Cell profiler defines a speckle as an area of enhanced pixel intensity 
relative to its immediate neighbourhood using a tophat filter. This filter used grayscale 
image erosion within a set radius (Approx. object diameter = 20 pixels; therefore 
radius = 10 pixels), and then dilation. The speckles are enhanced by this module 
making them easier to identify with the Identify Primary Object module. See figure 
56 (e-g) & figure 57 for example of identified puncta.  
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Figure 62 (a) shows an input ‘CorrCy3’ image prior to speckle enhancement; (b) 
shows image (a) post-enhance module. Dashed white line box in (a) and (b) highlight 
the area displayed in (c) and (d) which are pre- and post- enhancement module, 
Figure 62: Enhance Mitochondrial Fragments and Identification. 
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respectively. (e), (f) and (g) show zoomed input image; outlined mitochondrial puncta; 
and marks of identified objects.  
 
Step 6: Identify Primary Objects: Mitochondrial Fragments 
This step utilises the Identify Primary Objects module to identify the mitochondrial 
puncta in the images enhanced in step 5. To identify mitochondrial puncta in 
enhanced x40 objective Cy3 channel images of MitoHealth stained SN4741 cells we: 
Select > Identify Primary Objects module 
Select > FilteredImage (output image from previous module) as input image 
Input > ‘Puncta’ (or other user-defined name) to assign to identified objects 
Select object diameter range > Min= 2; Max= 35 
Select > ‘Yes’ to discard objects outside the diameter range 
Select > ‘Yes’ to discard objects touching the bored of the image 
Select > ‘Per Object’ as Thresholding strategy and ‘Otsu’ as thresholding method 
Select > ‘Cytoplasm’ (previously identified tertiary objects) as masking objects 
Select > ‘Three classes’ thresholding and minimize the ‘weight variance’ 
Assign> Middle intensity pixels to ‘Foreground’ 
Note: Using ‘Per object’ thresholding strategy relies on the identification of a cellular 
compartment in a previous Cell Profiler module. In this example, SN4741 cell 
‘Cytoplasm’ is identified by Identify Tertiary Object module. Using this strategy 
means each individual cell cytoplasm has its own applied threshold. Pixels outside of 
the object are considered background. Cell Profiler suggests this as a useful method 
for identifying particles is cellular sub-compartments if staining varies between 
objects/cell-to-cell. Otsu method of thresholding (named after Nobuyuki Otsu) 
calculates image threshold by minimising the variance within the pixel that are 
considered to be classed and assigned to foreground or background (Otsu, 1979; 
Sezgin & Sankur, 2004). Cell Profilers’ application of Otsu thresholding method can 
be applied to assign pixels to either two-classes (foreground and background), or 
three-classes (foreground, mid-ground and background). Two-class is selected as 
foreground (regions of interest i.e. puncta) background are easily distinguishable 
following enhancement module.  
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Select > ‘Automatic’ smoothing method for thresholding 
Input > ‘1.0’ as Threshold correction factor with ‘0.001’ lower and ‘0.005’ as upper 
bounds on threshold 
Select > ‘No’ to automatically calculate size of smoothing filter for object de-clumping 
Input > ‘5’ as size of smoothing filter 
Select > ‘No’ to automatically calculate allowed distance between local intensity 
maxima 
Input > ‘5’ to suppress local maxima that are closer than this minimum allowed 
distance 
Select > ‘No’ to retain outlines of identified puncta 
Select > ‘Never’ to fill holes in identified objects 
Select > ‘Continue’ to handling of excessive number of identified objects- as puncta 
are small and therefore the number of puncta identified per image is usually high. 
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Images illustrating mitochondrial puncta identified with automated image analysis Cell 
Profiler pipeline. Image (a) is an example input image to the Identify Primary Objects 
module; (b) illustrated the outlines of identified mitochondrial puncta, and (c) shows 
object masks of identified mitochondrial puncta. Dashed boxes on (a), (b) and (c) 
indicate where Cell Profiler zoom function has been utilised to generate images (d), 
(e) and (f) respectively for illustrative purposes. 
 
 
 
 
 
 
 
 
Figure 63: Identification of Mitochondrial Puncta 
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Measurement Modules 
Step 7: Measure Object Size and Shape 
Although the Measure Object Size and Shape module can measure a vast array 
shape and area features, I will use this module to measure object size (area in pixels) 
of each cells mitochondrial puncta, cytoplasm and True Doughnut respective to Cell 
Profiler pipeline. 
To measure size and shape of object using Measure Object Size and Shape: 
Select > Measure Object Size and Shape module 
Select > ‘Cytoplasm’ or ‘Puncta’ or ‘True Doughnut’ or any combination of identified 
objects 
Note: Specific shape or size measurements (e.g. area) to output into spreadsheet is 
defined in a later module. This module simply selects which objects the 
measurements should be taken from. 
 
Step 8: Measure Object Intensity: True Doughnut or Cytoplasm 
To measure the intensity of identified objects we use the Measure Object Intensity 
Cell Profiler module. To do so; 
Select > ‘CorrCy3’ illumination corrected image as image to measure. 
Select > ‘True Doughnut’ or ‘Cytoplasm’ (or other object) identified in previous 
modules to measure 
Note: CorrCy3 image, as opposed to a Raw Image, is selected to acquire intensity 
measurements as this image has previously undergoes illumination correction during 
the pre-processing stage. Specific object intensity measurements (e.g. mean, 
median, minimum, maximum intensity) to output into spreadsheet is defined in a later 
module. This module simply selects which objects the measurements should be taken 
from. 
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Step 9: Relate Objects: assign mitochondrial fragments to cell cytoplasm.  
The Relate Objects Cell Profiler module is used here to assign a relationship between 
‘children’ objects (e.g. puncta) with ‘parent’ objects (e.g. cytoplasm). This module can 
be utilised in order to count the number of puncta per SN4741 cytoplasm and calculate 
a mean measurement value for all ‘children’ objects which are associated with each 
‘parent’ object. Objects (e.g. mitochondrial puncta) are considered ‘children’ of a 
‘parent’ object (e.g. a cell cytoplasm) if the child object is found within or at the edge 
of a ‘parent’ object. To assign the relationship between mitochondrial puncta and a 
cell cytoplasm: 
Select > ‘Puncta’ as input child objects (identified in second Identify Primary Objects 
module) 
Select > ‘Cytoplasm’ as input parent objects (Identified in Identify Tertiary Objects 
module) 
 
Step 10: Mask Objects to relate puncta to cytoplasm of origin 
The Mask Objects module hides regions of the input image which are not regions of 
interest. This then aids in the assignment of puncta to a cell cytoplasm of interest and 
allows for cell-by-cell puncta counts. In this example only SN4741 cell cytoplasm is 
selected as a region of interest and subsequently aids in exporting the Parent-Child 
(Cytoplasm- Puncta) data in the Export to Spreadsheet module which follows. To 
create a mask from previously identified objects (i.e cytoplasm): 
Select > ‘Filtered Red’ (the output of Enhance or Suppress Feature module) as input 
image 
Input > ‘Mask Red’ as (user defined) name for output image 
Select > ‘objects’ and ‘Cytoplasm’ to select object (cytoplasm) for mask. 
Select > ‘No’ to invert mask to ensure mask is produced from the foreground area 
within the masking objects (cytoplasm). 
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Step 11: Export to Spreadsheet: Output data into MS Excel Spreadsheet 
The final module in these Cell Profiler protocols is the Export to Spreadsheet. Here 
we assign a folder/file destination and name for the output data.  
Select > ‘Elsewhere’ and then ‘browse’ for desired output file location. 
Select > ‘Yes’ to add prefix to file output file name  
Input > ‘Name’ (user-defined) prefix for output filename (e.g. MitoMMP or MitoPuncta) 
Select > ‘No’ to overwrite without warning (Does not affect protocol- decided by end 
user) 
Select > ‘No’ to add metadata columns to object data file (Does not affect protocol) 
Select > ‘Yes’ to limit output to a size that allowed in Excel. If ‘no’ is selected, then 
upon exceeding limit on Excel spread sheet the pipeline will be terminated without 
data outputted.   
Select > ‘NaN’ to represent data points which are numerical values are ‘infinite’ or 
‘undefined’ in output spreadsheet 
Select > ‘Yes’ to select the measurements to export. The user can define which data 
are outputted to spread sheet. By selecting ‘No’ all data types will be outputted. 
 
Select the following data outputs from drop down box ‘select measurement to export’. 
To export number of nuclei (cell count) and puncta per image: 
Image > Count > Nuclei; 
Image > Count > puncta;  
To export area of the objects True Doughnut and Cytoplasm: 
True Doughnut > Area Shape > Area; 
Cytoplasm > Area Shape > Area; 
To export intensity of mitohealth staining intensity in S4741 peri-nuclear area: 
True Doughnut > Intensity > Mean Intenisty 
To export cell-by-cell puncta counts: 
Cytoplasm > Children > Puncta > Count 
211 
 
Select > ‘Yes’ to calculate the per-image mean values for object measurement. Cell 
Profiler will calculate mean intensity, mean area, mean number of puncta per cell etc. 
for each image will then be exported into spreadsheet. Median and standard deviation 
measurements per image can also be calculated if desired.  
File > Save Project As > input user defined project name. to save the Cell Profiler 
image analysis pipeline for future use. 
Cell profiler protocol can now be opened and used on image set. To allow modules to 
run in sequence in an automated fashion select: 
File > Analyze Images. A spreadsheet will be populated and saved as an output upon 
termination of all executable algorithms/modules in the Cell Profiler pipeline. This 
pipeline can be applied to experimental repeats.  
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Below is a table (Table 19) containing the names and functions of the Cell Profiler 
algorithm modules used in the above protocol(s). 
Table 19: Cell Profiler Modules and Functions 
Cell Profiler Module Function 
Correct Illumination - 
Calculate  
Calculates an illumination function that is used to 
correct uneven illumination/lighting/shading or to 
reduce uneven background in images. 
Correct Illumination - Apply  Applies an illumination function, usually created by 
Correct Illumination Calculate, to an image to correct 
for uneven illumination (uneven shading). 
Identify Primary Objects  Identifies biological components of interest in 
grayscale images containing bright objects on a dark 
background (e.g. nuclei or speckles). 
Identify Secondary Objects  Identifies objects (e.g., cell body) using objects 
identified by another module (e.g., nuclei) as a 
starting point, or seed. 
Identify Tertiary Objects  Identifies tertiary objects (e.g., cytoplasm) by 
removing smaller primary objects (e.g. nuclei) from 
larger secondary objects (e.g., cell body), leaving a 
ring shape. 
Enhance Or Suppress 
Features  
Enhances or suppresses certain image features (e.g. 
speckles, ring shapes, and neurites), which can 
improve subsequent identification of objects (such as 
mitochondrial fragments). 
Measure Object Size 
Shape  
Measures several area and shape features of 
identified objects. 
Measure Object Intensity  Measures several intensity features for identified 
objects. 
Relate Objects  Assigns relationships; all objects (e.g. speckles) 
within a parent object (e.g. nucleus) become its 
children. 
Export To Spreadsheet Exports measurements into one or more files that can 
be opened in Excel or other spreadsheet programs. 
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Once these Cell Profiler pipelines (Cell Profiler Pipeline: Measuring Mitochondrial 
Membrane Potential and Cell Profiler Pipeline: Measure SN4741 Mitochondrial 
Fragmentation) have been constructed it is then possible to automate image analysis 
for hundreds or thousands of images.  
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5.2.4. Cell Preparation for Electron Microscopy 
SN4741 cells were treated as described in (Chapter 4) and fixed using a mix of para- 
and glutaraldehyde at experimental endpoint prior to analysis via electron microscopy. 
The only exceptions were that the SN4741 cells were seeded at 30,000 cells per well 
in 1 mL of culture medium in specialised six well plates containing filters (received 
from Prof Christian). Identical treatment concentrations to those in (Chapter 4- see 
figure 28 B for experimental timeline) were applied to the SN4741 cells with the 
exception that the reagents were administered in 1mL additions rather than the 100 
µL previously described.  
At the experimental endpoint, well filters were rinsed once with PBS then promptly 
immersed in fixative solution to avoid drying of cells and minimise exposure to air, and 
left to fix at room temperature for 2 hrs.  For transit to Professor Helen Christian, 
University of Oxford, fix was gently removed and replaced with 10-fold weaker dilution 
of final fixative solution diluted in PBS. Wells were filled and the lid was sealed onto 
the culture vessel using parafilm before being placed into polystyrene box containing 
ice blocks (4°C). Samples were transported to our collaborator, Professor Helen 
Christian from the Department of Physiology, Anatomy and Genetics at the University 
of Oxford to perform morphological analysis using TEM. 
For preparation of fixative: Fresh 12% paraformaldehyde and 25% glutaraldehyde 
solution (Grade I, 25% in H2O, specially purified for use as an electron microscopy 
fixative) was purchased from SIGMA-ALDRICH (Cat no. G5882). 12% PFA and 25% 
glutaraldehyde were diluted in PBS to produce the final fixing solution comprising of 
2.5% glutaraldehyde and 2% PFA. Final fixing solution was adjusted to pH 7.2 using 
1M sodium hydroxide (NaOH), a basic compound used to increase pH level, and 1M 
Hydrogen Chloride (HCl) acid, used to acidify the solution as necessary. This mixture 
of fixatives was advised by Professor Christian to achieve the best ultrastructure 
preservation for TEM analysis of mitochondria morphology. 
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5.3. Results 
5.3.1. 24hr Acyl-Ghrelin Pre-treatment Attenuates the Loss of MMP 
Induced by Rotenone 
 
SN4741 cells were stained using Mitochondrial Health HCS stain following treatment 
regimen described in Chapter 4 (figure 28B). 52 x40 magnification images were 
acquired per well using the In Cell Analyser 2000 (GE Healthcare). Perinuclear 
mitochondria staining intensity was measured by an automated image analysis 
pipeline developed in Cell Profiler.  24hr AG treatment significantly increases mean 
fluorescent intensity and attenuates the complex 1 induced loss of MMP in SN4741 
cells. Statistical analysis was performed by One-way ANOVA with Bonferroni's 
Multiple Comparison Test post-hoc analysis on Graph Pad Prism 5 software, with 
P<0.001 (***). 
 
 
 
Figure 64 :Acyl-Ghrelin Pre-Treatment Attenuates the Rotenone Induced Loss 
of MMP Intensity. 
216 
 
5.3.2. 24hr Acyl-Ghrelin Pre-treatment Attenuates Rotenone-induced 
Mitochondrial Fragmentation. 
 
SN4741 cells were stained using Mitochondrial Health HCS stain following treatment 
regimen seen in Chapter 4 (figure 28B). 52 x40 magnification images were acquired 
per well using the In Cell Analyser 2000 (GE Healthcare). Cytoplasmic mitochondrial 
fragmentation was measured by an automated image analysis pipeline developed in 
Cell Profiler. AG treatment significantly decreases mean mitochondrial fragmentation 
induced by complex 1 inhibitor rotenone in SN4741 cell. Statistical analysis was 
performed by One-way ANOVA with Bonferroni's Multiple Comparison Test post-hoc 
analysis on Graph Pad Prism 5 software, with P<0.001 (***). 
 
 
 
Figure 65: Acyl-Ghrelin Pre-Treatment Attenuates the Rotenone Induced 
Mitochondrial Fragmentation. 
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5.2.3. Electron microscopy analysis of mitochondria  
Treatment and fixation of SN4741 cells with vehicle, 24hr AG, 10nM rotenone and 
10nM rotenone with 24hr AG pre-treatment was performed at Swansea University. 
SN4741 cells were also treated with 100nM rotenone as a positive control for 
mitochondrial fragmentation.  Following preparation, duplicate samples were 
transported to Professor Helen Christian’s Laboratory in St. Mary’s College, Oxford 
University for analysis using TEM. Professor Christian, who has extensive knowledge 
and expertise in TEM and mitochondrial analysis kindly carried out the TEM analysis 
on our behalf and provided descriptions of mitochondrial morphology and health.  
  
TEM images acquired of vehicle treated SN4741 cell show mitochondria that appear 
healthy, quite electron-dense with compact cristae (figure 66a).  TEM images of 
SN4741 cell mitochondria treated with AG (1µM) also appear healthy, quite electron-
dense with compact cristae. Whereas, rotenone (10nM) treatment causes 
mitochondrial swelling and loss of mitochondrial cristae indicated by asterisk symbol 
(*) in (figure 66b). TEM images of SN4741 cells following 24hr 1µM AG pre-treatment 
prior to 10nM rotenone treatment appear electron dense and contain compact cristae. 
AG appears to protect mitochondria from rotenone induced damage (figure 66d). TEM 
images of SN4741 cells treated with a higher dose of rotenone (100nM) appear 
stressed, swollen and show a loss of cristae. Stressed mitochondria which are swollen 
and show a loss of cristae are indicated with asterisk symbols (*) in figure 66c)  
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 (a-d) are representative TEM images of SN4741 cells acquired by Professor Helen 
Christian, Oxford University following vehicle treatment (a); 10nM rotenone treatment 
(b); 100nM rotenone treatment (c) and 1µM AG pre-treatment followed by 10nM 
rotenone treatment (d). Images are arranged side by side to compare altered 
mitochondria ultrastructure between groups; AG appears to protect mitochondria from 
rotenone induced damage. SN4741 cell mitochondria appear healthy, electron dense 
and compact with cristae following vehicle (a) and 1µM AG pre-treatment followed by 
10nM rotenone treatment (d). SN4741 cell mitochondria appear stressed, swollen and 
show a loss of cristae in rotenone treated samples (b and c). Swollen mitochondria 
expressing a loss of cristae are indicated with asterisk symbols (*) in images (b) and 
(c). Image (c) shows evidence of rotenone induced mitophagy. Example SN4741 
nuclei are labelled ‘Nucleus’ in image (a). 
 
 
 
 
Figure 66: TEM Images of SN4741 Cells suggests AG Pre-Treatment Protects 
Mitochondria from Rotenone Induced Damage 
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Table 20 Results of EM Image Analysis on 10 SN4741 Cells per Treatment group. 
Mean Number of Mitochondria Scored per Unit Area and Standard error of the 
mean (SEM) 
Treatment Group Mitochondrial Number / Area (µm2) 
Longitudinal 
Sections/Area 
Transverse 
Section/Area  
Total 
Mitochondria/Area 
Mitophagy 
events/Area 
 
Vehicle  
0.13 +/-0.02 
 
 
0.27 +/- 0.05 
 
 
0.4 +/- 0.07 
 
0 
1µM AG 0.15 +/-0.02 
 
0.31 +/- 0.05 
 
0.45 +/- 0.07 
 
0 
10nM Rotenone 0.1 +/-0.03 
 
 
0.2 +/- 0.06 
 
0.3 +/-0.07 
 
0.13 +/- 0.06 * 
increase vs vehicle 
 
1µM AG + 10nM 
Rotenone 
0.05 +/-0.01 ** 
decrease vs 
vehicle 
 
 
0.45 +/- 0.06* 
increase vs 
rotenone only 
 
 
0.51+/- 0.075 NS vs 
vehicle 
 
0.026 +/- 0.004 ** 
increase vs 10nM 
rotenone group 
100nM Rotenone 0.068 +/-0 .02 * 
decrease vs 
vehicle 
 
 
0.18 +/- 0.046* 
decrease vs 
vehicle 
 
 
0.25 +/-0.06 * 
decrease vs vehicle 
 
0.24 +/- 0.08 ** 
increase vs vehicle 
 
 
Longitudinal Mitochondrial Sections per Unit Area 
No significant difference in longitudinal mitochondria per unit area was observed in 
1µM AG and 10nM rotenone treated SN4741 cells versus vehicle treated cells. 
However, a significant (**) decrease in number of longitudinal mitochondria per unit 
area was observed in SN4741 cells treated with 1µM AG + 10nM rotenone versus 
control. Moreover, SN4741 cells treated with 100nM rotenone also showed a 
significant (*) decrease in longitudinal mitochondria per unit area versus vehicle 
treated cells. 
Transverse Mitochondrial Sections per Unit Area 
No significant difference in longitudinal mitochondria per unit area was observed in 
1µM AG, 10nM rotenone, and 1µM AG + 10nM rotenone treated SN4741 cells versus 
vehicle treated cells. However, a significant (*) increase in number of transverse 
mitochondrial sections per unit area was observed in SN4741 cells treated with 1µM 
AG + 10nM rotenone versus 10nM rotenone treated cells. Moreover, SN4741 cells 
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treated with 100nM rotenone also showed a significant (*) decrease in longitudinal 
mitochondria per unit area versus vehicle treated cells. 
Total Mitochondria per Unit Area 
No significant difference in total counts of mitochondria per unit area was observed in 
1µM AG, 10nM rotenone, and 1µM AG + 10nM rotenone treated SN4741 cells versus 
vehicle treated cells. However, a significant (*) decrease in the overall number of 
mitochondria per unit area was observed in SN4741 cells treated with 100nM 
rotenone versus vehicle treated cells.  
 
 
Mitophagy/Degenerating Mitochondria per Unit Area 
The number of mitochondria undergoing mitophagy was also scored. No significant 
difference in mitophagy events per unit area was observed in 1µM AG treated SN4741 
cells versus vehicle treated cells. A significant (*) increase in mitophagy events was 
observed in SN4741 cells treated with 10nM rotenone versus control. This number of 
mitophagy events is increased as the dose of rotenone is increased from 10nM 
rotenone to 100nM rotenone. With 100nM rotenone treatment, a more significant (**) 
number of mitophagy events per unit area are observed in SN4741 cells. Interestingly, 
1µM AG + 10nM rotenone treated SN4741 cells do not show a significant increase in 
mitophagy events per unit area versus control. However, there is a significant (**) 
increase in the number of mitophagy events observed per unit area in 1µM AG + 
10nM rotenone treated SN4741 cells versus SN4741 cells solely treated with 10nM 
rotenone. 
Statistical analysis 
10 SN4741 cells per group were analysed for mitochondrial counts and morphology. 
Statistical analysis was carried out in Graph Pad prism version 5 using one-way 
ANOVA with Bonferroni post-hoc test. Experiment was performed in duplicate. 
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TEM images show that rotenone treatment causes mitochondrial stress, swelling and 
loss of mitochondrial cristae. The observed degeneration is not apparent when 
SN4741 cells are pre-treated with AG (figure 66d). 
The total number of mitochondria per area (µm2) is significantly decreased (*) in 
100nM rotenone treated SN4741 cells versus control group.  10nM rotenone or AG 
pre-treated SN4741 cells do not show a significant increase or decrease in total 
mitochondria versus vehicle. 
Mitophagy events are significantly elevated in both 10nM rotenone and 100nM 
rotenone treated SN4741 cells versus vehicle. There is no significant difference in 
mitophagy events in rotenone treated SN4741 cells following AG pre-treatment 
relative to vehicle treatment. However, there is a significant difference between the 
number of mitophagy events versus samples treated with only 10nM rotenone 
suggesting that mitophagy might be playing a role in the upkeep of healthy 
mitochondria in rotenone challenged SN4741 cells that have undergone AG pre-
treatment.   
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5.4. Conclusions 
 
The experimental procedures carried out in this chapter allows us to conclude the 
following. 
• Cell profiler can be used to automate the identification of nuclei/ the seed of the 
experiment upon which an automated image analysis pipeline may be constructed 
for cell-by-cell analysis.  
• Experimental pipeline to measure mitochondrial health staining intensity in peri-
nuclear area has been developed. 
• 24hr AG treatment reverses rotenone-induced decrease in MMP. 
• Cell Profiler protocol has been extended by the application of add-on software 
modules to identify and measure mitochondrial fragmentation. 
• Rotenone-induced mitochondrial fragmentation is inhibited in cells pre-treated 
(24hrs) with AG. 
• Electron microscopy and analysis performed by Professor Helen Christian at St. 
Mary’s College, Oxford University showed (n=2) that rotenone induced 
mitochondrial swelling and ultrastructural cristae deformities is attenuated by 24hr 
AG pre-treatment. Furthermore, 100nM rotenone treatment exacerbated the 
detrimental effects of rotenone treatment, inducing an increased incidence of 
mitochondrial perturbations  
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5.5. Discussion 
In this results chapter, we have described and constructed an automated image 
analysis pipeline developed in Cell Profiler software which identifies, measures and 
quantifies cellular characteristics from 2D images. Like the paper by (Sakamuru, et 
al., 2016); we outline, step-by-step, an automated images-based MMP assay which 
we utilise to measure and quantify the effects of AG and rotenone on SN4741 cell 
MMP. Image analysis plays a vital role in the study of PD models, with the need for it 
at an all-time high.  This demand can be attributed to two major contributing factors.  
The exponential rise in microscope power provides researchers with a key insight into 
cell behaviour and neurotoxin effects. The ability of TEM to provide images of such 
significantly higher resolution than light microscopy makes it a key tool in analysis of 
PD models. TEM is also utilised in various other fields, with the prevailing notion being 
that it is among the most effective forms of microscopy available today. Another 
considered factor is the rise in human cell models, an example being iPSC derived 
neurons from PD patients, a more reliable model for testing neuroprotection against 
PD in humans.  The need to study these models on a graphic platform is of integral 
importance to further the understanding of PD in humans, its symptoms and potential 
neuroprotective therapies.  Image analysis led to some crucial findings within the 
current study, detailed in the conclusions above.    
 
As cellular powerhouses, mitochondria are integral in the production of ATP (Agarwal, 
2011; Mitchell, 1961) and the generation of a MMP which can be measured as a 
critical parameter for the evaluation of mitochondrial integrity and function (L. B. Chen, 
1988). Moreover, mitochondrial dysfunction, inclusive of collapsed MMP, have been 
linked with neurodegenerative diseases such as PD (Knott & Bossy-Wetzel, 2008; 
Pieczenik & Neustadt, 2007) and cell death via apoptosis, necrosis and autophagy 
(Lemasters et al., 2002).  
Rotenone is an inhibitor of Complex I of the ETC. Rotenone inhibits mitochondrial 
electron transport by acting at complex I (NADH CoQ1 reductase) of the respiratory 
chain and preventing the transfer of electrons from iron-sulphur centres and 
subsequent reduction of ubiquinone. Inhibition results in an interference with NADH 
in the process of generating ATP (Treberg, Quinlan, & Brand, 2011). Moreover, as 
coenzyme Q is unable to accept electrons from inhibited mitochondrial electron 
transport chain complex I, an overload of electrons is backed-up in the mitochondrial 
matrices. An excessive pool of electrons can result in increased reduction of cellular 
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oxygen and subsequent reduction to ROS. ROS can damage local mitochondrial 
proteins, mitochondrial DNA and other non-mitochondrial cellular components (Mehta 
& Li, 2009).  
Rotenone is utilized to replicate cellular and physiological features in in vitro and in 
vivo models of PD and is known to contribute to cell/neuron death by mitochondrial 
membrane depolarization (Y. Moon, et al., 2005); increasing ROS production 
(Nataraj, Manivasagam, Thenmozhi, & Essa, 2017) unbalancing cellular antioxidant 
mechanisms (H. Ding, Gao, Zhu, Xiong, & Liu, 2008); and facilitating the opening of 
mitochondrial permeability pore which results in the release of cytochrome-C (Cyt-C) 
into the cytoplasm - an event associated with activation of pro-apoptotic pathways 
(Doran & Halestrap, 2000; Ott, Robertson, Gogvadze, Zhivotovsky, & Orrenius, 
2002).   
Inhibition of complex I (NADH: Ubiquinone oxidoreductase) by rotenone induced 
oxidative stress is thought to be the key contributor to its toxicity in DAergic neurones 
by decreasing MMP (Testa, et al., 2005). Rotenone reduces MMP, which enhances 
mitochondrial permeability. The increase in mitochondrial permeability leads to an 
increased movement of Cyt-C, from its anchoring at the inner mitochondrial 
membrane to the cytosol. This event can initiate programmed cell death by apoptosis 
(X. Liu, Kim, Yang, Jemmerson, & Wang, 1996). Once in the cytosol, Cyt-C 
complexed with other pro-apoptotic factors such as Apaf-1, dATP, Caspase 3 and 
Caspase 9 to drive apoptosis (X. Jiang & Wang, 2004). In line with this, our data 
shows that mild (10nM) rotenone treatment is sufficient to cause SN4741 cell loss. 
The cell loss observed following 24hr treatment with 10nM rotenone coincides with a 
significant reduction in SN4741 MMP which may be mediating the effect. 
TEM imaging and analysis showed vehicle treated SN4741 cell mitochondria as 
tightly packed cristae-dense and electron-rich. However, following rotenone 
treatment, mitochondria appeared large and swollen, often with irregular cristae 
distribution throughout - some of which were completely lacking in cristae in large 
areas. AG treatment alone showed no significant difference in mitochondrial 
morphological ultrastructure compared to vehicle samples. Analysis of AG pre-treated 
SN4741 cells followed by rotenone challenge show a reverse in perturbed 
mitochondrial cristae and mitochondrial swelling. Adverse rotenone-induced 
ultrastructural alterations are also apparent in the substantia nigra neurones of PD 
model rats following a 42-day treatment regimen with the complex I inhibitor. In this 
in vivo PD rat study, ultrastructural mitochondrial perturbation by rotenone, coincided 
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with increased apoptosis, and cleaved caspase 3 index; and a decreased complex I 
activity and ATP production level - effects which were attenuated upon increasing 
concentrations (0 to 400mg/kg) of baicalein treatments. The same study showed 
baicalein induced mitobiogenesis in in vitro rotenone treated SH-SY5Y cells (X. Zhang 
et al., 2017). It may be possible that AG pre-treatments exert similar cellular 
mechanisms of protection as the bioactive flavone, baicalein. These mechanisms 
include retention of MMP - reducing the decrease in MMP brought about by rotenone 
– and the inhibition of Cyt-C release. (X. Zhang, et al., 2017). Studies by (Andrews, 
et al., 2009) suggest that increased mitochondrial biogenesis is a key contributor to 
AG mediated neuroprotection in an MPTP model, highlighting that the AG mediated 
protection in both models may be working in similar ways. 
The rotenone PD model has also been used extensively to investigate potential novel 
neuroprotective treatments which are thought to contribute to cell survival via 
mitochondrial-related mechanisms. Many studies have shown that neuroprotective 
effects of their chosen test agent have attenuated rotenone-induced perturbances via 
sustainment of MMP (Seoposengwe, van Tonder, & Steenkamp, 2013), (Filomeni, et 
al., 2012; Hao, et al., 2017; Mendivil-Perez, Velez-Pardo, & Jimenez-Del-Rio, 2016). 
Data from our in vitro rotenone PD model shows that 24hr pre-treatment with AG 
prevents rotenone-induced cell loss and reduction in MMP. These matched 
observations made by (Yu, Xu, Shen, & Jiang, 2016) in their rotenone PD model which 
used MES23.5 DAergic cells. This study showed ghrelin mediating protective effects 
by preventing mitochondrial dysfunction and inhibiting the release of Cyt-C to 
MES23.5 cytosol and subsequently decreasing the induction of apoptosis. In non-
neuronal cells, ghrelin treatment decreases markers of oxidative stress and retains 
their MMP which is considered one of the key contributors to doxorubicin induced cell 
death in cardiomyocytes (Z. Xu et al., 2008). 
Interestingly, ghrelin mediated anti-apoptotic and cyto-protective effects were not 
observed in fresh human neutrophils. Ghrelin treated neutrophils had no effect on 
apoptotic events such as regulation of BAX: Bcl-2 ratio or cleavage of caspase 3 and 
did not appear to modulate factors involved in regulating apoptosis. The opposite was 
observed upon lipopolysaccharide treatment of neutrophils. Moreover, pre-treatment 
with physiological levels (100nM) of ghrelin in this study did not exert any effect on 
human neutrophil MMP nor did it extend human neutrophil lifespan in vitro (B. Li et 
al., 2016). Although rotenone is used widely to generate in vitro and in vivo PD 
models, there are few detailing the effects of AG neuroprotection and MMP retention 
in the context of a rotenone induced-PD models. 
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SN4741 cell exhibited increased mitochondrial fragmentation following 24hr rotenone 
(10nM) challenge. This result is in line with literature showing that rotenone does 
indeed induce mitochondrial fragmentation in other cultured cells. For example, 
rotenone-induced AMPK-dependant mitochondrial fragmentation is observed in U20S 
osteosarcoma cells and mouse embryonic fibroblast (MEF) cells following a 30-
minute treatment. In this study, an ETC complex III inhibitor also induced a 
fragmented mitochondrial phenotype which was AMPK-dependant. This paper 
suggests that the fragmented morphology, induced by the ETC inhibitors, is a result 
of cellular stress rapidly activating AMPK which in turn phosphorylates a number of 
downstream substrates including ACC, Raptor and ULK within 15-minutes. This effect 
was shown to be AMPK-dependant as mitochondrial fragmentation was significantly 
attenuated when AMPK signalling was abolished (Toyama, et al., 2016). The 
mitochondrial fragmentation observed was dependent on recruitment and localization 
of GTPase dynamin-related protein-1 (DRP-1) to the outer mitochondrial membrane. 
Moreover, the phosphorylation of serine 155 and serine 172 of mitochondrial fission 
factor (MMF) was essential for recruitment of DRP-1 to mitochondrial surface 
(Toyama, et al., 2016).   
A dose-dependent increase in fragmented mitochondrial phenotype was also 
observed when COS-7 fibroblast-like cells were treated with increasing doses of 
rotenone. In this study involving COS-7 cells, increasing concentration of rotenone 
resulted in an increased formation of mitochondria with spherical morphology 
(Passmore, Pinho, Gomez-Lazaro, & Schrader, 2017). This decrease in MMP and 
concomitant increase in mitochondrial fragmentation has also been identified in an in 
vitro 6-OHDA PD model utilising SH-SY5Y neuroblastoma cells (Gomez-Lazaro, 
Bonekamp, Galindo, Jordan, & Schrader, 2008). In this model, the fragmentation was 
also DRP1-dependent.  Therefore, decreased MMP and concomitant increase in 
mitochondrial fragmentation, appears to be a common cellular response observed in 
at least two in vitro PD models which are associated with increased cell toxicity- as is 
observed in our model. 
It is generally considered that the accumulation of mitochondrial dysfunction is 
associated with mitochondrial fragmentation, neurodegenerative disease and ageing 
(Ferguson, Mockett, Shen, Orr, & Sohal, 2005). Interestingly, a study in drosophila 
melanogaster (fruit fly) show that mild induction of Drp1-induced mitochondrial fission 
during the fly midlife promotes a longer and healthier lifespan. The upregulation of 
Drp1 and subsequent initiation of mitochondrial fission in young adult flies (day 0- 30) 
had no effect on longevity. However, when Drp1-induced mitochondrial fragmentation 
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was initiated in flies during their mid-life period (day 30-37) a significant increase in 
lifespan and health-span was observed. The study suggests that this effect observed 
is the result of improved mitochondrial function; attenuation of age-associated losses 
in mitochondrial proteins and a decrease in the accumulation of ubiquitin inclusions 
in fly flight muscles and increased facilitation of autophagy/mitophagy (Rana et al., 
2017).    
Studies appear to indicate that, at least in some cells, AMPK is activated by 
mitochondrial stressors which trigger mitochondrial fission and fragmentation, at least 
partly, as a result of MFF phosphorylation and DRP-1 recruitment to the mitochondrial 
membrane. Moreover, a rapid AMPK-dependent initiation of mitochondrial fission and 
fragmentation might serve as a protective method to prepare mitochondria and cells 
for clearance via mitophagy (Youle & van der Bliek, 2012). Together these 
observations highlight that a deeper understanding of mitochondrial dynamics and 
mitophagy must be developed to address age related neurodegenerative diseases. 
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6. Chapter 6: Discussion  
 
This thesis has aimed to develop our understanding of the orexigenic stomach 
hormone AG as a potential neuroprotective agent against Parkinson’s Disease. 
The first results chapter (chapter 2) characterized the mouse midbrain, and more 
specifically identified co-localisation of TH+ and GFP-GHSR+ neurones in the (mouse) 
SN using IHC. We conclude that that GHSR is expressed in Girk2+ (SN) neurones in 
vivo. We also characterised key protein markers that are important to the study. Using 
immunofluorescence (IF) techniques, we show SN4741 midbrain derived neurones 
express TH+, Girk2+, Calbindin- and GHSR+ immunoreactivity. The SNpc contain a 
mix of neurone types of which A9 and A10 subtypes of dopamine neurones 
predominate (Bjorklund & Dunnett, 2007). Our IF analysis show that SN4741 cells are 
of the A9 (Girk2+) subtype which are preferentially degenerated in PD (Codrich et al., 
2017; Hirsch, Graybiel, & Agid, 1988). Furthermore, we show that the SN4741 cells, 
on which we modelled our in-vitro rotenone-based neurotoxicity PD model, expressed 
detectable levels of key ghrelin axis proteins, GHSR1a, APT-1 & MBOAT4, thus 
confirming their suitability. This was confirmed using PCR and Western blot 
techniques. Literature eludes to AG mediating neuroprotection by decreasing 
neuroinflammation and microglial activation, increased mitophagy, as well as 
enhanced mitochondrial function and biogenesis. Although the exact mechanisms are 
yet to be elucidated GHSR1a agonists hold potential to be utilised as therapies 
(Andrews, 2011). Efficacy of AG as a neuroprotective agent was then tested using 
experimental models of PD.  
Data (chapter 3) showed that the administration of AG via minipump attenuated 
6OHDA-induced loss of TH+ neurones in the rat SNpc and amphetamine-induced 
rotations. Other data (not included) extracted from the same photo-micrographs 
showed a significant decrease in the size of DAergic (TH+) SNpc neurone size 
following lesioning. 
In chapter 4, we report the development of an in-vitro rotenone-induced neurotoxicity 
PD model using midbrain-derived SN4741 neurones. We show that 24hr treatment of 
SN4741 neurones with rotenone (10nM) induced a significant decrease in SN4741 
cell number and cell viability and increased cell cytotoxicity in complete (full) and 
substrate restricted (SR) (60%) cell culture media. The cytotoxic effect of rotenone 
was not mediated via Caspase 3/7 activity, at least in neurones cultured in full 
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medium. Building on these observations we show that direct treatment of SN4741 
neurones with AG and GHSR1a agonist, JMV2894, exerted a protective effect. This 
effect was amplified in SN4741 neurones cultured in SR media. Furthermore, we 
showed that inhibition GHSR1a by D-Lys3 attenuated AG-mediated neuroprotection. 
This suggest that the direct binding AG to GHSR1a and resulting downstream events 
are integral for AG-mediated neuroprotection in our model. Subsequently, a thymidine 
analogue (EdU) pulse chase experiment was utilised to confirm that the resulting cell 
survival was not the result of an AG-induced increase in cell proliferation. 
Interestingly, SN4741 protein lysates following 5-minute treatment with AG increased 
protein expression of pAMPK and fatty acid metabolism regulator pACC. SN4741 
cells treated with GHSR1a agonist JMV2894 for 5 minutes also showed an increase 
in AMPK phosphorylation but a decreased phosphorylation of ACC. 
At the 24hr timepoint post-AG treatment, SN4741 cells expressed a significant 
increase in AMPK phosphorylation and despite an increase in ACC phosphorylation 
the fold change was not statistically significant. These data suggest, along with other 
literature, that AG-mediated neuroprotection may be the result of GHSR1a agonism 
and subsequent downstream signalling via phosphorylation of AMPK (Bayliss, 
Lemus, Stark, et al., 2016) resulting in enhanced mitochondrial function (Andrews, et 
al., 2009). Since mitochondrial dysfunction and its associated mechanisms (e.g. 
mitophagy) are implicated in a range of age-related disorders such as PD, we studied 
AG-mediated neuroprotection in the context of mitochondrial health. 
In chapter 5 we investigated the effects of AG treatment on mitochondrial function, 
specifically MMP and dynamics (i.e. fragmentation phenotype). We concluded that 
the rotenone treatment administered in our in vitro model was sufficient to induce a 
depolarization of MMP and an increase in mitochondrial fragmentation. These cellular 
events were reversed in cells pre-treated with AG, suggesting that AG’s 
neuroprotection may be the result of maintaining mitochondrial membrane potential. 
Other studies indicate increased mitochondrial biogenesis and function (particularly 
the buffering of ROS by UCP-2) as a key mechanism by which AG protects DAergic 
neurones from neurotoxin insult (Andrews, 2011; Andrews, et al., 2009). To obtain 
measurements on mitochondrial health, we developed an automated image analysis 
pipeline using open-source CellProfiler software to measure fluorescence intensity of 
a mitochondrial health marker in the perinuclear area of treated SN4741 cells. This 
protocol was expanded to quantify the mitochondrial fragments in the SN4741 cell 
soma. 
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To conclude, we show that AG prevents DAergic cell loss in vivo and in vitro. GHSR1a 
agonist, JMV2894, also promotes SN4741 cell survival in our in vitro rotenone induced 
model of PD. Therefore, our data support a role for GHSR1a agonists as potential 
neuroprotective agents against PD. 
 
6.1. Proposed Mechanisms and Pathways of Ghrelin 
Neuroprotection in PD Models  
Studies by (Bayliss, Lemus, Santos, et al., 2016; Bayliss, Lemus, Stark, et al., 2016) 
highlight a potential mechanism by which AG mediates neuroprotection on DAergic 
neurones on the SNpc. These studies identify AMPK activation and increased 
mitochondrial function that is dependent on the action of an integral mitochondrial 
protein, UCP-2 in buffering the excessive production of ROS and ultimately reducing 
the pro-apoptotic Bax-Bcl2 ratio. Although we did not investigate the effect of AG-
mediated increase in mitochondrial MMP on the buffering of ROS; we did however 
show AG’s direct protective effects on SN4741 cells to be dependent on the GHSR1a 
receptor.  
The exact mechanism by which rotenone-induced SN4741 cytotoxicity and cell loss 
is yet to be elucidated. Published literature propose that rotenone induces cell death 
by apoptotic events both in vitro and in vivo (Ahmadi et al., 2003; Sonia Angeline, 
Chaterjee, Anand, Ambasta, & Kumar, 2012). Our in vitro investigations failed to link 
SN4741 cell loss and increased cytotoxicity with the increase in activity of pro-
apoptosis marker, Caspase-3/7. These data suggest that rotenone-induced SN4741 
cell loss and cytotoxicity is either governed by an alternative mechanism or that 
apoptotic events (involving caspase 3/7 activity) may have occurred prior to our 
analysis. To investigate this further, we could analyse caspase 3/7 translocation to 
the nucleus and measure its fluorescence intensity (FI) along our experimental 
timeline and at earlier timepoints. 
Ghrelin is produced by X/A cells in the stomach at times of negative energy balance. 
It is post-transcriptionally modified to AG by enzymatic activity of GOAT which 
catalyses the addition of an acyl side chain to the nascent ghrelin peptide at serine 3 
(Kojima, et al., 2016; Kojima, et al., 1999). The acylation of ghrelin is integral for its 
ability to activate GHSR1a by binding to the exposed receptor on cell surfaces (J. 
Yang, Brown, Liang, Grishin, & Goldstein, 2008). Activation of GHSR1a by AG 
regulates growth hormone release, initiation of feeding, and regulation of energy 
homeostasis (Lall, Tung, Ohlsson, Jansson, & Dickson, 2001; Tschop, Smiley, & 
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Heiman, 2000), which is governed activation of orexigenic neuropeptide Y (NPY) and 
agouti-related protein (AgRP) neurones (H. Y. Chen et al., 2004) in the arcuate 
nucleus of the hypothalamus (Dickson, Leng, & Robinson, 1993; Kojima, et al., 1999). 
Both acylated and un-acylated forms of ghrelin are BBB permeable and upon release 
from the stomach, travel via the bloodstream to the brain (Banks, Tschop, Robinson, 
& Heiman, 2002) to exert hypothalamic and extra-hypothalamic effects (Andrews, 
2011). Aside from regulation of metabolic homeostasis, ghrelin plays a role in many 
non-metabolic functions such as enhancing learning and memory via increased 
hippocampal synaptic plasticity (Diano, et al., 2006), modulating anti-anxiety and anti-
depression like behaviour (Lutter et al., 2008). But importantly, its neuroprotective 
mechanisms have been observed in many neurodegenerative disease models. 
Examples of this include decreasing microglial activation in amyotrophic lateral 
sclerosis (S. Lee, Kim, Li, & Park, 2012) and neuroprotection, memory consolidation 
and learning in models of Alzheimer’s disease (Gahete, Cordoba-Chacon, Kineman, 
Luque, & Castano, 2011). Suggesting that AG-mediated neuroprotection may be 
utilised across a range of diseases, possibly by the similar mechanism of action as 
that observed in models of PD (Andrews, 2011).  
The neuroprotective effects of AG may be multifaceted. Studies show that AG-
mediated neuroprotection on DAergic neurones in neurotoxin-induced models of PD 
is governed by (i) attenuating the pro-inflammatory effects of microglial activation (M. 
Moon, et al., 2009), (ii) attenuating the activation of pro-apoptotic events by caspase 
activation (H. Jiang, Li, Wang, & Xie, 2008; X. Jiang & Wang, 2004) and (iii) increasing 
mitochondrial function (Andrews, et al., 2009). PD-inducing neurotoxins such as 
MPTP (Meredith & Rademacher, 2011), 6-OHDA (Y. Glinka, Tipton, & Youdim, 1996; 
Y. Y. Glinka & Youdim, 1995) and rotenone (Xiong et al., 2012) appear to replicate 
the degenerative pathology of PD via inhibition of mitochondrial function (at least 
partly via complex 1 inhibition) which result in increased ROS production and deficits 
in the production of ATP.  
A considerable amount of literature has placed emphasis on metabolic energy sensor 
AMPK as an integral link in a pathway between neuroprotective agents and cellular 
events associated with neuroprotection. AMPK is a highly evolutionarily conserved 
regulator of energy homeostasis which is predominantly regulated allosterically by the 
binding of cellular energy molecules on its gamma subunit (Jeon, 2016). The allosteric 
competition is between ATP, which allows access of a phosphatase enzyme to 
Threonine 172, and AMP or ADP which blocks phosphatase access (Hawley et al., 
1996). Therefore, AMPK phosphorylation is dependent on the ratio of cellular energy 
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molecules AMP/ATP and ADP/ATP (Jeon, 2016).  Upon activation at times of 
negative energy balance, AMPK phosphorylates acetyl-Coenzyme-A carboxylase 
(ACC) or sterol regulatory element-binding protein (SREBP). Phosphorylation of 
these downstream targets results in inhibition of fatty acid, cholesterol and triglyceride 
synthesis and activates the cellular uptake and utilisation of fatty acids as an energy 
source by β-oxidation (Jeon, 2016). AMPK also appears to have tissue specific roles, 
such as GLUT4+ mediated glucose uptake in skeletal muscle via phosphorylation of 
Rab-GTPase activating protein; stimulation of glycolysis and inhibition of glycogen 
synthesis via activation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2/3 
and glycogen phosphorylase and inhibition of glycogen synthase (Jeon, 2016). In liver 
hepatocytes, AMPK mediated inhibition of hepatocyte nuclear factor 4 (HNF4) and 
CREB regulated transcription coactivator 2 (CRTC2) reduced gluconeogenesis (Jeon, 
2016). AMPK activation is also known to upregulate autophagy via downstream 
signalling through ULK1 and upregulate mitochondrial biogenesis (J. Kim, Kundu, 
Viollet, & Guan, 2011) via PGC-1α which contribute to buffering of excessive ROS 
(Deas, Wood, & Plun-Favreau, 2011; Shin et al., 2011). 
AMPK consists of three subunits with various isoforms; these are α1, α2, β1, β2, γ1, 
γ2 and γ3 (Carling et al., 1994). The alpha subunit plays a catalytic role whilst beta 
and gamma subunits are engaged in regulatory roles (Crute, Seefeld, Gamble, Kemp, 
& Witters, 1998). The integrity of AMPK is paramount in maintenance of cellular 
energy homeostasis and AMPK dysfunction or loss of activity has implications in 
diseases such as diabetes (Jorgensen et al., 2004; O'Neill et al., 2011; Wahlqvist et 
al., 2012) as well as PD (J. Kim, et al., 2011). In line with metabolic alterations of type 
2 diabetes, whole body deletion of the AMPK α2 subunit in mice showed increased 
insulin resistance and impaired glucose tolerance (Jorgensen, et al., 2004). 
Furthermore, a study by (O'Neill, et al., 2011) showed the deletion of beta subunits 
(β1 and β2) specifically in the muscles of mice showed an increased insulin resistance 
and a dysfunctional mitochondrial phenotype. Interestingly, the anti-diabetes type 2 
drug metformin is thought to decrease the risk of developing PD as diabetes patients 
provided with metformin show a reduced risk of developing PD (Wahlqvist, et al., 
2012).  Taken together, we postulate that activators of AMPK could be used to tackle 
a range of diseases with associated mitochondrial dysfunctions. Thus, highlighting a 
potential for re-purposing of AMPK-specific type-2 diabetes to act as neuroprotective 
PD therapeutics, and vice versa. Another important downstream event occurring as a 
consequence of AMPK activation is autophagy of damaged cellular organelles (or 
mitophagy for damaged mitochondria). A negative energy balance, which can occur 
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as a result of perturbed mitochondrial function, results in AMPK phosphorylation and 
downstream inhibition of mTOR and phosphorylation of ULK1 which are integral in 
the induction of autophagy (J. Kim, et al., 2011). 
The mechanism for ghrelin neuroprotection in DAergic neurones in PD models can 
be linked to the attenuation of pro-inflammatory effects of microglia (M. Moon, et al., 
2009) and effects of downstream GHSR1a signalling. (Andrews, et al., 2009) shows 
AG-mediated enhancement in mitochondrial function and reduction of neurotoxin 
(MPTP) induced ROS production via UCP-2. Phosphorylation of the metabolic sensor 
AMPK, downstream of GHSR1a activation via AG, was found to be integral in the 
neuroprotective effects of exogenous AG administration as depletion of β1 and β2 
subunits of AMPK abolished DAergic neurone protection in mice (Bayliss, Lemus, 
Stark, et al., 2016). This strongly suggests that intracellular energy sensor AMPK is 
key to eliciting neuroprotection in PD models. AMPK was also shown to play a key 
role in mitigating mitochondrial and DAergic neurone dysfunction in a drosophila 
model of PD (Ng et al., 2012) where a parkinsonian phenotype was observed in parkin 
and LRRK2 null flies. This phenotype was abolished upon activation of AMPK 
supporting the idea that AMPK plays a role in neuroprotection in PD (Ng, et al., 2012). 
Other in vivo studies have shown activation of AMPK via pharmaceuticals, such as 
resveratrol  (Jin, Wu, Lu, Gong, & Shi, 2008) and guanidinopropionic acid (GPA), 
mediated AMPK-dependant increases in mitochondrial function and biogenesis 
(Horvath et al., 2011). The anti-diabetes drug metformin is also a known activator of 
AMPK (Meng et al., 2015). The activation of AMPK in an in vitro alpha synuclein model 
of PD attenuated SH-SY5Y cell loss (Dulovic et al., 2014). However, not all studies 
show AMPK activation to be associated with beneficial effects. A study by (P. Jiang 
et al., 2013) reported that overactivation AMPK resulted in facilitation of alpha 
synuclein accumulation and inhibition of neurite outgrowth. AMPK activation has also 
been associated with enhanced mitophagy/autophagy (Wu et al., 2011) and 
enhanced mitochondrial biogenesis (Reznick & Shulman, 2006). AMPK activation 
inhibits downstream mTOR and phosphorylated Ulk1 to enhanced autophagy (J. Kim, 
et al., 2011). Mitochondrial biogenesis increases the mass and number of individual 
mitochondria to deal with cellular demands such as the requirement for increased 
ATP (energy) expenditure, buffering of excessive ROS production and to compensate 
for dysfunctional mitochondria (Sanchis-Gomar, Garcia-Gimenez, Gomez-Cabrera, & 
Pallardo, 2014; Valero, 2014). 
As neurodegenerative diseases are strongly associated with mitochondrial 
dysfunction and oxidative stress, DNA damage, proteins and membrane lipids (Lin & 
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Beal, 2006) the buffering of oxidative species and regulation of healthy mitochondrial 
turnover via autophagy (mitophagy) is integral to maintain viable cellular homeostasis 
by removal of damaged cellular components. Damaged mitochondria are targeted by 
PINK1 which recruits cytosolic Parkin to surround the damaged organelle. The 
accumulation of PINK1 leads to an increase in Parkin's E3 ubiquitin ligase activity, 
and recruitment of Parkin to the outer membrane of the dysfunctional mitochondrion. 
Parkin ubiquitinates outer mitochondrial membrane proteins to trigger selective 
autophagy (mitophagy) (Pickrell & Youle, 2015; Vives-Bauza et al., 2010). The 
defective clearance of damaged mitochondria (and other cellular organelles) are 
associated with hereditary PD (Kitada, et al., 2009). These genetic defects lead to 
perturbed PINK1 and Parkin function which ultimately affects the clearance of 
damaged mitochondria by mitophagy leading to an accumulation of dysfunctional 
mitochondria, a restriction in ATP production and increased ROS production which 
predisposes cells to degeneration (Deas, et al., 2011; Wood-Kaczmar, et al., 2008). 
In DAergic cells Parkin is also involved in reducing the quantity of PARIS which is an 
inhibitor of PGC-1α and its target gene NRF-1 (Scarpulla, 2011). A study by (Shin, et 
al., 2011) shows that Parkin is integral for modulating optimal mitochondrial 
biogenesis as the overexpression of PARIS in DAergic SNpc neurones results in cell 
death. Furthermore, the study suggests that the Parkin–PARIS–PGC-1α pathway 
may be important in regulating mitochondrial biogenesis which is implicated in 
neuroprotection as it maintains optimal levels of mitophagy (Bayliss & Andrews, 2013; 
Shin, et al., 2011). Another downstream substrate of AMPK activation is SIRT1. 
Increasing SIRT1 activity increases the activity of its downstream target PGC-1α the 
master regulator of mitochondrial biogenesis. The importance of the AMPK-SIRT1-
PGC-1α pathway in increasing mitochondrial biogenesis to maintain function and 
avoid metabolic decline is shown in in vivo and in vitro SIRT1 KO experiments (Price 
et al., 2012) where the maintenance of mitochondrial integrity and function, as well as 
the increased mitochondrial biogenesis exerted by neuroprotective agent, resveratrol, 
is abolished with SIRT1 KO. Notably, published work has shown resveratrol exert 
neuroprotection in a rotenone model of PD via AMPK-SIRT1-autophagy pathway 
(Wu, et al., 2011) to protect against rotenone-induced apoptosis. These data suggest 
that the upregulation of PGC-1α through AMPK and PARIS and /or SIRT1 (AMPK-
PARIS-PGC-1α pathway and / or AMPK-SIRT1-PGC-1α pathway) is integral to the 
maintenance of mitochondrial function and mitophagy under normal cellular 
conditions. Furthermore, the increased mitochondrial damage, excessive ROS 
production and swamping of autophagy and degradative systems caused by 
mitochondrial neurotoxins used in PD models increase the cells reliance on such 
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pathways. In this instance neuroprotective agents such as resveratrol and AG may 
induce intracellular signalling via AMPK and its downstream targets and effector 
proteins to increase mitochondrial turnover by Parkin and Pink mediated autophagy 
and degradation; increased mitochondrial biogenesis to cope with increased cellular 
energy demand to buffer excessive ROS and thus prevent damage to cellular 
organelle. Together this illustrates that ghrelin-mediated neuroprotection observed in 
models of PD may be the direct effect of reduced oxidative stress via enhanced 
mitochondrial biogenesis and UCP2 action and the enhancement of autophagy 
(mitophagy) to clear damaged organelles (e.g. mitochondria). AMPK appears to be 
an important intracellular signalling molecule capable of governing ghrelin-mediated 
neuroprotection through these pathways. Further research will be required to 
determine whether ghrelin-GHSR1a signalling is linked to the enhancement of 
mitophagy via the PINK1/Parkin pathway. 
 
 
 
 
 
6.2. Future Investigations 
Although our studies find that AG exerts neuroprotection on DAergic neurones in our 
in vivo 6-OHDA PD model and in vitro rotenone PD model further investigation is 
required to identify the cellular mechanism underpinning the neuroprotection 
observed.  
Here, using pharmacological inhibition of GHSR1a, we show that AG’s direct 
neuroprotective effects are mediated via this receptor. However, due to the failure of 
rotenone to induce cell loss in our later neurotoxicity assay, we were not able to 
determine whether AG-mediated neuroprotection was dependent on activation of 
AMPK. To elucidate whether AMPK is essential for this effect the experiment should 
be repeated with a new stock of rotenone, as current vials may have lost efficacy due 
oxidation. Alternatively, siRNA could be utilised to knockdown AMPK expression in 
SN4741 neurones. A Western blot could be run to confirm target knockdown before 
performing the assay. It is important to remember that AMPK is a master regulator of 
many downstream signalling cascades as described earlier in this chapter. Therefore, 
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caution must be taken when interpreting data as the effects observed may be the 
result signalling via other cellular pathways. In this case, it might be benefitial to KO 
or inhibit effector proteins such as PGC-1a further down the signalling pathway to limit 
off-target effects.  The same would be true for the development of PD-therapeutics. 
Here in our studies we utilise two different neurotoxin models to investigate AG-
mediated neuroprotection. There is potential to use a range of toxin models in vitro 
and in vivo. Such studies are warranted to identify whether there is a common AG 
signalling pathway that would provide a common mechanism to target potential 
therapies. 
Rotenone is a robust PD-inducing neurotoxin for modelling aspects of PD. Besides 
the degeneration of DAergic neurones, the accumulation of intracellular protein 
aggregates which are inclusive of miss-folded proteins such as alpha synuclein and 
poly-ubiquitin is another key hallmark of human PD pathology. In in vitro and in vivo 
tests; rotenone causes both DAergic cell degeneration and accumulation alpha-
synuclein aggregates (Giráldez-Pérez, Antolín-Vallespín, Muñoz, & Sánchez-Capelo, 
2014; Hao, et al., 2017). As such we could investigate whether alpha-synuclein 
accumulation is modulated in our in vitro rotenone-induced neurotoxicity assay as a 
marker of pathogenesis. 
Our data shows that treatment with rotenone induces a fragmented SN4741 
mitochondrial phenotype compared to vehicle treated cells and also that AG pre-
treatment is sufficient to inhibit the degree of fragmentation. To provide more detail 
and understanding of the mitochondrial fission/fusion dynamics surrounding the 
detrimental effects of neurotoxin treatment and neuroprotective effects of AG pre-
treatments, we should utilise live fluorescence or confocal microscopy to enable us to 
follow the events in real-time through treatment periods as opposed to only analysing 
at experimental endpoints. Moreover, the emergence and utilisation of high- or super-
resolution microscopy such as the DeltaVision systems developed by GE Healthcare 
should be used to gain further insight. The DeltaVision systems are a flexible platform 
that caters for a wide range of cell imaging including live cell imaging- which is one of 
the fastest growing areas in cell biology imaging. DeltaVision systems combine 
modern imaging technologies with the ability to analyse acquired high- or super-
resolution images to provide qualitative and quantitative data outputs. A super-
resolution would allow us to gain a greater understanding of the underlying 
mechanisms of AG neuroprotection in our PD model and others. With the correct 
fluorophores it would be possible to track mitochondrial fission and fusion dynamics 
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and mitophagy/autophagy in the context of our in vitro rotenone neurotoxicity assay, 
in live SN4741 cells in real-time. Two examples include the role of dynamin-related 
protein-1 (Drp1) which is shown to localize and cluster at areas of the mitochondrial 
network and form a multimeric ring around the area undergoing fission (Smirnova, et 
al., 2001). A technique described by (Smirnova, et al., 2001) where Drp1 is fused to 
green fluorescent protein (GFP) and transfected into mammalian cells from time-lapse 
photography is a possible avenue to explore with SN4741 cells. Since Drp1 is critically 
associated with mitochondrial fission in healthy and pathological cell biology (Hu, 
Huang, & Li, 2017) it may be a valuable target to investigate the effects of rotenone-
induced mitochondrial fragmentation and subsequent reversal of this phenotype in 
AG-pre-treated SN4741 cells. It is possible that rotenone increases Drp1 recruitment 
to the mitochondrial membrane whilst AG inhibiting this recruitment or increases the 
activity of proteins that increase mitochondrial fusion events - such as mitofusin and 
OPA (Benard & Karbowski, 2009).  
Another proposed neuroprotective mechanism is enhanced mitophagy (autophagy) 
(Bayliss & Andrews, 2013). Microtubule-associated protein 1A/1B-light chain 3 (LC3) 
is recruited to the autophagosome membrane during the clearance of cellular material 
destined for degradation during autophagy (Tanida, et al., 2008). This could also be 
analysed using real-time super resolution microscopy with co-labelling of 
mitochondria along with this GFP-LC3 (Premo™ Autophagy Sensor LC3B-GFP 
BacMam 2.0, P36235 Thermo Fischer). The use of different fluorophores would allow 
us to investigate whether AG pre-treatment in SN4741 cells enhances the rate of 
autophagic clearance of mitochondria in our assay. A recently performed pilot study 
supports a role for AG in promoting LC3-GFP autophagosome formation in SN4741 
cells (see figure 67 below). 
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Graph (a) shows 24hr treatment with 1µM AG significantly increases cytoplasmic 
LC3-GFP fluorescence intensity versus vehicle treated cells (P<0.001). Positive 
control for autophagosome formation, chloroquine (100µM) induces a greater 
significant increase in cytoplasmic LC3-GFP fluorescence intensity. Images and 
represent illustration of LC3-GFP cytoplasmic accumulations (b) vehicle, (c) 1µM AG 
and (d) 100µM chloroquine treated SN4741 cells. Each treatment was performed in 
quadruplicate with only 1 experimental repeat and therefore must be repeated. One-
way ANOVA with Bonferroni’s post-hoc analysis on graph pad prism 5 software, with 
P<0.05 (*), P<0.01 (**), P<0.001 (***) and P<0.0001 (****) considered significant. 
 
Autophagy mediates the clearance of damaged or dysfunctional organelle (including 
mitochondria) for lysosomal degradation (Tanida, et al., 2008). This pilot data 
suggests that up-regulation of autophagy system could aid in turnover of damaged 
organelle for lysosomal degradation and potentially be a mechanism underpinning 
AG-mediated SN4741 cell survival. Moreover, a study by (Mizushima, 2009) describe 
methods for monitoring LC3-GFP transgenic mice, thus, it would be possible to 
investigate the role of AG-mediated neuroprotection and autophagy in in-vitro models 
and in vivo models. Notably, a recent report suggests that AG-mediates an increase 
in autophagy via AMPK (Ezquerro, Fruhbeck, & Rodriguez, 2017) and others show 
AG-stimulated autophagy in cortical rat neurones(Ferreira-Marques et al., 2016).  
 
Our PD model shows that direct AG pre-treatment attenuates rotenone-induced 
SN4741 cell loss and cytotoxicity. However, we are yet to test the utilisation of AG 
treatments post neurotoxin insult. By doing so we may investigate the AG’s (or 
GHSR1a agonist) efficacy as a neuroprotective agent for PD patients. Therefore, it is 
Figure 67: AG Enhances LC3-GFP Formation in SN4741 Cells. 
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integral that further work seeks to elucidate the action of direct AG treatment on cells 
once the PD-like insult has already been administered. This is important as PD 
patients show no overt phenotype until a large proportion of SNpc DAergic neurones 
have degenerated. Our experimental paradigms administered AG prior to neurotoxin 
administration. This means that AG mediated neuroprotection may work as a 
preventative method for PD onset. However, this does not inform us whether any AG 
neuroprotective effects will be observed if AG is administered after the onset of lesion 
or incubation with neurotoxin. Therefore, with our current data it is not possible to 
determine whether AG can reverse or slow detrimental effects induced by 
neurotoxins. As 6-OHDA is a potent and rapidly-acting DAergic neurotoxin (Simola, 
et al., 2007), post-lesion treatment may prove challenging. An alternative model is the 
intra-striatal 6-OHDA lesion which produces a slower progression of dopaminergic 
cell loss in SNpc as 6-ODHA is carried retrogradely from nigrostriatal projections in 
the striatum to the SN and depletes nigrostriatal dopamine concentrations. This 
delayed onset of nigrostriatal DAergic neurone degradation provides progressive 
depletion of DA in SN and striatum which is more characteristic of the human disease. 
A drawback of this technique is the 6OHDA lesion-induced motor dysfunctions and 
behavioural changes appear to be reversible (Alvarez-Fischer et al., 2008).  
Since the reason for the onset of sporadic PD is still unknown, genetic models in 
animals expressing known familial PD mutations may provide the most effective tool 
for understanding the mechanisms underpinning PD progression and testing of novel 
therapeutics.  
PD models based on genetic/familial PD include LRRK, SNCA, A53T, PINK1 and 
PARKIN. Leucine-rich Repeat Kinase 2 LRRK2 is encoded for by the PARK8 gene in 
humans and is associated with an increased risk of developing PD (Paisan-Ruiz et 
al., 2004). Mutations in the PARK8 gene are associated with autosomal dominant 
inheritance of familial PD and appears to be the most prevalent familial PD gene 
mutation (Q. Xu, Shenoy, & Li, 2012). Transgenic mouse models expressing mutant 
LRRK2 develop dysfunctional motor symptoms which progress with age. LRRK2 
mutant models also exhibit deficient DA signalling, DAergic nigrostriatal axonopathies 
(Sepulveda, Mesias, Li, Yue, & Benson, 2013) and hyperphosphorylation of protein 
tau (Guerreiro et al., 2016). Collectively, LRRK2 animal models robustly replicate 
behavioural, neurochemical and pathological features of PD (Q. Xu, et al., 2012). 
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Alpha-synuclein (α-Synuclein) is a 140-amino acid protein coded for by the SNCA 
gene in humans (Y. Xia et al., 2001). Alpha-Synuclein is thought to contribute to PD 
pathogenesis by forming soluble oligomeric conformations that are toxic and result in 
neuronal death (Stefanis, 2012). It is thought that secreted alpha-synuclein exerts 
deleterious effects on surrounding cells and by depositing and aggregating in 
neighbouring cells and contributing to disease propagation.  Animal models of alpha-
synuclein show the aggregates may be deposited in various brain areas. Evidence 
shows that DAergic metabolism may be related to alpha-synuclein and its 
conformational plasticity which suggests there may be a parallels between 
dopaminergic neurodegeneration and Lewy body (LB) formation- the two major 
hallmarks of PD (Giráldez-Pérez, et al., 2014). The aggregation of alpha-synuclein in 
PD is also associated with the two-point mutations, A53T and A30P, which are linked 
with familial early-onset PD. These mutant alpha-synuclein exhibited an increased 
propensity to aggregate with other mutant synuclein and wild-type α-synuclein, which 
is thought account for the correlation of these mutations with Parkinson's disease (J. 
Li, Uversky, & Fink, 2001). 
PTEN-induced putative kinase 1 (PINK1) is a mitochondrial serine/threonine-protein 
kinase encoded by the PINK1 gene (Narendra et al., 2010). PINK1 protein acts 
upstream of Parkin. Parkin, also named Parkinson juvenile disease protein 2, is a 
426amino acid enzyme protein, encoded by PARK2 gene and located on the 6q 
chromosome (Miklya, Goltl, Hafenscher, & Pencz, 2014). Studies in drosophila show 
that KO of PINK1 results in major indirect flight muscle and dopaminergic neuronal 
degeneration accompanied by locomotive defects related to mitochondrial 
dysfunctions (Clark et al., 2006). Drosophila lacking PINK1 or Parkin exhibit swollen 
mitochondria and reduced ATP levels. Moreover, parkin knockout mice showed 
deficits in nigrostriatal DA neurotransmission and striatal synaptic plasticity (Kitada, 
et al., 2009). This suggests that any of the resulting physiological symptoms in 
drosophila and rodent models of PINK1 or Parkin. Which is to be expected as they 
are integral in protecting cells from stress-induced mitochondrial dysfunction (Gautier, 
et al., 2008). 
Although the underpinning mechanism of familial PD pathology in humans and in their 
animal model counter parts are not fully elucidated it is not irrational to propose that 
a therapeutic could be deemed anti-PD if it reversed the dysfunctional effects 
observed in the animal models of PD. Furthermore, since the entire mechanistic 
pathway of mutant (or sporadic) PD pathology is not elucidated, a PD therapeutic 
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could work to upregulate compensatory mechanisms such as mitophagy or 
mitochondrial biogenesis to compensate for impaired energy (ATP) production. 
 
Induced Pluripotent Stem Cells (iPSC) experimental techniques developed by 
(Takahashi et al., 2007; Takahashi & Yamanaka, 2006) allow adult dermal fibroblast 
cells to be reprogrammed to their pluripotent stem cells state by use of the four factors 
Oct3/4, Sox2, Klf4, and c-Myc, where they may then be pushed down a lineage 
towards any cell phenotype such as DAergic neurones. Thus, it is possible to generate 
DAergic neurones from iPSC lines derived from PD patient fibroblasts (Byers, Lee, & 
Reijo Pera, 2012) to more effectively model PD in vitro. A study using two iPSC lines 
from PD patients with p.G2019S mutation in LRRK2 gene and another carrying a full 
gene triplication of the SNCA gene was produced by (Byers, et al., 2012). Their 
studies compared wild-type DAergic iPSC lines with PD patient-derived iPSC lines 
and showed increased sensitivity to hydrogen peroxide, MG-132 and 6-OHDA-
induced capsase-3 activation in the patient derived line. IPSCs which were derived 
from SNCA mutant patients exhibited increased sensitivity to hydrogen peroxide-
induced stress. These cells also showed an increased the rate of early ubiquitin-
positive puncta/accumulations. Since these iPSC derived DAergic neurones produce 
a clinical resemblance of patients afflicted with genetic and sporadic PD, these models 
may be used to elucidate the molecular pathology underpinning PD and be used to 
generate of novel therapeutic agents for alleviation of relevant disease phenotypes. 
Moreover, the multifaceted investigation into the electrical activity, DA release 
kinetics, energy metabolism and other cellular and molecular fundamentals in PD 
patient-derived iPSC will increase knowledge of PD pathology and aid in approaches 
to develop new PD therapies. The use of human cells may also prove particularly 
useful for delineating disease pathogenesis given the species-specific differences in 
dopamine metabolism (Burbulla et al., 2017). 
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6.3. Other perspectives: Drug re-purposing for neuroprotection 
There is a current demand for the re-purposing of therapeutically approved drugs for 
other disease. The efficacy and application of re-purposed drugs relies heavily on the 
elucidation of the mechanisms underpinning PD pathology which can be investigated 
using genetic models of PD which recapitulate specific aspects of pathology 
associated with familial PD. The purposing of pharmaceuticals as opposed to 
development of new drugs has the benefit of being subsequently approved by FDA 
and other health and safety administrative bodies for patient use. Once such example 
is the anti-diabetic drug metformin, currently used to restore insulin sensitivity in type 
2 diabetics, is known to activate AMPK (Meng, et al., 2015). Since AMPK activation 
and downstream signalling elicits a range of neuroprotective effects in PD models 
(Hang, Thundyil, & Lim, 2015), there is potential for re-purposing this pharmaceutical 
for the treatment of PD.  Moreover, the fact that patients undergoing metformin 
treatment are at a decreased risk of developing PD reinforces this view (Wahlqvist, et 
al., 2012). 
Other compounds such as Guanidinopropionic acid (GPA), a creatine monohydrate 
analogue which is a common additive in dietary supplements used by body builders 
and athletes have shown strong anti-hyperglycemic effects in hyperglycemia in KKAy 
and C57BL6Job/ob mice and increases blood glucose uptake in rhesus monkeys 
(Meglasson et al., 1993). Other studies have also shown GPA to induce an AMPK-
dependant increases in mitochondrial function and biogenesis (Horvath, et al., 2011). 
Moreover, this same study showed that GPA-fed mice in an MPTP mouse model of 
PD exhibited no loss of TH neurones versus mice that were fed with chow not 
containing GPA. This highlights the potential for GPA to be studied as a potential 
protective agent in PD. Collectively, it is reasonable to propose that any 
pharmaceutical capable activating AMPK and downstream increases in autophagy 
and mitochondrial function would find efficacy as an anti-PD therapeutic. 
There is growing evidence that another anti-type 2 diabetes drug, exenatide, may be 
re-purposed as a treatment for PD patients as they may share some common 
underlaying cellular mechanisms of disease pathology such as mitochondrial 
dysfunction (Athauda & Foltynie, 2016). There is a body of evidence that indicates 
that insulin is BBB-permeable and plays a role in influence a range processes in the 
brain including neuronal survival and growth, dopaminergic transmission, 
maintenance of synapses and pathways involved in cognition and that insulin 
signalling pathways may contribute to the development of the pathological features of 
Parkinson's disease. As such, exenatide, a glucagon-like peptide 1 (GLP-1) receptor 
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agonist has been highlighted as drug for possible re-purposing to PD patients. In vitro 
and in vivo tests suggest that exenatide may act via the GLP-1 receptor to influence 
neuronal insulin signalling to activate intracellular protein kinase B (AKT) and its 
downstream substrates which include mTOR and glycogen synthase 3β (GSK3β) to 
influence neuronal survival pathways, increase mitochondrial function and reduce 
neuroinflammation (Athauda & Foltynie, 2016). Other data also suggests that 
downstream GLP-1 signalling induced by exenatide effects Mitogen Associated 
Protein Kinase (MAPK) activity (Baggio & Drucker, 2007). The activation of MAPK is 
thought to induce long term potentiation, synaptic plasticity (Thomas & Huganir, 2004)  
and also stabilization of dendritic spines (Goldin & Segal, 2003; Thomas & Huganir, 
2004). Current literature suggests that exenatide-mediated PD neuroprotection is 
mediated via perpetuation of striatal dopamine neurotransmission (Harkavyi et al., 
2008; Ventorp et al., 2017) which is thought to be the result of intracellular cyclic AMP 
(K. S. Kim et al., 1993).  
Finally, other chemicals may be utilised to enhance the cognitive decline associated 
with neurodegenerative diseases such as PD. Non-peptide ghrelin mimetics such as 
GSK894490A and CP-464709-18 used by  (Atcha, et al., 2009) improved 
performance in the novel object recognition and modified water maze tests in male 
Lister hooded rats. This study demonstrated that these BBB-permeable small-
molecule GHSR1a agonists improve cognition and enhance learning and memory 
substantiating their potential as novel therapeutics for PD. 
 
6.4. Other beneficial side effects of acyl-ghrelin and GHSR1a 
receptor agonists for PD patients 
GHSR1a agonists such as AG hold potential for treating cachexia and impaired 
gastric motility typical observed in PD patients. Cachexia is also termed a wasting 
syndrome is characterised by loss of weight, muscle atrophy, fatigue, weakness, and 
significant loss of appetite in someone who is not actively trying to lose weight. This 
is one such symptom observed in the late stages of diseases such as cancer and 
Parkinson’s disease (D'Amelio et al., 2006). GHSR1a agonism by AG stimulates 
appetite and feeding behaviour (Wren et al., 2000). This is also true for a range of 
small-molecule synthetic peptide and non-peptide ligands of the GHSR1a (Bresciani, 
Tamiazzo, et al., 2008). A study by (Moulin, et al., 2007) investigated in vitro binding 
and in vivo biological activity effect of trisubstituted 1,2,4-triazole structured GHSR1a 
receptor ligands. They concluded that a number of these ligands held potent 
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stimulation of food intake in vivo (e.g. JMV2894); whilst others GHSR1a ligands held 
potential as potent inhibitors of hexarelin-induced food intake (e.g. JMV2959 and 
JMV3021). Hexarelin is a potent synthetic GHSR1a agonist and inducer of food intake 
(Bresciani, Pitsikas, et al., 2008). Thus, highlighting the potential for utilising GHSR1a 
agonists such as AG and its synthetic counterparts as initiators of feeding activity. 
However, this study did show that in vitro binding of agonists to GHSR1a is not a 
predictor of their in vivo endocrinological effects and that other receptors may play a 
role in regulating these endocrinological and extra-endocrinological effects. Moreover, 
a study using the same GHSR1a agonist as we utilised in our rotenone-induced PD 
model, JMV2894, antagonized cisplatin-induced weight loss in a rat model of 
cachexia (Bresciani et al., 2016). Again, highlighting the modulatory effects of 
GHSR1a agonists as a potential treatment of cachexia. 
Another symptom typical of PD is reduced gastric motility and gastrointestinal (GI) 
dysfunction at the early stages of disease progression (Anselmi, Toti, Bove, Hampton, 
& Travagli, 2017). It is postulated that disruption of the nigro-vagal nerve pathway, 
which is thought to control gastric tone and motility, might be involved in the prodromal 
gastric dysmotility observed in early-stage PD. The extent of the impairment in gastric 
motility seen in PD patients occurs in approximately 42% of PD patients who 
experience complications in motor function (Bestetti, Capozza, Lacerenza, Manfredi, 
& Mancini, 2017). This study suggests that common PD treatment, L-DOPA, may 
contribute to the delay in gastric emptying by effecting DAergic neurones in the 
stomach. Moreover, the study suggests that dosage of Aromatic L-amino acid 
decarboxylase inhibitor (dopa-decarboxylase inhibitor) and increasing concentration 
of L-DOPA may contribute to the GI dysfunctions and thus effects the efficacy of their 
treatment. Ghrelin promotes gastric motility via the GHSR1a in a direct pathway from 
the arcuate nucleus of the hypothalamus which regulates gastric motility via 
stimulation of the vagus nerve (Bestetti, et al., 2017). 
Therefore, there appears to be potential in re-purposing and utilising molecules and 
pharmaceuticals which agonise GHSR1a in the arcuate nucleus to increase gastric 
motility and feeding behaviour to alleviate patient symptoms and improve quality of 
PD patient life. 
In summary, the work presented here support a role for AG and GHSR1a agonists as 
potential therapeutics to treat PD. Further work is needed to delineate the 
mechanisms of action and neuroprotective efficacy in more diverse models of 
disease. 
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